Cartilage-hair hypoplasia

Mendelian MONDO:0009595 Pathograph 70 Show in embeddings browser osteochondrodysplasia immuno-osseous dysplasia autosomal recessive disease

Cartilage-hair hypoplasia (CHH) is an autosomal recessive immuno-osseous dysplasia caused by biallelic variants in the noncoding RNA gene RMRP. Its variable manifestations include metaphyseal chondrodysplasia, disproportionate short stature, fine or sparse hair, immune dysfunction, anemia, Hirschsprung disease and increased malignancy risk. Promoter variants can reduce RNA expression, while transcribed-region variants can impair RNase MRP complex function. Studies demonstrate defective pre-rRNA processing, altered ribosome abundance and cell-proliferation defects; the contributions of mRNA turnover, small-RNA regulation and telomere homeostasis to individual tissues remain incompletely resolved. Immune dysfunction may become clinically apparent in adulthood, and malignancy can occur without preceding clinical immune symptoms.

Ask OpenScientist

Ask a research question about Cartilage-hair hypoplasia. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

🏷

Classifications

IUIS Category

ISDS Skeletal Nosology

👪

Inheritance

Autosomal recessive inheritance HP:0000007

CHH is autosomal recessive, arising from biallelic variants in RMRP. Heterozygous carriers are asymptomatic and do not show the cellular proliferation defect, although telomerase activity is reduced in carriers in a gene-dose-dependent manner, so the carrier state is not entirely silent at every molecular level. Each sib of an affected individual has a 25% recurrence risk.

Autosomal recessive inheritance

Show evidence (4 references)

PMID:32506568 SUPPORT Human Clinical

"Cartilage-hair hypoplasia (CHH) is an autosomal recessive syndromic immunodeficiency with skeletal dysplasia, short stature, hypotrichosis, variable degree of immune dysfunction and increased incidence of anaemia, Hirschsprung disease and malignancy."

States the autosomal recessive mode of inheritance alongside the defining multisystem phenotype.

PMID:22420014 SUPPORT Human Clinical

"If both parents are known to be heterozygous for an RMRP pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier."

GeneReviews recurrence risks used in counselling families.

PMID:42170584 SUPPORT Human Clinical

"humans carrying pathogenic variants in a single allele remain asymptomatic (8, 64) and do not demonstrate cell proliferation defects (42)"

Establishes that heterozygous carriers are unaffected at both the clinical and the cellular proliferation level.

+ 1 more reference

Discussions and Knowledge Gaps

By what route does deficiency of a ubiquitously expressed non-coding RNA produce failure of enteric neural crest colonization, and why does this manifest as Hirschsprung disease in only a minority of patients?

KNOWLEDGE GAP OPEN gap_chh_hirschsprung_mechanism

Attached to

pathophysiology#Enteric Aganglionosis pathophysiology#Delayed G2-to-M Progression

The association between CHH and Hirschsprung disease is established, but the link from RMRP dysfunction to enteric aganglionosis is unknown. Reduced proliferation or migration of enteric neural crest cells is a testable hypothesis. Existing cell-cycle findings in other cell types do not establish that mechanism or explain incomplete penetrance. Hypoplastic gut in a model must also be distinguished from loss of enteric ganglia.

Proposed experiments

Enteric neural crest colonization under graded RMRP deficiency

exp_chh_enteric_crest_colonization

Track enteric neural crest cell proliferation, migration velocity and terminal colonization of the distal gut across a graded allelic series of RMRP deficiency, using the zebrafish model and patient-derived enteric neural crest-like cells, and test whether the colonization front fails to reach the hindgut within the developmental window. Measure Cyclin B2 turnover in the migrating population to test the cell-cycle account specifically.

Decision criterion

A dose-dependent colonization defect accompanied by impaired neural crest proliferation and rescue after RMRP correction would support this mechanism. Normal colonization in one model would limit its applicability but would not exclude effects of other alleles, developmental stages or species.

Supporting outcome

RMRP-dependent proliferation or migration defects contribute to impaired enteric neural crest colonization.

Refuting outcome

Colonization remains normal under the tested conditions despite documented RMRP dysfunction, weakening this model-specific hypothesis.

Show evidence (1 reference)

PMID:42170584 SUPPORT Human Clinical

"Hirschsprung's disease (HD) is a well-known comorbidity of CHH, although the pathogenetic link between RMRP deficiency and HD remains unknown."

Explicit statement in the review literature that this mechanism is unknown, which is what makes it a knowledge gap rather than an omission.

What are the relative contributions of immune dysfunction and cell-intrinsic RMRP effects to lymphoma susceptibility in CHH?

KNOWLEDGE GAP OPEN gap_chh_cancer_surveillance_versus_cell_autonomous

Attached to

pathophysiology#Malignancy Predisposition pathophysiology#Impaired Telomere Maintenance pathophysiology#Delayed G2-to-M Progression

Lymphoma risk is elevated, but its causal basis is unresolved. Malignancy can occur without preceding clinical immune symptoms; this does not demonstrate normal immune function or exclude impaired surveillance. Cell-cycle and telomere abnormalities measured in selected patient cells motivate investigation of intrinsic susceptibility, but have not been established in every tissue or in the malignant clone. Immune and intrinsic mechanisms may coexist, and cancer risk after HSCT is not determined by these observations.

Proposed experiments

Genomic and clonal characterization of CHH-associated lymphomas

exp_chh_lymphoma_clonal_origin

Sequence CHH-associated lymphomas for mutational signatures of replication stress and telomere crisis, quantify telomere length and cyclin dysregulation within the malignant clone against the patient's own non-malignant lymphocytes, and determine Epstein-Barr virus status systematically rather than opportunistically. Compare against sporadic diffuse large B-cell lymphoma and against lymphomas arising in non-CHH immunodeficiencies.

Decision criterion

Enrichment of replication-stress or telomere-crisis signatures relative to appropriate lymphoma controls would support an intrinsic contribution, especially with functional validation. Absence of enrichment would be inconclusive about immune surveillance and other intrinsic mechanisms.

Supporting outcome

CHH-associated lymphomas show functionally supported intrinsic RMRP-related susceptibility in addition to any immune contribution.

Refuting outcome

The tested genomic signatures are not enriched, weakening those specific intrinsic hypotheses without proving a purely immune mechanism.

Show evidence (2 references)

PMID:10064668 SUPPORT Human Clinical

"This study confirms an increased risk of cancer, especially non-Hodgkin's lymphoma, probably attributable to defective immunity, among patients with CHH."

The surveillance attribution is offered as probable, not demonstrated, which is the opening this gap addresses.

PMID:31379817 SUPPORT Human Clinical

"Of the 15 patients with non-skin cancer, eight had no preceding clinical symptoms of immunodeficiency."

Absence of prior clinical symptoms limits clinical prediction; it does not establish normal immune function.

How does loss of RMRP reduce telomerase activity when telomerase gene transcript levels are normal?

KNOWLEDGE GAP OPEN gap_chh_telomerase_post_transcriptional_mechanism

Attached to

pathophysiology#Impaired Telomere Maintenance

Reduced telomerase activity was not explained by relative telomerase-gene transcript levels in the studied lymphocytes. Protein abundance, assembly, localization and cell-state effects remain candidates. The reported TERT-RMRP complex has RNA-dependent RNA polymerase activity and should not be equated with the telomerase holoenzyme. A relationship between impaired ribosome production and telomerase function is plausible but has not been demonstrated in CHH.

Proposed experiments

Localizing the post-transcriptional telomerase defect in CHH lymphocytes

exp_chh_telomerase_assembly_step

In patient lymphocytes across an allelic series, quantify TERT protein abundance, TERC levels, telomerase holoenzyme assembly and trafficking, and TERT-RMRP complex formation, and test whether restoring TERT protein alone rescues telomerase activity. Run the same panel in cells where ribosome synthesis is limited independently of RMRP, to separate a specific TERT-RMRP effect from a general translational ceiling.

Decision criterion

Identify which protein, assembly or trafficking defect tracks reduced activity and responds to RMRP correction. Reproduction by an independent ribosome perturbation would support a shared route, but specificity and mediation would require rescue experiments and control of cell activation and proliferation.

Supporting outcome

A specific post-transcriptional RMRP-telomerase mechanism independent of general ribosome limitation

Refuting outcome

Independent ribosome perturbation reproduces the defect, weakening a uniquely RMRP-specific explanation while leaving the mediating steps unresolved.

Show evidence (2 references)

PMID:28126377 SUPPORT Human Clinical

"Telomerase deficiency in patients with CHH is not mediated by abnormal telomerase gene transcript levels relative to those of endogenous genes."

The measured relative transcript levels do not explain the activity deficit; the result does not establish one particular post-transcriptional mechanism.

PMID:28126377 SUPPORT Human Clinical

"These findings suggest that telomere deficiency is implicated in the CHH disease phenotype through an as yet unidentified mechanism."

The authors state directly that the mechanism is unidentified.

Does haematopoietic stem cell transplantation ever rescue linear growth in CHH, and if so, what distinguishes the patients in whom it does?

KNOWLEDGE GAP OPEN gap_chh_hsct_effect_on_linear_growth

Attached to

pathophysiology#Growth Plate Chondrocyte Differentiation Failure pathophysiology#Multilineage Bone Marrow Progenitor Failure

Reports of growth after HSCT differ: older summaries describe persistent growth failure, whereas GeneReviews reports catch-up growth, possibly related to fewer infections, and two promoter-variant cases reportedly normalized growth. Improved linear growth does not by itself establish reversal of skeletal dysplasia. Genotype, age, chronic illness, nutrition and conditioning may contribute to differences. These observations do not establish skeletal growth as an indication for HSCT.

Proposed experiments

Genotype-stratified growth trajectories before and after transplantation

exp_chh_growth_trajectory_after_hsct

Compare longitudinal height trajectories against CHH-specific curves before and after HSCT, with age- and genotype-matched untransplanted comparators. Record nutrition, infection burden, conditioning, pubertal development and skeletal imaging. Analyze promoter and transcribed-region variants separately where numbers permit, while accounting for indication and survivor bias.

Decision criterion

A reproducible change in growth trajectory would support an association with HSCT, while accompanying clinical and skeletal findings could distinguish catch-up growth from structural change. Observational comparisons alone would not establish causality or justify transplantation for growth.

Supporting outcome

A subgroup shows reproducible improvement in linear growth associated with HSCT after adjustment for major measured confounders.

Refuting outcome

No meaningful trajectory difference is detected within the precision and follow-up of the study.

Show evidence (3 references)

PMID:20375313 SUPPORT Human Clinical

"allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment for the severe immunodeficiency, while growth failure remains unaffected"

The abstract summarizes earlier reports of persistent growth failure, which must be read alongside later observations of catch-up growth.

PMID:42170584 SUPPORT Human Clinical

"Skeletal features are not altered by HSCT (68); however, two patients normalized their growth after HSCT, one homozygous and another compound heterozygous for promoter region duplications"

Carries both sides of the discrepancy in one sentence, including the variant class shared by the two exceptional patients; the evidence is limited because two cases cannot settle the question either way.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK84550/pdf/Bookshelf_NBK84550.pdf SUPPORT REVIEW SYNTHESIS Human Clinical

"HSCT has resulted in normalization of T lymphocyte numbers & function, resolution of autoimmune manifestations, & catch-up growth, probably due to ↓ infections."

GeneReviews reports catch-up growth and proposes reduced infections as an explanation. Full-text PDF of the GeneReviews chapter, PMID:22420014.

Can conclusions about CHH pathogenesis be validated in a mammalian whole-organism system, given that Rmrp knockout mice die before embryonic day 6.5 while heterozygotes are healthy?

HUMAN MODEL MISMATCH OPEN mismatch_chh_no_viable_mouse_model

Attached to

pathophysiology#RMRP Non-Coding RNA Loss of Function pathophysiology#Growth Plate Chondrocyte Differentiation Failure

The reported mouse disruption is lethal before embryonic day 6.5, whereas heterozygotes are healthy despite reduced RMRP expression. This limits that model for studying the viable human disease, but does not exclude future hypomorphic or conditional models. Zebrafish knockouts permit developmental analysis before larval death and show partial pharmacological rescue; whether the same response occurs in a mammalian growth plate is unresolved. Mammalian cell and tissue studies provide complementary evidence without reproducing the complete organismal phenotype.

Proposed experiments

Hypomorphic and conditional Rmrp mouse alleles reproducing patient variants

exp_chh_hypomorphic_mouse_knockin

Generate knock-in mice carrying the founder n.71A>G variant and a promoter-region insertion allele, plus a chondrocyte-conditional deletion, and characterize growth-plate architecture, limb proportion, immune reconstitution and erythropoiesis. Test whether beta-catenin inhibition rescues the skeletal phenotype in a mammalian growth plate as it partially does in zebrafish.

Decision criterion

A viable hypomorphic or tissue-specific allele that reproduces relevant patient phenotypes would enable mammalian tests of the proposed pathway. Failure of the selected constructs would limit those designs, not prove that no murine disease model can exist.

Supporting outcome

A graded mammalian model of RMRP deficiency is achievable and can validate the zebrafish rescue

Refuting outcome

The tested alleles fail to reproduce the relevant phenotype, requiring alternative dosage, tissue or developmental designs.

Show evidence (2 references)

PMID:42170584 SUPPORT Model Organism

"Mouse model for RMRP deficiency has never been established, as Rmrp knockout by insertion of DNA elements upstream the promoter was lethal early in embryonic development before embryonic day (E) 6.5"

Establishes the absence of a viable mouse null, the core of this mismatch.

PMID:42170584 SUPPORT Model Organism

"Hemizygous mice missing one RMRP allele showed 50% decrease of RMRP expression in embryonic fibroblasts and were healthy"

The reported heterozygous mice were unaffected despite reduced expression; this does not establish the effects of all hypomorphic alleles.

⚙

Pathophysiology

RMRP Promoter Expansion

Insertions, duplications, and triplications between the RMRP TATA box and transcription start site can impair promoter function. These are regulatory alleles of a noncoding RNA gene. CHH requires an affected second allele; a promoter allele may be paired with a transcribed-region allele, and surviving patients with biallelic promoter variants have been reported.

RMRP hgnc:10031

Genetic context RMRP hgnc:10031 allele_type: promoter insertions, duplications, or triplications functional_impact_category: LOSS_OF_FUNCTION

Affected regions (reference genome)

RMRP promoter between TATA box and transcription start site promoter

One or both disease-associated alleles affect promoter spacing; an isolated heterozygous carrier state is not sufficient for CHH.

Downstream

Reduced RMRP Transcript Abundance Promoter spacing alterations impair transcription in functional assays; reduced transcript abundance was also observed in a homozygous promoter-duplication patient.

Show evidence (2 references)

PMID:11207361 SUPPORT In Vitro

"Insertion mutations immediately upstream of the coding sequence silence transcription while mutations in the transcribed region do not."

The original functional study distinguished upstream insertion effects on transcription from the tested transcribed-region variants. Its reference to coding sequence means the transcribed noncoding RNA, not a protein-coding region.

PMID:37115363 SUPPORT Human Clinical

"This study provides further evidence that homozygous RMRP promoter duplications reduce but do not abrogate transcript expression and are not universally embryonically lethal."

The homozygous promoter-duplication case refutes universal embryonic lethality of this allele class.

Reduced RMRP Transcript Abundance

Reduced availability of the RMRP RNA is one route to functional deficiency, particularly for promoter expansion alleles. The measured reduction in a promoter-duplication patient does not distinguish expression changes across all tissues from cell-type-specific effects. Transcribed-region variants need not reduce total RNA abundance.

RMRP hgnc:10031

Downstream

RMRP Non-Coding RNA Loss of Function Reduced availability of the RNA component limits RMRP-dependent activity. The amount of residual RNA and the consequences in individual tissues depend on the alleles.

Show evidence (1 reference)

PMID:37115363 SUPPORT Human Clinical

"The patient was found to have severely reduced RMRP transcript abundance (P < 0.01)"

Transcript quantification in a patient with a homozygous promoter duplication supports reduced RNA abundance. A single blood-derived measurement does not establish the expression pattern in every tissue.

RMRP Transcribed-Region Variants

Pathogenic substitutions and small sequence alterations affect the transcribed noncoding RNA. They may alter RNA structure or interactions rather than change a protein sequence. The founder variant is n.71A>G on NR_003051.3, termed 70AG in older functional literature. The consequences of this experimentally studied allele should not be assigned to all transcribed-region variants.

RMRP hgnc:10031

Genetic context RMRP hgnc:10031 Genomic context: noncoding exon allele_type: pathogenic substitutions and small alterations of the RMRP transcript functional_impact_category: LOSS_OF_FUNCTION

Homozygous or compound-heterozygous disease genotypes affect a noncoding RNA; protein missense terminology does not apply.

Downstream

Reduced Intact RNase MRP Complex The founder substitution reduces intact complex abundance in engineered cells despite preserved total RMRP levels.

Show evidence (2 references)

PMID:17701897 SUPPORT Computational

"Mapping of nucleotide conservation to the two-dimensional structure of the RMRP gene revealed that disease-causing mutations either affect evolutionarily conserved nucleotides or are likely to alter secondary structure through mispairing in stem regions."

Sequence and structural analysis supports disruption of conserved RNA features; it does not demonstrate the same molecular defect for every allele.

PMID:35115551 SUPPORT In Vitro

"Moreover, the 70AG mutation caused a reduction in intact RNase MRP complexes."

Engineered K562 cells carrying the founder substitution showed reduced intact complex abundance; this result is not assumed for every RMRP allele.

Reduced Intact RNase MRP Complex

Engineered K562 cells homozygous for the founder substitution have less intact RNase MRP complex and reduced RNA association of POP1 and RPP38. Total RMRP abundance is preserved, and SHAPE probing shows subtle local flexibility changes rather than extensive RNA refolding. Impaired complex stability is supported for this allele and cell system; the exact structural mechanism remains unresolved.

RMRP hgnc:10031

Downstream

RMRP Non-Coding RNA Loss of Function Reduced intact complex abundance provides a proximal explanation for impaired RNase MRP activity in the founder-variant model.

Show evidence (2 references)

PMID:35115551 SUPPORT In Vitro

"Moreover, the 70AG mutation caused a reduction in intact RNase MRP complexes."

Engineered K562 cells carrying the founder substitution showed reduced intact complex abundance; this result is not assumed for every RMRP allele.

PMID:35115551 SUPPORT INDIRECT In Vitro

"Levels of POP1 and RMRP are maintained in 70AG cells, so the reduced POP1 recovery in TRAPP indicates that the mutation likely destabilizes the POP1:RMRP interaction."

RNA-associated proteomics with preserved total RNA and protein levels supports impaired complex stability. The precise structural change remains an interpretation of the assays.

RMRP Non-Coding RNA Loss of Function

RMRP encodes the untranslated RNA component of RNase MRP. Disease-associated alleles reduce RNA availability or impair RNA-dependent function by allele-specific mechanisms. Promoter effects and impaired complex stability are distinct routes. Complete RMRP deficiency is lethal in experimental models, but these observations do not establish that every human disease allele retains activity or that all biallelic promoter variants are lethal.

RMRP hgnc:10031

Downstream

Impaired Pre-rRNA Processing RMRP dysfunction delays pre-rRNA processing in engineered cells and patient-derived fibroblasts.

Delayed G2-to-M Progression Founder-variant patient fibroblasts show delayed mitotic entry. The experiments did not isolate a single causal transcript or demonstrate rescue by restoring RMRP.

Impaired Telomere Maintenance Patient lymphocytes exhibit impaired telomere homeostasis, but the mechanism linking RMRP variants to telomerase deficiency is unresolved. The TERT-RMRP complex has RNA-dependent RNA polymerase activity and is not the telomerase holoenzyme.

Reduced RMRP-Derived Small RNA Abundance Patient-derived cell lines have reduced RMRP-derived small RNAs; how different alleles affect their production or stability remains uncertain.

Intestinal Enteropathy Gastrointestinal manifestations are associated with biallelic RMRP disease; the intervening mechanisms have not been demonstrated.

Impaired RNase MRP-Dependent mRNA Turnover Reduced Rmrp activity alters the abundance of mRNA substrates in experimental cells; the effects depend on allele and cellular context.

Reduced Thymic T-Cell Output CHH is associated with reduced thymic output; the intervening molecular steps are incompletely defined.

Increased Activation-Induced T-Cell Death Patient RMRP genotypes are associated with increased activation-induced lymphocyte death; the responsible molecular mediator is unresolved.

Malignancy Predisposition Biallelic RMRP disease is associated with increased cancer risk, through unresolved immune and cell-intrinsic pathways.

Enteric Aganglionosis Hirschsprung disease is associated with CHH, with no established sequence of molecular intermediates.

Multilineage Bone Marrow Progenitor Failure Functional marrow progenitor impairment is observed in CHH; its molecular intermediates and relationship to peripheral blood counts remain unresolved.

Show evidence (3 references)

PMID:11207361 SUPPORT Human Clinical

"We describe numerous mutations in the untranslated RMRP gene that cosegregate with the CHH phenotype."

The original identification of RMRP as the CHH gene and of the gene product as an untranslated RNA.

PMID:35115551 SUPPORT In Vitro

"Moreover, the 70AG mutation caused a reduction in intact RNase MRP complexes."

Engineered K562 cells carrying the founder substitution showed reduced intact complex abundance; this result is not assumed for every RMRP allele.

PMID:42170584 SUPPORT INDIRECT REVIEW SYNTHESIS Model Organism

"This, together with failure to produce RMRP knockout yeast or mice, suggests that RMRP expression might exhibit a dose-dependent phenotype correlation and that complete RMRP deficiency is lethal."

Reviews model-organism evidence for essentiality. This is indirect evidence about the viability of complete deficiency in humans.

Impaired Pre-rRNA Processing

RNase MRP dysfunction delays processing of pre-rRNA in ITS1. Patient-derived fibroblasts and engineered founder-variant K562 cells show altered precursor ratios consistent with reduced site-2 cleavage. In the engineered cells, the ratio of mature short to long 5.8S rRNA is unchanged; older qPCR findings of extended species may instead reflect accumulated precursors. The findings support a processing defect without requiring the same precursor profile in every cell type.

rRNA processing GO:0006364 ↓ DECREASED

Experimental models

RMRP founder-variant K562 cells CELL LINE The founder substitution delays pre-rRNA processing and reduces mature rRNA and intact RNase MRP complex abundance. Total RMRP RNA is not significantly reduced, and the mature 5.8S short-to-long ratio is unchanged.

Downstream

Reduced Cytosolic Ribosome Abundance Impaired precursor maturation reduces ribosome production in the founder-variant cell model.

Show evidence (3 references)

PMID:35115551 SUPPORT In Vitro

"Human cells engineered with the most common CHH mutation (70AG in RMRP) show specifically impaired pre-rRNA processing, resulting in reduced mature rRNA and a reduced ratio of cytosolic to mitochondrial ribosomes."

Engineered founder-variant cells show impaired processing and a reduced cytosolic-to-mitochondrial ribosome ratio; this does not demonstrate altered composition of individual ribosomes.

PMID:35115551 SUPPORT In Vitro

"Patient-derived human fibroblasts with CHH-linked mutations showed similar pre-rRNA processing delay."

Confirms the processing delay in primary patient cells rather than only in engineered or cancer-derived lines.

PMID:35115551 SUPPORT In Vitro

"However, the 5.8SS to 5.8SL ratio was the same in parental and 70AG cells, at approximately 1.25"

The mature 5.8S isoform ratio was unchanged in this model, qualifying extrapolation from yeast or older precursor assays.

Reduced Cytosolic Ribosome Abundance

Founder-variant K562 cells have reduced per-cell mature rRNA and a reduced ratio of cytosolic to mitochondrial ribosomes. RNA-associated proteomics and total-proteome measurements support this finding. These are measurements of abundance and relative pools, not proof of a changed protein composition of each ribosome. High biosynthetic demand is a candidate explanation for tissue vulnerability rather than an established account of all CHH manifestations.

ribosome biogenesis GO:0042254 ↓ DECREASED

Downstream

Impaired T-Lymphocyte Proliferation Reduced ribosome production may restrict expansion of activated T cells. Ex vivo Rmrp disruption shows both defects; the study did not perform an isolated ribosome rescue.

Growth Plate Chondrocyte Differentiation Failure Allele-level correlations between rRNA cleavage impairment and skeletal severity support a role for ribosome dysfunction, while tissue-specific intermediates remain unresolved.

Show evidence (1 reference)

PMID:35115551 SUPPORT In Vitro

Connects the processing defect to lower mature rRNA and a reduced cytosolic-to-mitochondrial ribosome ratio in engineered cells.

Impaired RNase MRP-Dependent mRNA Turnover

RNase MRP has reported mRNA-processing functions in addition to pre-rRNA processing. Rmrp knockdown increases cyclin B2 and viperin transcript abundance in ATDC5 cells. Functional studies across RMRP alleles associate impaired mRNA cleavage with extraskeletal features. The contribution of individual substrates to patient lymphocyte, marrow, and hair abnormalities remains unresolved; these findings do not identify cyclin B2 as the proven cause of the separately measured G2 delay in patient fibroblasts.

Show evidence (2 references)

PMID:28743979 SUPPORT In Vitro

"Reduced Rmrp RNA levels indeed resulted in elevated levels of RNase MRP substrates Clb2 and Viperin mRNAs, as well as an accumulation of an ITS1 pre-rRNA processing intermediate."

Rmrp knockdown in mouse ATDC5 cultures increased substrate transcript abundance. Transcript abundance supports impaired turnover but does not by itself measure direct cleavage kinetics.

PMID:17701897 SUPPORT In Vitro

"We recently demonstrated that mutations may affect both messenger RNA (mRNA) and ribosomal RNA (rRNA) cleavage and thus cell-cycle regulation and protein synthesis."

The functional study distinguishes mRNA and rRNA processing effects across the CHH-anauxetic dysplasia spectrum.

Delayed G2-to-M Progression

Fibroblasts from five adults homozygous for the founder RMRP variant proliferate slowly and are delayed before mitotic entry. EdU labeling and time-lapse imaging localized the delay to G2; S-phase and mitotic duration were largely preserved, without excess cell death. Transcriptomics implicates multiple cell-cycle regulators. These observations do not establish impaired cyclin B2 RNA cleavage as the specific cause of the G2 delay.

G2/M transition of mitotic cell cycle GO:0000086 ↓ DECREASED

Experimental models

CHH patient-derived fibroblast cell-cycle and transcriptome model PRIMARY CELL CULTURE Directly measures cell-cycle progression and transcriptome changes in patient-derived cells carrying the disease genotype.

Animal models

rmrp knockout zebrafish Zebrafish partially recapitulates Shows reduced proliferation and increased apoptosis, but does not resolve the G2-to-M delay measured in patient fibroblasts.

Downstream

Impaired T-Lymphocyte Proliferation Reduced proliferation is a proposed contributor to this manifestation, but the fibroblast G2 experiment does not establish the causal chain in the affected tissue.

Abnormal Hair Production Reduced proliferation is a proposed contributor to this manifestation, but the fibroblast G2 experiment does not establish the causal chain in the affected tissue.

Growth Plate Chondrocyte Differentiation Failure Reduced proliferation is a proposed contributor to this manifestation, but the fibroblast G2 experiment does not establish the causal chain in the affected tissue.

Abnormal spermatogenesis Reduced proliferation is a proposed contributor to this manifestation, but the fibroblast G2 experiment does not establish the causal chain in the affected tissue.

Show evidence (3 references)

PMID:31551465 SUPPORT In Vitro

"Cell-cycle studies indicated that the CHH cells were delayed specifically in the passage from G2 phase to mitosis."

Direct measurement in patient-derived cells localizing the block to the G2-to-M transition, which is what this node asserts.

PMID:31551465 SUPPORT In Vitro

"Transcriptome analysis identified 35 significantly upregulated and 130 downregulated genes in CHH fibroblasts. The downregulated genes were significantly connected to the cell cycle."

Differential expression analysis of patient fibroblast RNA sequencing supports cell-cycle dysregulation; enrichment does not prove a specific causal step.

PMID:31551465 SUPPORT Computational

"Multiple other pathways, involving regulation of apoptosis, bone and cartilage formation, and lymphocyte function, were also affected, as well as PI3K-Akt signaling."

Pathway enrichment generates hypotheses about affected programs rather than demonstrating their functional activation in each clinical tissue.

Impaired Telomere Maintenance

Patient lymphocyte subsets show shortened telomeres and reduced telomerase activity. Normal relative transcript levels for telomerase components did not explain the activity defect. The mechanism remains unidentified. RMRP binding to TERT in some cell lines forms an RNA-dependent RNA polymerase complex and does not establish a direct role in the telomerase holoenzyme. A separate case-control study found shorter telomeres particularly in children, without an association between relative telomere length and clinical or laboratory features within CHH.

telomere maintenance GO:0000723 ↓ DECREASED

Downstream

Short telomere length Connects the molecular arm to its directly measured clinical correlate.

Impaired T-Lymphocyte Proliferation Impaired telomere homeostasis is a candidate contributor to lymphocyte growth defects, but association does not establish this direction of causality.

Show evidence (4 references)

PMID:28126377 SUPPORT Human Clinical

"Here we show that telomere length and telomerase activity are impaired in primary lymphocyte subsets from patients with CHH."

Direct measurement of both telomere length and telomerase activity in patient lymphocytes.

PMID:28126377 SUPPORT Human Clinical

"Telomerase deficiency in patients with CHH is not mediated by abnormal telomerase gene transcript levels relative to those of endogenous genes."

The measured relative transcript levels did not explain the activity defect; the result does not identify its mechanism.

PMID:27986801 SUPPORT Human Clinical

"Compared with age-matched and sex-matched healthy controls, median RTL was significantly shorter in patients with CHH (n=40 pairs, 1.05 vs 1.21, p=0.017), but not in mutation carriers (n=48 pairs, 1.16 vs 1.10, p=0.224)."

Independent quantification of telomere shortening in a larger patient cohort.

+ 1 more reference

Reduced RMRP-Derived Small RNA Abundance

RMRP produces the short RNAs RMRP-S1 and RMRP-S2. Their steady-state levels were reduced in two founder-variant patient fibroblast lines and one patient-derived B-cell line. Production is Dicer-dependent in HEK293 cells, but the route from each disease allele to reduced small-RNA abundance is unresolved. Abundance changes in these cell lines do not establish loss of silencing activity in hair follicles or growth plates.

small rna regulatory model

Downstream

Altered Small RNA-Mediated Gene Regulation Reduced small-RNA abundance may affect target regulation if functional thresholds are crossed; that step has not been measured in patient growth plates or hair follicles.

Show evidence (2 references)

PMID:24009312 SUPPORT In Vitro

"RMRP-S1 and -S2 are significantly reduced in two fibroblast cell lines and a B-cell line derived from CHH patients."

Measured small-RNA reduction in patient-derived cultured cells.

PMID:24009312 SUPPORT In Vitro

"Thus, the reduction in RMRP-S1 and -S2 was dependent upon complete knockdown of Dicer for 24 h, suggesting that their mechanism of biogenesis is Dicer dependent."

Dicer depletion in HEK293 cells supports a role in small-RNA biogenesis; it is not an experiment in patient hair follicles.

Altered Small RNA-Mediated Gene Regulation

Mechanism confidence: Hypothetical

Reduced RMRP-S1 and RMRP-S2 may alter developmental gene regulation. Mimic/inhibitor experiments in HEK293 cells identified regulated transcripts and confirmed effects on PTCH2 and SOX4 RNA and protein. Pathway enrichment suggested relevance to skeletal, hair, and hematopoietic features. These perturbation experiments support a candidate mechanism; they do not demonstrate that reduced endogenous small RNAs cause those manifestations in patients.

small rna regulatory model

Downstream

Abnormal Hair Production A proposed consequence of altered developmental gene regulation; tissue-specific causality has not been demonstrated.

Growth Plate Chondrocyte Differentiation Failure A proposed consequence of altered developmental gene regulation; tissue-specific causality has not been demonstrated.

Show evidence (2 references)

PMID:24009312 SUPPORT In Vitro

"QRT-PCR assays revealed a significant rise of both PTCH2 and SOX4 RNA after transfection of RMRP-S1 and -S2 inhibitors, compared with mock-transfected cells (Fig. 10A)."

Inhibitor experiments in HEK293 cells support regulation of these transcripts. The direction and effect size in patient tissues were not established.

PMID:24009312 SUPPORT INDIRECT BACKGROUND In Vitro

"Knowing the importance of thresholds in determining the effectiveness of miRNAs in RISC (60), the functional consequences of the reductions in RMRP-S1 and -S2 must be determined by further investigations in appropriate stem and differentiated somatic cells associated with CHH phenotypes."

The authors explicitly leave the functional consequences of patient-cell small-RNA reductions for future tissue-relevant experiments.

Growth Plate Chondrocyte Differentiation Failure

RMRP expression rises during hypertrophic chondrocyte differentiation in mouse growth plates and ATDC5 cultures. Rmrp knockdown impairs hypertrophic markers, matrix accumulation, and mineralization in vitro. Patient fibroblasts induced toward a chondrocyte-like state also show reduced hypertrophic differentiation. These models support a role for RMRP in cartilage maturation, consistent with the paucity and disorganization of growth-plate chondrocytes in CHH. The responsible RNA substrates and relative contributions of ribosome synthesis, cell-cycle regulation, and small RNAs remain unresolved. Wnt/beta-catenin activation and partial pharmacological rescue are findings from the zebrafish model, not established human mechanisms.

chondrocyte CL:0000138

chondrocyte differentiation GO:0002062 ↓ DECREASED chondrocyte hypertrophy GO:0003415 ↓ DECREASED endochondral ossification GO:0001958 ↓ DECREASED

Experimental models

Rmrp-deficient ATDC5 chondrogenic cell model CELL LINE Measures chondrogenic differentiation and hypertrophy after Rmrp interference.

Patient fibroblast-derived chondrocyte transdifferentiation PRIMARY CELL CULTURE Patient cells acquire a chondrocyte-like phenotype with impaired commitment to terminal differentiation. RNA sequencing and selected protein assays identify altered BMP, FGF, and IGF-1 pathway components.

Animal models

rmrp knockout zebrafish Zebrafish partially recapitulates Reproduces dysregulated chondrogenesis and abnormal ossification, and implicates Wnt/beta-catenin as a reversible effector.

Downstream

Metaphyseal chondrodysplasia Growth-plate disorganization produces the metaphyseal dysplasia that names the disease.

Disproportionate short-limb short stature Failure of endochondral elongation in the limbs produces disproportionate short stature.

Genu varum A skeletal manifestation associated with CHH; the precise route from altered chondrocyte differentiation to this finding is not established.

Limited elbow extension A skeletal manifestation associated with CHH; the precise route from altered chondrocyte differentiation to this finding is not established.

Joint hypermobility A skeletal manifestation associated with CHH; the precise route from altered chondrocyte differentiation to this finding is not established.

Lumbar hyperlordosis A skeletal manifestation associated with CHH; the precise route from altered chondrocyte differentiation to this finding is not established.

Short metacarpal The same failure of endochondral growth shortens the short tubular bones of the hands and feet.

Coxa vara A skeletal manifestation associated with CHH; the precise route from altered chondrocyte differentiation to this finding is not established.

Scoliosis A skeletal manifestation associated with CHH; the precise route from altered chondrocyte differentiation to this finding is not established.

Show evidence (7 references)

PMID:28743979 SUPPORT In Vitro

"Genetic interference with Rmrp RNA expression in ATDC5 cultures caused a deregulation of chondrogenic differentiation, with a prominent impact on hypertrophy and changes in pre-rRNA processing and rRNA levels."

Direct chondrocyte evidence coupling impaired pre-rRNA processing to deranged differentiation in the same experiment.

PMID:28743979 SUPPORT Model Organism

"Expression of Rmrp RNA and RNase MRP protein subunits was detected in the murine growth plate and during the course of chondrogenic differentiation of ATDC5 cultures, where Rmrp RNA expression was found to be correlated with chondrocyte hypertrophy."

Shows expression in normal mouse growth plates and during cultured-cell differentiation; it does not establish exclusive tissue-specific expression.

PMID:42170584 SUPPORT Human Clinical

"Histological examination of the patient's bone back in 1960s demonstrated the paucity of cartilage cells and disturbed columnar tissue organization"

Human histological correlate: the growth plate is hypocellular and loses its columnar architecture.

+ 4 more references

Impaired T-Lymphocyte Proliferation

Peripheral T cells from patients with CHH can proliferate poorly after stimulation. Experiments demonstrate altered cell-cycle distribution and increased activation-induced death; Rmrp disruption in primary mouse T-cell cultures also impairs expansion and pre-rRNA processing. These findings support cell-intrinsic dysfunction, but the relative contributions of RNA processing, telomere homeostasis, and other pathways remain unresolved.

T cell CL:0000084

T cell proliferation GO:0042098 ↓ DECREASED

Experimental models

Rmrp-disrupted primary mouse T-cell cultures PRIMARY CELL CULTURE Rmrp disruption impairs expansion of viable activated T cells and changes pre-rRNA precursor abundance.

Downstream

Cellular and Humoral Immune Dysfunction Defective T-cell expansion contributes to variable cellular immune dysfunction; laboratory severity does not precisely predict an individual clinical course.

Show evidence (2 references)

PMID:21570718 SUPPORT In Vitro

"As shown in Fig 4, proliferation of CD3+ lymphocytes from patients with CHH was impaired."

Patient PBMC cultures stimulated with anti-CD3, with or without IL-2, showed impaired T-cell proliferation.

PMID:35115551 SUPPORT In Vitro

"This showed that disruption of RMRP markedly impaired T cell proliferation."

CRISPR perturbation of activated primary mouse T cells provides ex vivo evidence; it is classified as an in-vitro experiment.

Reduced Thymic T-Cell Output

Reduced numbers of recent thymic emigrants indicate impaired thymic T-cell generation. This phenotype can occur even without clinically significant immunodeficiency and need not imply a uniform thymic architectural defect in all patients.

Downstream

Decreased total T cell count Reduced thymic production can contribute to low peripheral T-cell numbers, together with peripheral proliferation and survival defects.

Cellular and Humoral Immune Dysfunction Reduced replenishment of naive T cells may contribute to immune dysfunction; its clinical impact is variable.

Show evidence (1 reference)

PMID:21570718 SUPPORT Human Clinical

"As shown in Fig 2, both the absolute and relative numbers of RTEs were significantly reduced in the patients with CHH, regardless of their age, compared with published normal values."

Reduced recent thymic emigrants support decreased thymic output, including in patients without significant clinical infections.

Increased Activation-Induced T-Cell Death

Activated patient lymphocyte cultures show increased apoptosis or late apoptotic/necrotic cell fractions. This contributes to reduced expansion alongside cell-cycle abnormalities. The result is specific to stimulated lymphocytes and should not be generalized to patient fibroblasts, where increased death was not detected.

Downstream

Impaired T-Lymphocyte Proliferation Increased loss of activated T cells contributes to poor culture expansion.

Show evidence (1 reference)

PMID:21570718 SUPPORT In Vitro

"As shown in Fig 6, the percentage of both early and late apoptotic cells was increased in patients with CHH versus healthy controls, reaching a statistically significant difference for late apoptotic/necrotic cells on culture with anti-CD3 mAb 1 IL-2"

Annexin-V/7-AAD assays measured increased activation-associated cell death in patient lymphocyte cultures; significance depended on the assay condition.

Cellular and Humoral Immune Dysfunction

Immune dysfunction ranges from laboratory abnormalities without frequent infections to symptomatic humoral or combined immunodeficiency, including SCID in some patients. T-cell counts, naive subsets, and recent thymic emigrants can be reduced; B-cell and antibody defects are variable. Clinical progression, including adult-onset disease, occurs in a subset rather than universally. Clinical history, function testing, and serial assessment are needed together.

Downstream

Combined immunodeficiency Cellular and humoral defects can combine into clinically significant immunodeficiency.

Recurrent respiratory infections Impaired host defense predisposes to recurrent infections, although some patients remain clinically asymptomatic.

Severe varicella zoster infection Impaired cellular defense can permit severe varicella.

Decreased specific antibody response to vaccination Some patients have impaired specific antibody responses despite preserved total immunoglobulin levels.

Chronic Airway Injury Recurrent respiratory infections can contribute to airway damage, with substantial variation in progression.

Immune Dysregulation and Autoimmunity Immune abnormalities may also affect tolerance, although the responsible mechanisms remain unresolved.

Malignancy Predisposition Defective immune surveillance is a proposed contributor to malignancy risk, rather than a demonstrated sole mechanism.

Show evidence (2 references)

PMID:31379817 SUPPORT Human Clinical

"Half of the patients (57%, n = 46) manifested no symptoms of immunodeficiency during follow-up while 19% (n = 15) and 24% (n = 19) demonstrated symptoms of humoral or combined immunodeficiency, including six cases of adult-onset immunodeficiency."

These categories were assigned from clinical symptoms, not solely laboratory results. Absence of infections does not imply normal immune testing.

PMID:31379817 SUPPORT Human Clinical

"In a significant proportion of patients (17/79, 22%), clinical features of immunodeficiency progressed over time."

The longitudinal cohort demonstrates progression in a minority of participants, not inevitable deterioration.

Multilineage Bone Marrow Progenitor Failure

A study of eight patients with a history of anemia found reduced erythroid, megakaryocyte, and usually granulocyte-macrophage colony formation. Stronger stimulation revealed normal or increased erythroid progenitor numbers, supporting functional impairment rather than simple depletion. The culture defect did not correlate with peripheral blood counts. Clinical anemia is often macrocytic and more severe in early childhood, but persistent transfusion dependence occurs in a severe subgroup.

erythroid progenitor cell CL:0000038

erythrocyte differentiation GO:0030218 ↓ DECREASED

Experimental models

Patient bone marrow progenitor colony-forming assay PRIMARY CELL CULTURE Measures colony formation across erythroid, megakaryocyte and granulocyte-macrophage lineages in patient-derived progenitors.

Downstream

Macrocytic anemia Failure of erythroid colony formation produces a macrocytic anemia.

Anemia Connects the progenitor defect to the general clinical phenotype.

Decreased total neutrophil count The granulocyte-macrophage arm of the colony-formation defect can decompensate into clinical neutropenia, though it usually does not.

Show evidence (4 references)

PMID:7895753 SUPPORT In Vitro

"The present study shows defective in vitro colony formation in all myeloid lineages in patients with CHH, which is in accordance with the suggestion of a common cell proliferation defect in CHH."

Establishes that the marrow defect spans lineages and is read by the authors as the same proliferation defect seen elsewhere.

PMID:7895753 SUPPORT In Vitro

"The impaired growth was not caused by a decreased number of progenitors as shown by erythroid cultures. The erythroid progenitors were incapable of colony formation in culture conditions sufficient for colony formation by normal progenitors."

Distinguishes a functional proliferation defect from progenitor depletion, which is the specific claim this node makes.

PMID:42170584 SUPPORT Human Clinical

"Bone marrow erythroid hypoplasia and poor growth of erythroid precursors have been demonstrated in all CHH patients with severe anemia who underwent bone marrow examinations"

In-patient marrow correlate of the culture findings for the severely anemic subgroup.

+ 1 more reference

Immune Dysregulation and Autoimmunity

Clinical autoimmune manifestations occurred in 11 of 104 Finnish patients and were associated with higher mortality and recurrent serious infections. Autoantibody positivity can occur without corresponding clinical disease. The mechanisms of impaired tolerance remain uncertain; normal regulatory T-cell counts do not exclude functional defects. Asthma and rhinitis diagnoses are common, but not all reported respiratory symptoms have demonstrated allergic mechanisms.

Downstream

Autoimmunity Loss of tolerance manifests as clinical autoimmune disease.

Autoimmune hemolytic anemia Autoimmune destruction of red cells is one reported manifestation.

Asthma These clinical diagnoses are reported in CHH; their relationship to immune dysregulation and the contribution of true allergy remain incompletely established.

Allergic rhinitis These clinical diagnoses are reported in CHH; their relationship to immune dysregulation and the contribution of true allergy remain incompletely established.

Show evidence (4 references)

PMID:30410491 SUPPORT Human Clinical

"Clinical autoimmunity was common (11/104, 10.6%) and included conditions previously undescribed in subjects with CHH (narcolepsy, psoriasis, idiopathic thrombocytopenic purpura, and multifocal motor axonal neuropathy)."

Quantifies clinical autoimmunity and establishes the breadth of the spectrum.

PMID:30410491 SUPPORT Human Clinical

"AI diseases are common in Finnish patients with CHH and are associated with higher mortality, recurrent pneumonia, sepsis, high IgE and/or undetectable IgA levels."

Establishes the mortality association that makes this arm clinically consequential.

PMID:30410491 SUPPORT Human Clinical

"Several patients demonstrated serum autoantibody positivity without compatible symptoms."

Autoantibody positivity without compatible symptoms does not establish clinical autoimmune disease.

+ 1 more reference

Malignancy Predisposition

CHH confers increased risk of lymphoma and basal cell carcinoma. Both defective immune surveillance and cell-intrinsic consequences of RMRP dysfunction are proposed contributors, but neither explains all cases. Malignancy can develop without preceding clinical immunodeficiency. Normal cancer incidence among unaffected relatives supports a disease association without ruling out environmental contributions, including the contribution of sun exposure to skin cancer risk.

Downstream

Non-Hodgkin lymphoma This malignancy is observed at increased frequency in CHH; the molecular route from RMRP dysfunction is incompletely resolved.

Basal cell carcinoma This malignancy is observed at increased frequency in CHH; the molecular route from RMRP dysfunction is incompletely resolved.

Neoplasm This malignancy is observed at increased frequency in CHH; the molecular route from RMRP dysfunction is incompletely resolved.

Show evidence (7 references)

PMID:18698627 SUPPORT Human Clinical

"During the follow-up (2,365 person-years; mean 19.2 years), 14 cases of cancer were diagnosed in the CHH cohort (expected number 2.0; SIR 7.0, CI 3.8-12). Non-Hodgkin lymphoma was the most frequent cancer type (n = 9; SIR 90.2, CI 39.0-180)"

Registry-based quantification of the overall and lymphoma-specific excess risk against population expectation.

PMID:18698627 SUPPORT Human Clinical

"In addition, ten patients had basal cell carcinoma of the skin (expected number 0.3; SIR 33.2, CI 16-61)."

Quantifies the second component of the cancer excess.

PMID:10064668 SUPPORT Human Clinical

"The cancer incidence among the siblings or the parents did not differ from the average cancer incidence in the Finnish population."

No excess was detected in unaffected relatives; this comparison does not exclude environmental effects or gene-environment interactions in affected patients.

+ 4 more references

Chronic Airway Injury

Recurrent infection and inflammation can contribute to structural lung disease in CHH. Bronchiectasis can occur without hypogammaglobulinemia and its course is variable. The follow-up MRI study found stable or improved imaging in 14 participants over a median 6.8 years, but two of the three participants with established bronchiectasis lacked repeat imaging. This selected cohort cannot establish the course of advanced bronchiectasis. Lung disease is an important cause of mortality, without having the highest cause-specific standardized mortality ratio in the longitudinal mortality study.

Downstream

Bronchiectasis Repeated airway infection and inflammation produce irreversible bronchial dilatation.

Recurrent pneumonia Impaired clearance and damaged airways predispose to repeated pneumonia.

Show evidence (5 references)

PMID:33675005 SUPPORT Human Clinical

"Patients with cartilage-hair hypoplasia are prone to recurrent respiratory tract infections, and the prevalence of bronchiectasis ranges from 29 to 52%."

Reports bronchiectasis prevalence across differently selected cohorts; this sentence alone does not prove the direction of causality between infections and airway damage.

PMID:31379817 SUPPORT Human Clinical

"Altogether 20 patients had deceased (SMR = 7.0, 95%CI = 4.3-11); most commonly from malignancy (n = 7, SMR = 10, 95%CI = 4.1-21) and lung disease (n = 4, SMR = 46, 95%CI = 9.5-130)."

Quantifies overall and lung-disease mortality; the full paper reports a higher standardized mortality ratio for lymphoid neoplasms.

PMID:33675005 SUPPORT Human Clinical

"In conclusion, our results suggest slow if any development of bronchiectasis in selected subjects with cartilage-hair hypoplasia."

The follow-up evidence is from a selected cohort with limited repeat imaging in participants with established bronchiectasis.

+ 2 more references

Abnormal Hair Production

Mechanism confidence: Hypothetical

An incompletely resolved defect of hair production underlies the fine or sparse hair typical of CHH. Functional allele comparisons associate hair hypoplasia with reduced mRNA cleavage, and small-RNA perturbation studies identify a candidate regulatory route. Neither result establishes a unique molecular cause in patient follicles. Hair appearance is variable, including normal hair in some patients; direct follicular histology is not established by the cited clinical descriptions.

Downstream

Fine hair Hair-production dysfunction is a proposed tissue-level route to this clinical feature; the specific follicular lesion remains unresolved.

Sparse hair Hair-production dysfunction is a proposed tissue-level route to this clinical feature; the specific follicular lesion remains unresolved.

Show evidence (3 references)

PMID:22420014 SUPPORT Human Clinical

"Other findings include joint hypermobility, fine, silky hair, immunodeficiency, anemia, increased risk for malignancy, gastrointestinal dysfunction, and impaired spermatogenesis."

Establishes fine silky hair as a characteristic feature of the spectrum.

PMID:17701897 SUPPORT In Vitro

"reduced mRNA cleavage, and thus cell-cycle impairment, predicts the presence of hair hypoplasia, immunodeficiency, and hematological abnormalities and thus increased cancer risk"

An association across tested alleles supports an mRNA-processing hypothesis, without demonstrating a unique causal route in patient follicles.

PMID:24009312 SUPPORT Computational

"Pathway analysis identified regulated genes that function in skeletal development, hair development and hematopoietic cell differentiation including PTCH2 and SOX4 among others, linked to major CHH phenotypes."

Pathway enrichment motivates a small-RNA regulatory hypothesis; it does not directly demonstrate defective hair development.

Intestinal Enteropathy

Persistent or recurrent diarrhea in CHH may accompany malabsorption or enteropathy. In the Finnish cohort, duodenal villous atrophy occurred in some patients despite negative celiac testing. Infection and immune dysregulation are possible contributors; systematic histology was limited and a single mechanism has not been established. This process is distinct from congenital enteric aganglionosis.

Downstream

Chronic diarrhea Enteropathy is one potential cause of chronic diarrhea; infectious and other causes also require evaluation.

Show evidence (1 reference)

PMID:30410491 SUPPORT Human Clinical

"The presence of DVA in three subjects with negative celiac screen underscores the necessity for systematic endoscopic evaluation of CHH individuals with gastrointestinal complaints."

A small number of patients had duodenal villous atrophy without positive celiac testing; this does not establish autoimmune enteropathy in all patients with diarrhea.

Enteric Aganglionosis

Hirschsprung disease occurs at increased frequency in CHH. The developmental link between RMRP dysfunction and absent enteric ganglion cells is unknown; intestinal epithelial abnormalities in zebrafish do not establish the cause of human aganglionosis.

Downstream

Aganglionic megacolon Absence of enteric ganglion cells produces the Hirschsprung phenotype.

Show evidence (1 reference)

PMID:42170584 SUPPORT REVIEW SYNTHESIS Human Clinical

"Hirschsprung’s disease (HD) is a well-known comorbidity of CHH, although the pathogenetic link between RMRP deficiency and HD remains unknown."

The association is established, while the mechanistic link is unresolved.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Blood 6

Decreased total neutrophil count HP:0001875

Show evidence (2 references)

PMID:42170584 SUPPORT Human Clinical

"Single patients also have neutropenia, either intrinsic or autoimmune"

Establishes neutropenia as an occasional feature and names both candidate mechanisms; the single-patient framing is why no frequency is assigned.

PMID:25764362 SUPPORT Human Clinical

"CHH is associated with a broad spectrum of mild-to-moderate, cell-mediated immunodysfunction, including occasionally severe combined immune deficiency, neutropenia, lymphopenia, disordered erythrogenesis, and a predisposition to lymphoma"

Independent listing of neutropenia among the recognized haematologic features of CHH.

Decreased total T cell count HP:0005403

Show evidence (1 reference)

PMID:28284971 SUPPORT Human Clinical

"Patients with clinically suggested CID showed decreased median CD3+, CD8+ and RTE counts"

Directly reports reduced T cell counts in the clinically affected subgroup.

Anemia FREQUENT HP:0001903

Show evidence (2 references)

PMID:42170584 SUPPORT Human Clinical

"In a cohort of 88 Finnish patients, low hemoglobin levels were common in childhood (54/74, 73%), in addition to macrocytosis (in 47%), but were not seen in adult subjects"

Reports low haemoglobin in 73% (54/74) of children, which maps to the FREQUENT band (30-79%); the same source notes its absence in adults, which is why the description is age-qualified.

PMID:10690856 SUPPORT Human Clinical

"Retrospective analysis of hematological data of 114 patients showed that the severity of the anemia and macrocytosis in CHH varies with age. The anemia was most severe in early childhood."

Independent confirmation of the age dependence of the anemia.

Macrocytic anemia HP:0001972

Show evidence (2 references)

PMID:39321258 SUPPORT Human Clinical

"Most authors have reported macrocytic anemia and blood transfusion as a common treatment approach in this patient group."

Establishes the macrocytic character of the anemia across the published literature.

PMID:42170584 SUPPORT Human Clinical

"Reticulocyte index and haptoglobin, iron and transferrin concentrations, as well as vitamin B12 and folate levels were normal."

Excludes nutritional and haemolytic causes for the macrocytosis, which is what makes it a marker of the intrinsic marrow defect.

Autoimmune hemolytic anemia HP:0001890

Show evidence (1 reference)

PMID:42170584 SUPPORT Human Clinical

"Apart from hypoplastic anemia, autoimmune hemolytic anemia (AIHA) has also been described in multiple patients and is the most common autoimmune phenomenon in CHH."

Establishes AIHA as the leading autoimmune feature and distinguishes it from the hypoplastic anemia.

Non-Hodgkin lymphoma HP:0012539

Show evidence (3 references)

PMID:18698627 SUPPORT Human Clinical

"Non-Hodgkin lymphoma was the most frequent cancer type (n = 9; SIR 90.2, CI 39.0-180) followed by squamous cell carcinoma (3), leukemia (1) and Hodgkin lymphoma (1)."

Quantifies the non-Hodgkin lymphoma excess against population expectation.

PMID:36211439 SUPPORT Human Clinical

"Lymphoma was diagnosed in young adulthood (median age 26.4 years, range from 6.4 to 69.5 years), mostly in advanced stage."

Establishes the age at presentation and the advanced stage driving the poor outcome.

PMID:36211439 SUPPORT Human Clinical

"Altogether, eleven CHH patients died due to lymphomas (11/16, 69%)."

Quantifies lymphoma mortality within the case series.

Digestive 2

Chronic diarrhea OCCASIONAL HP:0002028

Show evidence (2 references)

PMID:30410491 SUPPORT Human Clinical

"Gastrointestinal complaints, mostly persistent diarrhea, were also frequently reported (32/104, 31%)."

Reports gastrointestinal complaints in 31% (32/104), mostly persistent diarrhoea. This denominator does not establish a diarrhoea-specific frequency.

PMID:30410491 SUPPORT Human Clinical

"Significantly more patients with diarrhea reported arthralgia (18/23, 78% vs. 38/81, 47%, p = 0.011, B coefficient 1.41), as compared with those without diarrhea."

The comparison gives 23 patients with diarrhea and 81 without it; 23/104 is approximately 22%, distinct from the 31% with any gastrointestinal complaint.

Aganglionic megacolon OCCASIONAL HP:0002251

Show evidence (1 reference)

PMID:42170584 SUPPORT Human Clinical

"The prevalence of HD in the Finnish CHH cohort has increased from 9% (13/142) in the 20th century to 25% (8/32) in the 2000s"

Both reported figures, 9% and 25%, fall within the OCCASIONAL band (5-29%).

Genitourinary 1

Abnormal spermatogenesis HP:0008669

Show evidence (2 references)

PMID:22420014 SUPPORT Human Clinical

"Other findings include joint hypermobility, fine, silky hair, immunodeficiency, anemia, increased risk for malignancy, gastrointestinal dysfunction, and impaired spermatogenesis."

Names impaired spermatogenesis as a feature of the spectrum.

PMID:31551465 SUPPORT INDIRECT BACKGROUND Other

"A generalized defect in cell proliferation has been speculated to explain several of the clinical manifestations, including disorganized growth-plate chondrocyte maturation, hair hypoplasia, immunodeficiency and impaired spermatogenesis"

The authors propose a proliferation-based explanation; this sentence does not establish the mechanism of impaired spermatogenesis.

Head and Neck 1

Allergic rhinitis FREQUENT HP:0003193

Show evidence (2 references)

PMID:30410491 SUPPORT Human Clinical

"We confirmed the high prevalence of asthma (23%) and allergic rhinoconjunctivitis (39%)."

Reports allergic rhinoconjunctivitis in 39%, which maps to the FREQUENT band (30-79%).

PMID:30410491 SUPPORT Human Clinical

"Despite the history of allergic rhinitis, no eosinophils were observed in nasal cytology in five tested patients."

Retained negative finding qualifying the atopic interpretation; the evidence is limited because only five patients were tested.

Immune 7

Decreased specific antibody response to vaccination HP:0032140

Show evidence (2 references)

PMID:28284971 SUPPORT Human Clinical

"Seven out of eight (88%) patients who agreed to receive Pneumovax® vaccine demonstrated specific antibody deficiency (SAD)"

Reports the vaccine-challenge result: seven of eight participants demonstrated specific antibody deficiency. No frequency band is assigned because only eight patients consented, so the proportion is not a population estimate.

PMID:42170584 SUPPORT Human Clinical

"While B cell counts are often decreased, hypogammaglobulinemia is rare in patients with CHH; moreover, some individuals have hypergammaglobulinemia"

Establishes that total immunoglobulin concentration is usually preserved in CHH, which is why the humoral defect is curated here as an impaired specific antibody response rather than as decreased circulating immunoglobulin.

Combined immunodeficiency OCCASIONAL HP:0005387

Show evidence (3 references)

PMID:31379817 SUPPORT Human Clinical

Reports symptomatic combined immunodeficiency in 24% of an 80-patient prospective cohort, which maps to the OCCASIONAL band (5-29%).

PMID:28284971 SUPPORT Human Clinical

"We grouped patients as having: 1) no symptoms/signs of immunodeficiency (n=15, 27%), 2) features of humoral immunodeficiency only (n=26, 46%) and 3) features of combined immunodeficiency (CID, n=15, 27%)"

Independent cohort reporting 27%, consistent with the same band.

PMID:28284971 SUPPORT Human Clinical

"As mortality due to infections and malignancies is increased in CHH4, patients surviving into adulthood represent individuals with milder disease."

Ascertainment caveat retained: cohorts of living patients probably understate severity in the disease as a whole.

Recurrent respiratory infections HP:0002205

Show evidence (2 references)

PMID:33675005 SUPPORT Human Clinical

"Patients with cartilage-hair hypoplasia are prone to recurrent respiratory tract infections, and the prevalence of bronchiectasis ranges from 29 to 52%."

Establishes the recurrent respiratory infection phenotype.

PMID:42170584 SUPPORT Human Clinical

"In the clinical cohorts, 33-78% of the patients have normal infection history"

Retained counterweight: a large fraction of patients are not clinically infection-prone, so no frequency band is assigned.

Recurrent pneumonia HP:0006532

Show evidence (2 references)

PMID:31379817 SUPPORT Human Clinical

"pneumonia in the first year of life or recurrently in adulthood (OR = 7.6/19, 95%CI = 1.3-43/2.6-140)"

Establishes recurrent pneumonia as a prognostic risk factor rather than merely a manifestation.

PMID:33675005 SUPPORT Human Clinical

"Patients with subtle signs of bronchiectasis on imaging tended to have low immunoglobulin M levels, as well as suffered from pneumonia during the follow-up."

Links pneumonia during follow-up to the imaging changes in the same cohort.

Autoimmunity OCCASIONAL HP:0002960

Show evidence (1 reference)

PMID:30410491 SUPPORT Human Clinical

Reports clinical autoimmunity in 10.6% (11/104), which maps to the OCCASIONAL band (5-29%).

Asthma OCCASIONAL HP:0002099

Show evidence (1 reference)

PMID:30410491 SUPPORT Human Clinical

"We confirmed the high prevalence of asthma (23%) and allergic rhinoconjunctivitis (39%)."

Reports asthma in 23%, which maps to the OCCASIONAL band (5-29%).

Severe varicella zoster infection HP:0032170

Show evidence (3 references)

PMID:22420014 SUPPORT Human Clinical

"immediate high-dose intravenous acyclovir for varicella infection"

The management recommendation presupposes varicella as a recognized severe risk in this population.

PMID:42170584 SUPPORT Human Clinical

"This has not been reported in later case series; vice versa, the majority of patients with CHH clear varicella without antiviral medications or any complications"

Retained counterweight: severe varicella is a real but uncommon outcome, so no frequency band is assigned and the historical framing is qualified.

PMID:28284971 SUPPORT Human Clinical

"Lower median IgG2 concentrations (1.08 vs 1.96 g/l, p=0.016) were observed in patients who required hospitalization for VZV infection."

Supports the IgG2 association described here.

Integument 3

Fine hair HP:0002213

Show evidence (1 reference)

PMID:22420014 SUPPORT Human Clinical

"Other findings include joint hypermobility, fine, silky hair, immunodeficiency, anemia, increased risk for malignancy, gastrointestinal dysfunction, and impaired spermatogenesis."

Establishes fine silky hair as a characteristic feature.

Sparse hair HP:0008070

Show evidence (2 references)

PMID:32506568 SUPPORT Human Clinical

Names hypotrichosis as a defining feature of the syndrome.

PMID:42170584 SUPPORT Human Clinical

"Historically, CHH-HD has been associated with more severe growth failure, complete alopecia, and severe anemia"

Supports the severe end of the hair phenotype; the evidence is limited because complete alopecia is described in the Hirschsprung subgroup rather than of CHH generally.

Basal cell carcinoma HP:0002671

Show evidence (2 references)

PMID:18698627 SUPPORT Human Clinical

"In addition, ten patients had basal cell carcinoma of the skin (expected number 0.3; SIR 33.2, CI 16-61)."

Quantifies the basal cell carcinoma excess against population expectation.

PMID:42170584 SUPPORT Human Clinical

"Skin cancer in CHH develops only on sun-exposed areas (95); therefore, enhanced sun protection should be emphasized."

Supports the anatomical restriction to sun-exposed skin and the resulting management advice.

Limbs 5

Metaphyseal chondrodysplasia HP:0005871

Show evidence (2 references)

PMID:42170584 SUPPORT Human Clinical

"Radiologically, metaphyseal abnormalities included flaring, cupping, widening, cysts, fragmentation, and scalloping of metaphyses in the tubular bones, particularly at the knee."

Describes the specific radiographic metaphyseal changes of CHH.

PMID:42170584 SUPPORT Human Clinical

"Importantly, metaphyseal changes may not be apparent in the first 2 years of life"

Supports the diagnostic caveat that early radiographs may be uninformative.

Limited elbow extension VERY_FREQUENT HP:0001377

Show evidence (1 reference)

PMID:42170584 SUPPORT Human Clinical

"incomplete extension of elbows (present in 92%, 79/86 patients) despite overall ligamentous laxity (95%, 81/85)"

Reports incomplete elbow extension in 92% (79/86), which maps to the VERY_FREQUENT band (80-100%).

Genu varum FREQUENT HP:0002970

Show evidence (2 references)

PMID:42170584 SUPPORT Human Clinical

"lower limbs varus deformity (63%, 54/86), chest deformity (68%, 57/84), as well as lumbar lordosis (85%, 72/85) and scoliosis (21%, 18/86)"

Reports lower-limb varus deformity in 63% (54/86), which maps to the FREQUENT band (30-79%).

PMID:25764362 SUPPORT Human Clinical

"Of the cases reviewed, 32 patients had undergone surgery, most commonly to correct genu varum."

The primary report supplies the number operated; its text and conclusion use inconsistent percentage denominators.

Short metacarpal HP:0010049

Show evidence (2 references)

PMID:25764362 SUPPORT Human Clinical

"There is marked shortening of the metacarpals, metatarsals, and phalanges, with metaphyseal cupping"

Directly describes the shortened metacarpals this phenotype records, in the largest reported orthopaedic series of CHH patients.

PMID:42170584 SUPPORT Human Clinical

"Typical features in addition to short limbs include short hands"

Independent confirmation that short hands are a typical feature, though stated clinically rather than at the level of the individual bone.

Coxa vara OCCASIONAL HP:0002812

Show evidence (1 reference)

PMID:25764362 SUPPORT Human Clinical

"In our series, 27 % of the cases where radiographs were reviewed (19/71) showed coxa vara radiographically."

Reports coxa vara in 27% (19/71), which maps to the OCCASIONAL band (5-29%).

Musculoskeletal 3

Joint hypermobility VERY_FREQUENT HP:0001382

Show evidence (1 reference)

PMID:42170584 SUPPORT Human Clinical

"incomplete extension of elbows (present in 92%, 79/86 patients) despite overall ligamentous laxity (95%, 81/85)"

Reports ligamentous laxity in 95% (81/85), which maps to the VERY_FREQUENT band (80-100%).

Lumbar hyperlordosis VERY_FREQUENT HP:0002938

Show evidence (1 reference)

PMID:42170584 SUPPORT Human Clinical

"lower limbs varus deformity (63%, 54/86), chest deformity (68%, 57/84), as well as lumbar lordosis (85%, 72/85) and scoliosis (21%, 18/86)"

Reports lumbar lordosis in 85% (72/85), which maps to the VERY_FREQUENT band (80-100%).

Scoliosis OCCASIONAL HP:0002650

Show evidence (1 reference)

PMID:42170584 SUPPORT Human Clinical

"lower limbs varus deformity (63%, 54/86), chest deformity (68%, 57/84), as well as lumbar lordosis (85%, 72/85) and scoliosis (21%, 18/86)"

Reports scoliosis in 21% (18/86), which maps to the OCCASIONAL band (5-29%).

Respiratory 2

Bronchiectasis HP:0002110

Show evidence (2 references)

PMID:33675005 SUPPORT Human Clinical

"Patients with cartilage-hair hypoplasia are prone to recurrent respiratory tract infections, and the prevalence of bronchiectasis ranges from 29 to 52%."

Summarizes a range across cohorts that spans two frequency bands; ascertainment differences prevent assigning one frequency category.

PMID:42170584 SUPPORT Human Clinical

"In an unselected cohort of 34 Finnish patients, aged 13-68 years, 10 (29%) had bronchiectasis on chest HRCT imaging"

Gives the unselected-cohort figure anchoring the lower end of the range.

Neonatal respiratory insufficiency HP:0002093

Show evidence (1 reference)

PMID:42063088 SUPPORT Human Clinical

"Seven (37%) children needed respiratory support, including intubation and continuous positive airway pressure (CPAP), in the immediate newborn period."

Respiratory support was documented in 7/19 infants with additional neonatal information, not all 35 children in the cohort.

Cellular 1

Short telomere length HP:0031413

Show evidence (2 references)

PMID:27986801 SUPPORT Human Clinical

"In particular children (<18 years) with CHH had shorter telomeres than controls (median RTL 1.12 vs 1.26, p=0.008)."

Directly measures the shortened telomere phenotype in children.

PMID:28126377 SUPPORT Human Clinical

"Here we show that telomere length and telomerase activity are impaired in primary lymphocyte subsets from patients with CHH."

Independent measurement in lymphocyte subsets, adding the telomerase activity deficit.

Constitutional 1

Arthralgia FREQUENT HP:0002829

Show evidence (1 reference)

PMID:30410491 SUPPORT Human Clinical

"More than half of our patients (56/104, 54%) suffered from arthralgia or morning joint stiffness, but only one was diagnosed with genuine seronegative juvenile polyarthritis."

Documents the combined symptom measure and the distinction from inflammatory arthritis.

Growth 1

Disproportionate short-limb short stature VERY_FREQUENT HP:0008873

Show evidence (4 references)

PMID:22420014 SUPPORT Human Clinical

"CHH-AD spectrum disorders are characterized by severe disproportionate (short-limb) short stature that is usually recognized in the newborn, and occasionally prenatally because of the short extremities."

Establishes short-limb disproportionate short stature as a defining and near-universal feature of the spectrum, supporting the VERY_FREQUENT band.

PMID:42170584 SUPPORT Human Clinical

"The growth failure is progressive, particularly during the first year of life and during puberty, resulting in the median adult height of 131 cm for males and 123 cm for females"

Quantifies the adult height outcome described here.

PMID:42170584 SUPPORT Human Clinical

"While short stature was first thought to be invariably present in CHH patients, individuals with normal height have since been reported"

Retained qualification: short stature is characteristic but not obligatory, which is why the band is VERY_FREQUENT rather than obligate.

+ 1 more reference

Neoplasm 1

Neoplasm HP:0002664

Show evidence (2 references)

PMID:18698627 SUPPORT Human Clinical

"During the follow-up (2,365 person-years; mean 19.2 years), 14 cases of cancer were diagnosed in the CHH cohort (expected number 2.0; SIR 7.0, CI 3.8-12)."

Quantifies the overall cancer excess.

PMID:18698627 SUPPORT Human Clinical

"Nine of the 14 cancers were diagnosed in patients less than 45 years of age."

Supports the concentration of malignancy in younger patients.

🧬

Genetic Associations

RMRP (Pathogenic Variants)

Gene: RMRP hgnc:10031 gene page relationship_type: CAUSATIVE

Show evidence (10 references)

PMID:11207361 SUPPORT Human Clinical

"We describe numerous mutations in the untranslated RMRP gene that cosegregate with the CHH phenotype."

The original cosegregation evidence establishing RMRP as the CHH gene.

PMID:31551465 SUPPORT Human Clinical

"RMRP was the first non-coding nuclear RNA gene implicated in a disease."

Supports the historical significance noted here.

PMID:31551465 SUPPORT Human Clinical

"The founder mutation n.71 A > G (NCBI reference sequence: NR_003051.3) has been detected in almost all previously reported Finnish patients with CHH either in homozygous or heterozygous state3."

Specifies the founder allele and its reference sequence, and its dominance in the Finnish population.

+ 7 more references

💊

Medical Actions

Hematopoietic stem cell transplantation

Action: hematopoietic cell transplantation Ontology label: Hematopoietic Cell Transplantation NCIT:C15431

Platform: Cell therapy

Allogeneic HSCT can correct severe immune dysfunction and transfusion-dependent anemia. In a historical European series of 16 transplanted patients, 10 were long-term survivors, with normalization of T-cell numbers and function and resolution of autoimmunity. Skeletal dysplasia is not established as corrected by HSCT, although catch-up growth has been reported, possibly because infections decrease. Indications in mildly symptomatic patients remain debated; timing should account for severe infections, organ damage, and malignancy.

Mechanism Target:

RESTORES Impaired T-Lymphocyte Proliferation — Replacing the haematopoietic compartment with donor cells carrying functional RMRP restores lymphocyte numbers and function.

Show evidence (1 reference)

PMID:20375313 SUPPORT Human Clinical

"T-lymphocyte numbers and function have normalized, and autoimmunity has resolved in all survivors."

Direct evidence that transplantation corrects the lymphoid arm modeled by this node.

RESTORES Multilineage Bone Marrow Progenitor Failure — Donor progenitors restore erythropoiesis, curing transfusion-dependent anemia.

Show evidence (1 reference)

PMID:42170584 SUPPORT Human Clinical

"The only curative option for severe anemia in CHH remains HSCT, with multiple case reports of successful resolution"

Direct evidence that transplantation corrects the marrow arm modeled by this node.

RESTORES Immune Dysregulation and Autoimmunity — Autoimmunity resolved in all long-term survivors of transplantation, consistent with the dysregulation being intrinsic to the haematopoietic compartment.

Show evidence (1 reference)

PMID:20375313 SUPPORT Human Clinical

"T-lymphocyte numbers and function have normalized, and autoimmunity has resolved in all survivors."

Direct evidence of resolution of the autoimmune arm after transplantation.

Show evidence (5 references)

PMID:20375313 SUPPORT Human Clinical

"Previous reports in single CHH patients with significant immunodeficiencies have demonstrated that allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment for the severe immunodeficiency, while growth failure remains unaffected."

The abstract summarizes older reports of persistent growth failure. This does not exclude the catch-up growth reported in later clinical synthesis and does not prove chondrocyte autonomy.

PMID:20375313 SUPPORT Human Clinical

"Of 16 patients, 10 (62.5%) were long-term survivors, with a median follow-up of 7 years."

Quantifies long-term survival in the largest reported transplanted cohort.

PMID:20375313 SUPPORT Human Clinical

"HSCT should be considered in CHH patients with severe immunodeficiency/autoimmunity, before the development of severe infections, major organ damage, or malignancy might jeopardize the outcome of HSCT and the quality of life in these patients."

Supports the timing argument for earlier transplantation.

+ 2 more references

Immunoglobulin replacement therapy

Action: immunoglobulin therapy Ontology label: Immunoglobulin Therapy NCIT:C62710

Platform: Other

Immunoglobulin replacement is considered for clinically relevant antibody deficiency, including low immunoglobulin or IgG subclass levels or inadequate vaccine responses. It supplies passive antibody but does not correct the underlying cellular defect; lung disease can progress despite treatment.

Mechanism Target:

BYPASSES Cellular and Humoral Immune Dysfunction — Passive antibody supplements inadequate humoral immunity without correcting the underlying RMRP-related defect.

Show evidence (1 reference)

PMID:22420014 SUPPORT Human Clinical

"consideration of prophylactic antibiotic therapy and/or immunoglobulin replacement therapy"

Establishes immunoglobulin replacement as recommended management for the immune defect.

Show evidence (2 references)

PMID:42170584 SUPPORT Human Clinical

"Hypogammaglobulinemia is present in some, but not all, of these patients, and immunoglobulin replacement therapy (IGRT) is often insufficient to prevent deterioration."

The evidence is limited because it establishes the therapy's use while limiting the claim of benefit against progressive lung disease.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK84550/pdf/Bookshelf_NBK84550.pdf SUPPORT REVIEW SYNTHESIS Human Clinical

"Consider IVIG if immunoglobulin or IgG subclass levels are low, or if vaccine responses are inadequate."

The indication includes functional antibody deficiency even when total IgG is preserved. Full-text PDF of the GeneReviews chapter, PMID:22420014.

Antimicrobial prophylaxis and treatment of infection

Action: antibiotic therapy Ontology label: Antibiotic Therapy NCIT:C15620

Platform: Small molecule

Infections are treated according to type, location and severity, with prophylactic antibiotics considered in selected patients. Antimicrobial management is directed at the consequences of the immune defect rather than at the defect itself.

Mechanism Target:

INHIBITS Chronic Airway Injury — Suppressing recurrent airway infection is the available lever on the infection-to-structural-damage sequence.

Show evidence (1 reference)

PMID:22420014 SUPPORT Human Clinical

"treatment of underlying infections based on their type, location, and severity; immediate high-dose intravenous acyclovir for varicella infection; consideration of prophylactic antibiotic therapy and/or immunoglobulin replacement therapy"

Establishes both treatment of infection and prophylaxis as recommended management.

Show evidence (1 reference)

PMID:22420014 SUPPORT Human Clinical

"physiotherapy and other acute and long-term medical management for bronchiectasis per pulmonologist"

Supports the specialist respiratory management arm alongside antimicrobials.

High-dose intravenous acyclovir for varicella

Action: antiviral therapy Ontology label: Antiviral Therapy NCIT:C16119

Agent: acyclovir CHEBI:2453

Platform: Small molecule

GeneReviews recommends prompt high-dose intravenous acyclovir when varicella develops in CHH to prevent severe complications. The recommendation addresses the risk of severe viral disease despite many patients having an uncomplicated course.

Mechanism Target:

INHIBITS Severe varicella zoster infection — Antiviral treatment suppresses viral replication and is intended to prevent or limit severe varicella complications.

Show evidence (1 reference)

PMID:22420014 SUPPORT Human Clinical

"immediate high-dose intravenous acyclovir for varicella infection"

States the specific antiviral recommendation for this population.

Show evidence (1 reference)

PMID:22420014 SUPPORT Human Clinical

"immediate high-dose intravenous acyclovir for varicella infection"

The GeneReviews management recommendation this treatment records.

Live viral vaccination after specialist immune assessment

Action: vaccination Ontology label: Vaccination NCIT:C15346

Platform: Vaccine

Live vaccines require individualized specialist assessment and are avoided in severe or clinically significant combined immunodeficiency. The Finnish study supports consideration in selected patients with no or mild clinical immune dysfunction. All five prospective varicella vaccine recipients had normal mitogen responses and normal IgG, although three were lymphopenic. One developed self-limited rash and knee swelling. This small, selected trial does not establish safety across the CHH spectrum; mild lymphopenia alone was not an absolute exclusion in the study.

Show evidence (7 references)

PMID:22420014 SUPPORT Human Clinical

"Agents/circumstances to avoid: Administration of live vaccines when signs of abnormal immunologic function or SCID are present."

The explicit GeneReviews agents-to-avoid warning, recorded verbatim.

PMID:42170584 SUPPORT Human Clinical

"as well as vaccine-strain rubella virus-induced skin granulomas"

Documents a realized live-vaccine complication in CHH, the concrete basis for the warning.

PMID:32849667 SUPPORT Human Clinical

"No serious adverse events have been recorded after immunization with live viral vaccines in Finnish patients with CHH. Patients generate humoral and cellular immune response to live viral vaccines."

The retrospective series and five-subject trial support selected use, but do not establish safety in severe clinical combined immunodeficiency or outside the studied population.

+ 4 more references

Red blood cell transfusion with iron chelation

Action: blood transfusion Ontology label: Blood Transfusion NCIT:C15192

Platform: Other

Severe anemia is managed with red cell transfusion, and iron chelation is recommended for those requiring repeated transfusion. Transfusion dependency typically presents in the first months of life and may remit spontaneously or recur after prolonged remission, so the requirement should be reassessed rather than assumed permanent.

Mechanism Target:

BYPASSES Multilineage Bone Marrow Progenitor Failure — Transfused red cells substitute for the erythropoiesis the marrow cannot sustain, without correcting the progenitor defect.

Show evidence (1 reference)

PMID:39321258 SUPPORT Human Clinical

"Most authors have reported macrocytic anemia and blood transfusion as a common treatment approach in this patient group."

Establishes transfusion as the standard supportive approach to the anemia.

Show evidence (2 references)

PMID:39321258 SUPPORT Human Clinical

"Recommended guidelines for managing anemia in CHH patients include iron chelation therapy for those requiring multiple blood transfusions, regular assessment of anemia symptoms, red blood cell parameters, and immune system function."

States the chelation and monitoring recommendations recorded here.

PMID:22420014 SUPPORT Human Clinical

"red blood cell transfusions for severe anemia with iron chelation as needed"

Independent statement of the same management pairing.

Orthopedic surgical management

Action: orthopedic surgical procedure Ontology label: Orthopedic Surgical Procedure NCIT:C16186

Platform: Surgery

Corrective osteotomy may be required for progressive varus deformity of the lower extremities. The North American review reported 32 patients who had undergone surgery, most often for genu varum. Published surgical percentages use inconsistent denominators, so a single population-wide percentage is not assigned.

Mechanism Target:

INHIBITS Genu varum — Realignment osteotomy corrects the varus deformity produced by asymmetric metaphyseal growth.

Show evidence (1 reference)

PMID:22420014 SUPPORT Human Clinical

"corrective osteotomies may be required for progressive varus deformity of the lower extremities"

States the surgical indication for the deformity targeted here.

Show evidence (1 reference)

PMID:25764362 SUPPORT Human Clinical

"Of the cases reviewed, 32 patients had undergone surgery, most commonly to correct genu varum."

The primary report supplies the number operated; its text and conclusion use inconsistent percentage denominators.

Growth hormone therapy, generally not recommended

Action: Pharmacotherapy NCIT:C15986

Platform: Peptide

Routine growth hormone treatment is not recommended because sustained benefit has not been established. A review describes eight patients with ineffective or temporary responses, but also reports improvement in a child without growth hormone deficiency. A later case report describes improved growth during approximately two years of treatment without final-height follow-up. Coexisting growth hormone deficiency warrants endocrine assessment, although replacement does not guarantee a growth response. These heterogeneous observations do not demonstrate correction of the underlying chondrocyte defect. Growth hormone did not improve erythroid colony formation in the cited anemia study.

Show evidence (6 references)

PMID:42170584 SUPPORT REVIEW SYNTHESIS Human Clinical

"Several case reports (altogether, of eight patients) have described GH therapy as ineffective or, at most, with temporary benefit"

Summarizes limited or absent benefit in reported cases, supporting the recommendation against routine use without proving universal futility.

PMID:42170584 SUPPORT REVIEW SYNTHESIS Human Clinical

"However, GH deficiency has also been reported in CHH patients, and for them, GH treatment might be beneficial"

Supports assessment for a potentially treatable endocrine contribution; benefit in an individual patient is not assured.

PMID:42170584 SUPPORT REVIEW SYNTHESIS Human Clinical

"In addition, in a single patient with genetically confirmed CHH and no GH deficiency, GH treatment improved height from −4.2 SDS prior to treatment at 3 years of age to −2.6 SDS at 6 years"

Records an exception without growth hormone deficiency. This single child's response does not establish sustained final-height benefit.

+ 3 more references

Pulmonary physiotherapy and bronchiectasis care

Action: Respiratory Therapy NCIT:C15322

Pulmonology-led care includes airway-clearance physiotherapy and individualized acute and long-term management of bronchiectasis. Imaging and clinical follow-up should reflect symptoms and existing disease severity.

Show evidence (1 reference)

PMID:22420014 SUPPORT Human Clinical

"physiotherapy and other acute and long-term medical management for bronchiectasis per pulmonologist"

GeneReviews explicitly includes pulmonary physiotherapy and specialist management.

Nutritional support for gastrointestinal disease

Action: Nutritional Support NCIT:C15433

Assess nutrition in patients with short bowel syndrome or malabsorption and address the underlying gastrointestinal condition. Hirschsprung disease and congenital megacolon require standard specialist management; persistent diarrhea warrants evaluation of infectious, inflammatory, and malabsorptive causes.

Show evidence (1 reference)

PMID:22420014 SUPPORT Human Clinical

"standard treatments for malignancies, congenital megacolon, Hirschsprung disease, and intestinal malabsorption; nutritional evaluation in those with short bowel syndrome;"

Supports gastrointestinal care and nutritional evaluation, without assuming a single cause of diarrhea.

Hormonal induction for delayed puberty

Action: Hormone Replacement Therapy NCIT:C15599

Assess pubertal development and investigate hypogonadism when puberty is delayed. Hormonal induction may be needed for pubertal maturation, according to endocrine evaluation.

Show evidence (1 reference)

PMID:22420014 SUPPORT Human Clinical

"hormonal induction as needed for pubertal maturation;"

GeneReviews describes conditional hormonal treatment, not universal therapy.

Sirolimus for anemia, single-case evidence

Action: Pharmacotherapy NCIT:C15986

Agent: Sirolimus NCIT:C1212

One patient with a clinical CHH diagnosis and ALPS-like immune dysregulation had improved anemia and erythroid colony growth during sirolimus treatment, deterioration after withdrawal, and improvement after restarting. Immune deficiency nevertheless progressed and ultimately required HSCT after cryptococcal meningoencephalitis. Both RMRP variants remained formally uncertain without functional validation, and somatic FAS disease was not excluded. This report is exploratory evidence, not an established CHH treatment or demonstration of a specific mTOR-mediated rescue mechanism.

Show evidence (2 references)

PMID:35663969 SUPPORT Human Clinical

"We report the case of a young girl presenting with transfusion-dependent erythropoietic failure and immunological features resembling autoimmune lymphoproliferative syndrome who responded well to empirical sirolimus."

A single uncontrolled case supports a possible treatment effect with substantial diagnostic and mechanistic limitations.

PMID:35663969 SUPPORT Human Clinical

"The patient eventually underwent a haploidentical bone marrow transplant due to progressive combined immunodeficiency manifested as cryptococcal meningoencephalitis."

The anemia response did not prevent progression of immune deficiency.

🔬

Diagnosis

Clinical and radiographic diagnosis

Diagnosis is established in a proband with characteristic clinical and radiographic findings. Metaphyseal changes may be absent in the first two years of life and some patients never show them, so normal radiographs do not exclude CHH.

skeletal radiography NCIT:C38101

Show evidence (2 references)

PMID:22420014 SUPPORT Human Clinical

"Diagnosis of a CHH-AD spectrum disorder is established in a proband with characteristic clinical and radiographic findings."

States the clinical and radiographic basis of diagnosis.

PMID:42170584 SUPPORT Human Clinical

"Some patients' radiographs show no signs of metaphyseal dysplasia despite evident short stature (19) or severe immunodeficiency"

Supports the caveat that radiographic normality does not exclude the diagnosis.

Molecular genetic testing

Identification of biallelic RMRP variants confirms the diagnosis and enables family studies, carrier testing and prenatal or preimplantation testing. Testing must specifically cover the non-coding gene including its promoter region, since standard exome capture may miss it; whole-genome sequencing, targeted panels fully covering RMRP, or copy-number assessment are the reliable options.

molecular genetic testing NCIT:C19770

Show evidence (2 references)

PMID:22420014 SUPPORT Human Clinical

"identification of biallelic pathogenic variants in RMRP by molecular genetic testing can confirm the diagnosis and allow for family studies"

Specifies the role of molecular testing relative to clinical diagnosis.

PMID:42170584 SUPPORT Human Clinical

"diagnostic approach can include whole-genome sequencing or targeted panels that fully capture the RMRP gene, including the promoter region, as well as copy number variation assessment"

Specifies the testing strategies that reliably cover a non-coding gene and its promoter.

Immunological assessment and surveillance

Baseline and serial assessment includes lymphocyte subsets and function, immunoglobulins, and age-appropriate vaccine responses. Immunophenotyping is one component of this broader evaluation. Laboratory abnormalities and clinical severity do not always align; progression can occur, including in adulthood, but is not universal.

Immunological Flow Cytometry NCIT:C113003

The ontology binding represents flow-cytometric immunophenotyping; proliferation, immunoglobulin and vaccine-response tests complement it.

Show evidence (3 references)

PMID:32506568 SUPPORT Human Clinical

"Regular follow-up by a multidisciplinary team should be implemented to address immune dysfunction in all patients with CHH, also in asymptomatic cases."

Directly supports assessing asymptomatic patients rather than testing on symptoms alone.

PMID:31379817 SUPPORT Human Clinical

"In conclusion, patients with CHH may develop adult-onset immunodeficiency or malignancy without preceding clinical symptoms of immune defect, warranting careful follow-up."

The prospective-cohort conclusion that makes lifelong surveillance the recommended model rather than symptom-triggered testing.

PMID:28284971 SUPPORT Human Clinical

"SAD may therefore be a marker of more severe disease and vaccine responses should be routinely studied after infancy."

Supports routine vaccine-response testing as part of immunological assessment.

Malignancy surveillance

Regular malignancy surveillance includes clinical and laboratory assessment and appropriate imaging. GeneReviews specifies annual examination and abdominal ultrasound every one to two years in children, with adult evaluation according to clinical needs. Follow-up continues beyond childhood because malignancy can develop without preceding clinical immune symptoms. Cohort observations support early detection but do not quantify the independent benefit of a particular screening schedule.

cancer screening NCIT:C15406

Show evidence (4 references)

PMID:22420014 SUPPORT Human Clinical

"Clinical and laboratory examination for manifestations of malignancy annually in children and as needed in adults; abdominal ultrasound every one to two years in children and as needed in adults."

States the surveillance schedule recorded here.

PMID:36211439 SUPPORT Human Clinical

"In almost all surviving lymphoma patients, the diagnosis was made either during routine follow-up or after evaluation for non-specific mild symptoms."

Survivors were often diagnosed during follow-up or evaluation of mild symptoms. This uncontrolled observation supports vigilance but does not estimate the survival benefit of screening.

PMID:36211439 SUPPORT Human Clinical

"Other CHH-related manifestations poorly predicted lymphoma development, implying that all CHH patients should be regularly screened for malignancy."

Supports universal rather than risk-stratified screening.

+ 1 more reference

Growth and musculoskeletal surveillance

Follow linear growth using CHH-specific curves and assess lower-limb joints and the spine clinically, with radiographs when indicated. The separate recommendation for routine annual spine radiography in anauxetic dysplasia should not be generalized to all patients with CHH.

X-Ray Imaging NCIT:C38101

Show evidence (1 reference)

PMID:22420014 SUPPORT Human Clinical

"Monitor growth using CHH-specific growth curves; clinical and (if warranted) radiographic examination of joints of the lower extremities and spine annually in childhood and as required in adulthood;"

Clinical monitoring and conditional radiography are recommended for the CHH spectrum.

Pregnancy and neonatal assessment

For an affected mother, GeneReviews advises considering planned cesarean delivery because of cephalopelvic disproportion. This differs from an unaffected mother carrying an affected fetus, for whom fetal CHH alone does not establish a cesarean indication. Prenatal short long bones can prompt genetic evaluation. Neonates require assessment for respiratory compromise, anemia, immune dysfunction and Hirschsprung disease; available neonatal frequencies come from a small retrospective Finnish cohort with incomplete records.

Show evidence (3 references)

PMID:22420014 SUPPORT Human Clinical

"Pregnancy management: Fetal growth is generally unaffected; therefore, planned cesarean section should be considered in term pregnancies in affected women due to cephalopelvic disproportion."

This recommendation concerns mothers who themselves have CHH, not all pregnancies with an affected fetus.

PMID:42063088 SUPPORT Human Clinical

"Abnormal growth was observed in prenatal ultrasound in 26/30 (87%) children."

Prenatal growth findings were frequent among children with available ultrasound records.

PMID:42063088 SUPPORT Human Clinical

"Indications for respiratory support included hypoventilation and pulmonary hypertension."

Supports planning for respiratory assessment; prematurity and other factors may contribute.

📊

Prevalence

Old Order Amish

Birth Prevalence 74.6 per 100,000 1–9 per 10,000 (births)

Estimated incidence of 1 in 1,340 births, the highest reported for any population; CHH is one of the classic Amish founder disorders, described by McKusick in the Old Order Amish of Lancaster County.

Show evidence (1 reference)

PMID:42170584 SUPPORT Human Clinical

"with an estimated incidence of 1 in 1,340 in Amish and 1 in 23,000 births in Finnish"

Direct source for the Amish birth incidence converted to the rate here.

Finland

Birth Prevalence 4.35 per 100,000 1–9 per 100,000 (births)

Estimated incidence of 1 in 23,000 births. CHH belongs to the Finnish disease heritage, and almost all Finnish patients carry the founder variant, which is why the Finnish cohort dominates the literature and why its figures should be read as founder-population figures rather than universal ones.

Show evidence (1 reference)

PMID:42170584 SUPPORT Human Clinical

"with an estimated incidence of 1 in 1,340 in Amish and 1 in 23,000 births in Finnish"

Direct source for the Finnish birth incidence converted to the rate here.

Old Order Amish

Carrier Frequency 5263.0 per 100,000 >1 in 1,000 (carriers)

Founder variant carrier rate of 1 in 19, reported alongside a Finnish carrier rate of 1 in 76.

Show evidence (1 reference)

PMID:42170584 SUPPORT Human Clinical

"The carrier rates of the founder variant are 1:19 and 1:76 among Amish and Finnish individuals, respectively"

Direct source for the Amish founder-variant carrier frequency.

🔀

Differential Diagnoses

Conditions with similar clinical presentations that must be differentiated from Cartilage-hair hypoplasia:

Anauxetic dysplasia MONDO:0011773

Overlapping Features The severe end of the same RMRP spectrum, reached by allele combinations producing the greatest loss of rRNA cleavage activity. It shares the molecular lesion but is skeletally far more severe and may include atlantoaxial subluxation and cognitive deficiency, while the hair, immune and haematologic features characteristic of CHH are not assumed to be present.

Distinguishing Features

Markedly more severe skeletal dysplasia, with the most pronounced short stature of the spectrum.
Atlantoaxial subluxation may be present in the newborn, which is not characteristic of CHH.
Cognitive deficiency may occur, which is not a feature of CHH.
Hair, immune and haematologic involvement is conditional rather than characteristic.

Show evidence (2 references)

PMID:17701897 SUPPORT Human Clinical

"Mutations in the RMRP gene lead to a wide spectrum of autosomal recessive skeletal dysplasias, ranging from the milder phenotypes metaphyseal dysplasia without hypotrichosis and cartilage hair hypoplasia (CHH) to the severe anauxetic dysplasia (AD)."

Places CHH and anauxetic dysplasia at different points of one allelic spectrum.

PMID:22420014 SUPPORT Human Clinical

"The most severe phenotype, AD, has the most pronounced skeletal phenotype, may be associated with atlantoaxial subluxation in the newborn, and may include cognitive deficiency."

Names the features that separate anauxetic dysplasia from CHH clinically.

Metaphyseal dysplasia without hypotrichosis Not Yet Curated MONDO:0009601

Overlapping Features The mild end of the same RMRP spectrum, distinguished from CHH by absence of hair involvement. Its status as a separate entity is doubtful: longitudinal follow-up of such individuals has revealed late-onset immune abnormalities typical of CHH, so the distinction may reflect age at assessment rather than a different disease.

Distinguishing Features

Absence of hypotrichosis, as reflected in the disease name.
Milder skeletal phenotype than CHH.
May be reclassified as CHH on longer follow-up once immune features emerge.

Show evidence (2 references)

PMID:17701897 SUPPORT Human Clinical

Places metaphyseal dysplasia without hypotrichosis at the mild end of the same spectrum as CHH.

PMID:42170584 SUPPORT Human Clinical

"However, the longitudinal follow-up of such individuals has revealed late-onset development of immune abnormalities typical for CHH."

Supports treating the distinction as provisional rather than a firm diagnostic boundary.

Schmid metaphyseal chondrodysplasia MONDO:0007983

Overlapping Features Autosomal dominant COL10A1-related metaphyseal dysplasia shares short stature and radiographic metaphyseal abnormalities with CHH. The absence of the characteristic extraskeletal manifestations of CHH helps distinguish it.

Distinguishing Features

Autosomal dominant COL10A1-related disease rather than autosomal recessive RMRP-related disease.
Metaphyseal dysplasia, especially of the proximal femur, without the characteristic extraskeletal manifestations of CHH.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK84550/pdf/Bookshelf_NBK84550.pdf SUPPORT REVIEW SYNTHESIS Human Clinical

"COL10A1 COL10A1-related metaphyseal dysplasia Schmid (See Schmid Metaphyseal Chondrodysplasia.) AD Short stature & radiographic metaphyseal abnormalities (metaphyseal dysplasia esp in proximal femur) resembling CHH No extraskeletal manifestations"

The GeneReviews differential table directly identifies the gene, inheritance, overlap and distinguishing features. Full-text PDF of the GeneReviews chapter, PMID:22420014.

Shwachman-Diamond syndrome MONDO:0009833

Overlapping Features Shwachman-Diamond syndrome overlaps with CHH through short stature, metaphyseal abnormalities, infections and anemia. Exocrine pancreatic insufficiency, neutropenia and poor weight gain are prominent distinguishing features; skeletal changes are usually milder.

Distinguishing Features

Exocrine pancreatic insufficiency and poor weight gain are principal manifestations.
Neutropenia is a principal hematologic feature.
Skeletal features are usually milder than in CHH.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK84550/pdf/Bookshelf_NBK84550.pdf SUPPORT REVIEW SYNTHESIS Human Clinical

"• Milder skeletal features (usually) • Principal manifestations: exocrine pancreatic insufficiency, neutropenia, poor weight gain, & growth deficiency"

The Shwachman-Diamond row in the GeneReviews differential table directly supports these distinctions. Full-text PDF of the GeneReviews chapter, PMID:22420014.

Dyskeratosis congenita MONDO:0015780

Overlapping Features Dyskeratosis congenita and related telomere biology disorders overlap with CHH through marrow failure, immune abnormalities, malignancy susceptibility and short telomeres. The classic mucocutaneous triad favors dyskeratosis congenita, whereas metaphyseal dysplasia and disproportionate short-limb stature favor CHH; neither diagnosis requires every characteristic finding.

Distinguishing Features

Classic mucocutaneous triad of dysplastic nails, reticular skin pigmentation and oral leukoplakia, which is not present in every patient.
Metaphyseal dysplasia and disproportionate short-limb stature favor CHH.
Caused by telomere maintenance genes rather than by RMRP.

Show evidence (2 references)

PMID:28126377 SUPPORT Human Clinical

"The CHH disease phenotype has some overlap with dyskeratosis congenita, a well-known "telomere disorder.""

Explicitly names the phenotypic overlap that makes this a mechanistically motivated differential.

PMID:20301779 SUPPORT REVIEW SYNTHESIS Human Clinical

"Classic DC is characterized by a triad of dysplastic nails, lacy reticular pigmentation of the upper chest and/or neck, and oral leukoplakia, although this may not be present in all individuals."

GeneReviews directly supports the classic distinguishing signs while acknowledging incomplete presentation.

📊

Related Datasets

RNA-seq of control and CHH fibroblasts transdifferentiated into chondrocyte-like cells arrayexpress:E-MTAB-10996

Bulk transcriptomes from four patient and four control fibroblast donors before and during chondrogenic transdifferentiation. The 24 samples represent repeated day 0, 1, and 3 measurements, not 24 independent donors.

human BULK RNA SEQ n=24 Illumina NextSeq

PMID:34988338

Show evidence (1 reference)

PMID:34988338 SUPPORT In Vitro

"Total RNA was isolated at three different time points during FDC transdifferentiation (Day 0, 1, and 3; in total 24 RNA samples) using the mirVana miRNA Isolation Kit (Thermo Fisher Scientific) according to the manufacturer's protocol."

Twenty-four culture samples derive from eight donors measured at three time points.

Transcriptomic analysis of CHH patient and control fibroblasts using STRT sequencing bioproject:PRJEB23608

RNA profiles from fibroblasts of five founder-variant patients and five matched controls across culture passages. The study retained 18 patient and 17 control samples after quality exclusions. Despite the STRT method name, each library used 10 ng of total RNA; this is not a single-cell transcriptomic atlas.

human BULK RNA SEQ

PMID:31551465

Show evidence (1 reference)

PMID:31551465 SUPPORT In Vitro

"Four samples (two case passages and two control passages) were excluded due to low 5′ capture rate, indicative of partial RNA degradation, leaving 18 and 17 acceptable samples for analysis, respectively (see Supplementary Table S3)."

The analytical sample counts are repeated culture passages from ten donors.

A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis [human] geo:GSE171019

Human K562 CRAC experiments identify RNAs interacting with tagged RNase MRP/P protein components after UV crosslinking. This is protein-RNA interaction profiling, not conventional transcript abundance RNA-seq.

human n=8

PMID:35115551

The human CRAC subseries of GSE171021. The same superseries also contains yeast experiments and a separate human RMRP SHAPE subseries.

A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis [RMRP_SHAPE] geo:GSE190787

In-cell SHAPE profiling of RMRP in wild-type and founder-variant cells with 1M7 or DMSO control. Targeted sequencing measures RNA modification sites to infer structure, rather than whole-transcriptome expression.

human n=12

PMID:35115551

A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis pride:PXD025029

Proteomic resource accompanying the engineered RMRP founder-variant cell study, including analyses of ribosome abundance and RNA-associated proteins.

human PROTEOMICS

PMID:35115551

🔬

Clinical Trials

NCT02383797 UNKNOWN

Phase 4, open-label, single-group VZV immunization study with five participants. Selection by disease severity and immune function limits applicability to patients without clinical immunodeficiency. The registry status was UNKNOWN on 2026-10-04; the last known status was active, not recruiting, with the last registry update in October 2019. Published results describe humoral and cellular responses, and one participant's rash and knee swelling that resolved without treatment. Publication of these results does not establish a current COMPLETED registry status.

Target Phenotypes: Severe varicella zoster infection HP:0032170 Decreased specific antibody response to vaccination HP:0032140

Show evidence (3 references)

clinicaltrials:NCT02383797 SUPPORT BACKGROUND Other

"The investigators will verify the development of immune response to vaccination by testing for VZV antibodies and cell-mediated immunity."

The registered protocol's stated objective, matching the immunization question this entry curates under live viral vaccination.

PMID:32849667 SUPPORT Human Clinical

"We conducted a clinical trial (ClinicalTrials.gov identifier: NCT02383797) of live VZV vaccine on five subjects with CHH who lacked varicella history, had no clinical symptoms of immunodeficiency, and were seronegative for VZV"

Ties the registered trial to its publication and states the enrolment criteria that scope its conclusion to mildly affected patients.

PMID:32849667 SUPPORT Human Clinical

"Clinical trial participants developed humoral and cellular responses to VZV vaccine. One trial participant developed post-immunization rash and knee swelling, both resolved without treatment."

Reports the trial outcome including its single adverse event; the evidence is limited because five participants cannot establish safety across the full CHH immune-deficiency spectrum.

🧫

Experimental Models

Rmrp-deficient ATDC5 chondrogenic cell model CELL_LINE

Rmrp RNA interference in mouse ATDC5 cultures impairs hypertrophic differentiation, matrix accumulation, and mineralization, alongside changes in pre-rRNA processing and rRNA abundance. The monolayer model does not reproduce growth-plate architecture or isolate one RNA substrate as the mediator.

Organism

mouse NCBITaxon:10090

Cell source

Mouse ATDC5 chondrogenic cell line

Culture

Monolayer chondrogenic differentiation culture with Rmrp RNA interference

Publication

PMID:28743979

Pathograph links

Growth Plate Chondrocyte Differentiation Failure recapitulates fidelity: moderate Measures chondrogenic differentiation and hypertrophy after Rmrp interference.

Limitations: A murine immortalized chondrogenic line in monolayer culture; it models the differentiation step but not growth-plate architecture, limb proportion, or any extraskeletal disease.

Readouts

Chondrogenic differentiation and hypertrophy

Direction: DECREASED

Interpretation: Cellular correlate of the growth-plate differentiation node.

Show evidence (1 reference)

PMID:28743979 SUPPORT In Vitro

Directly demonstrates the differentiation and hypertrophy defect.

Show evidence (1 reference)

PMID:28743979 SUPPORT In Vitro

Supports treating this model as informative for the growth-plate node.

Show evidence (1 reference)

PMID:28743979 SUPPORT In Vitro

Establishes the model, perturbation, molecular readout and cellular phenotype.

CHH patient-derived fibroblast cell-cycle and transcriptome model PRIMARY_CELL_CULTURE

Primary fibroblasts from five Finnish patients homozygous for the founder RMRP variant and five matched controls were assessed by RNA sequencing, pulse labeling, and time-lapse microscopy. Direct tracking localized the proliferation delay to G2-to-mitosis progression. Transcriptomic pathway associations do not establish the mechanism of disease in other tissues.

Organism

human NCBITaxon:9606

Cell source

Primary dermal fibroblasts from patients with cartilage-hair hypoplasia and healthy controls

Culture

Monolayer culture with pulse-labeling, time-lapse microscopy and RNA sequencing

Publication

PMID:31551465

Pathograph links

Delayed G2-to-M Progression recapitulates fidelity: moderate Directly measures cell-cycle progression and transcriptome changes in patient-derived cells carrying the disease genotype.

Limitations: Patient fibroblasts provide an accessible cellular phenotype, but they are not growth-plate, lymphocyte, or marrow cells. The study did not perform RMRP complementation, and multiple passages from each donor are repeated observations rather than independent patients.

Readouts

G2-to-mitosis transit time

Direction: INCREASED

Interpretation: Delayed passage from G2 into mitosis is the specific cell-cycle lesion this node asserts.

Show evidence (1 reference)

PMID:31551465 SUPPORT In Vitro

"Cell-cycle studies indicated that the CHH cells were delayed specifically in the passage from G2 phase to mitosis."

The direct measurement of the readout in patient cells.

Show evidence (1 reference)

PMID:31551465 SUPPORT In Vitro

"We combined transcriptome analysis with single-cell analysis using fibroblasts from CHH patients and healthy controls."

Establishes the model system and the two orthogonal measurement approaches.

Findings

CHH fibroblasts had 35 significantly upregulated and 130 downregulated genes; the downregulated set was enriched for cell-cycle functions.

"The downregulated genes were significantly connected to the cell cycle."

Show evidence (1 reference)

PMID:31551465 SUPPORT In Vitro

"Transcriptome analysis identified 35 significantly upregulated and 130 downregulated genes in CHH fibroblasts. The downregulated genes were significantly connected to the cell cycle."

The experimental result is quoted directly from the publication abstract.

Show evidence (1 reference)

PMID:31551465 SUPPORT In Vitro

"To directly assess cell cycle progression, we followed CHH fibroblasts by pulse-labeling and time-lapse microscopy."

Establishes the direct cell-cycle measurement rather than inference from static assays.

Patient bone marrow progenitor colony-forming assay PRIMARY_CELL_CULTURE

Colony assays in eight patients with CHH and a history of anemia demonstrate impaired myeloid progenitor function. Erythroid progenitor numbers were normal or increased under stronger stimulation, supporting a functional defect rather than depletion. Colony formation did not correlate with peripheral blood counts.

Organism

human NCBITaxon:9606

Cell source

Bone marrow and peripheral blood from patients with cartilage-hair hypoplasia

Culture

Semi-solid colony-forming assay for erythroid, megakaryocyte and granulocyte-macrophage progenitors

Publication

PMID:7895753

Pathograph links

Multilineage Bone Marrow Progenitor Failure recapitulates fidelity: high Measures colony formation across erythroid, megakaryocyte and granulocyte-macrophage lineages in patient-derived progenitors.

Limitations: Ex vivo culture in eight patients; the defect did not track peripheral blood counts, so it cannot serve as a severity readout for an individual patient.

Readouts

Erythroid, megakaryocyte and granulocyte-macrophage colony formation

Direction: DECREASED

Interpretation: Functional demonstration of the multilineage progenitor defect in patient cells.

Show evidence (1 reference)

PMID:7895753 SUPPORT In Vitro

"All patients showed decreased erythroid and megakaryocyte colony formation. Only one patient had a normal granulocyte-macrophage growth, while the others showed decreased numbers of colonies."

Reports the measured colony deficit across all three lineages.

Show evidence (1 reference)

PMID:7895753 SUPPORT In Vitro

"The present study shows defective in vitro colony formation in all myeloid lineages in patients with CHH, which is in accordance with the suggestion of a common cell proliferation defect in CHH."

Supports treating this assay as informative for the marrow-failure node.

Findings

Colony formation fails despite normal or increased progenitor numbers, identifying a functional proliferation defect rather than progenitor depletion.

"The impaired growth was not caused by a decreased number of progenitors as shown by erythroid cultures."

Show evidence (1 reference)

PMID:7895753 SUPPORT In Vitro

The experimental result is quoted directly from the publication abstract.

Show evidence (1 reference)

PMID:7895753 SUPPORT In Vitro

"In the present study erythroid, megakaryocyte, and granulocyte-macrophage colony formation in vitro by progenitors from bone marrow and blood was investigated in eight patients with CHH."

Establishes the model system, cell source and readout.

Patient fibroblast-derived chondrocyte transdifferentiation PRIMARY_CELL_CULTURE

Patient cells acquire a chondrocyte-like phenotype with impaired commitment to terminal differentiation. RNA sequencing and selected protein assays identify altered BMP, FGF, and IGF-1 pathway components.

Organism

human NCBITaxon:9606

Cell source

Dermal fibroblasts from four CHH patients and four control donors

Culture

High-density plating on aggrecan with TGF-beta3, ITS, and ascorbic acid; days 0, 1, and 3

Publication

PMID:34988338

Pathograph links

Growth Plate Chondrocyte Differentiation Failure partially recapitulates fidelity: moderate Patient cells acquire a chondrocyte-like phenotype with impaired commitment to terminal differentiation. RNA sequencing and selected protein assays identify altered BMP, FGF, and IGF-1 pathway components.

Limitations: Small donor cohort and short descriptive culture study. These are transdifferentiated fibroblasts, not primary growth-plate chondrocytes. COL10A1 reduction was not significant in this study, unlike the earlier experiment, and COL2A1 was not detected. Pathway causality requires functional perturbation.

Show evidence (2 references)

PMID:34988338 SUPPORT In Vitro

"We demonstrated that CHH fibroblasts are capable of transdifferentiating into chondrocyte-like cells, and show a reduced commitment to terminal differentiation."

The model retains chondrogenic capacity but has impaired terminal differentiation; it is not a complete failure to form chondrocytes.

+ 1 more reference

Show evidence (2 references)

PMID:34988338 SUPPORT In Vitro

"We demonstrated that CHH fibroblasts are capable of transdifferentiating into chondrocyte-like cells, and show a reduced commitment to terminal differentiation."

The model retains chondrogenic capacity but has impaired terminal differentiation; it is not a complete failure to form chondrocytes.

PMID:34988338 SUPPORT In Vitro

"The sample size presented in this study is limited to four individuals per group, however, considering the rarity of CHH it is a reasonable number."

The study used four patient and four control donors; repeated time points are not additional independent donors.

RMRP founder-variant K562 cells CELL_LINE

The founder substitution delays pre-rRNA processing and reduces mature rRNA and intact RNase MRP complex abundance. Total RMRP RNA is not significantly reduced, and the mature 5.8S short-to-long ratio is unchanged.

Organism

human NCBITaxon:9606

Cell source

K562 chronic myelogenous leukemia cells with CRISPR-engineered homozygous RMRP 70AG, compared with parental cells

Culture

Suspension culture; pre-rRNA analysis, FlowFISH, proteomics, RNA-protein interaction assays, and SHAPE RNA probing

Publication

PMID:35115551

Pathograph links

Impaired Pre-rRNA Processing partially recapitulates fidelity: moderate The founder substitution delays pre-rRNA processing and reduces mature rRNA and intact RNase MRP complex abundance. Total RMRP RNA is not significantly reduced, and the mature 5.8S short-to-long ratio is unchanged.

Limitations: An engineered malignant cell line tests one allele in a tractable system. It does not reproduce patient immune, cartilage, or hair phenotypes; clone-dependent effects were observed.

Show evidence (1 reference)

PMID:35115551 SUPPORT In Vitro

The engineered K562 founder-variant model links genotype to processing and ribosome abundance.

Show evidence (1 reference)

PMID:35115551 SUPPORT In Vitro

The engineered K562 founder-variant model links genotype to processing and ribosome abundance.

Rmrp-disrupted primary mouse T-cell cultures PRIMARY_CELL_CULTURE

Rmrp disruption impairs expansion of viable activated T cells and changes pre-rRNA precursor abundance.

Organism

mouse NCBITaxon:10090

Cell source

Naive antigen-specific OT-1 Rag-deficient mouse T cells isolated from peripheral lymph nodes

Culture

Ovalbumin-peptide activation followed by CRISPR electroporation at 24 hours and proliferation/pre-rRNA assays 48 hours later

Publication

PMID:35115551

Pathograph links

Impaired T-Lymphocyte Proliferation partially recapitulates fidelity: moderate Rmrp disruption impairs expansion of viable activated T cells and changes pre-rRNA precursor abundance.

Limitations: Ex vivo cultures contain heterogeneous CRISPR-generated alleles. This is not a whole-animal disease model, and guide-specific effects on proliferation and pre-rRNA accumulation were not fully concordant.

Show evidence (1 reference)

PMID:35115551 SUPPORT In Vitro

"This showed that disruption of RMRP markedly impaired T cell proliferation."

CRISPR perturbation was performed in activated primary mouse T-cell cultures, not in a viable whole-animal Rmrp knockout.

Show evidence (1 reference)

PMID:35115551 SUPPORT In Vitro

"This showed that disruption of RMRP markedly impaired T cell proliferation."

CRISPR perturbation was performed in activated primary mouse T-cell cultures, not in a viable whole-animal Rmrp knockout.

🐁

Animal Models

rmrp knockout zebrafish

Rmrp knockout zebrafish permit study of early chondrogenesis, ossification, cell proliferation and apoptosis, but survive only 12-14 days. Canonical Wnt/beta-catenin signaling is increased, and pharmacological inhibition partly alleviates skeletal abnormalities. This is preclinical developmental evidence; efficacy in mammalian CHH or patients has not been established.

Species

Zebrafish

Genotype

rmrp knockout

Publication

PMID:31237961

Pathograph links

Growth Plate Chondrocyte Differentiation Failure partially recapitulates fidelity: moderate Reproduces dysregulated chondrogenesis and abnormal ossification, and implicates Wnt/beta-catenin as a reversible effector.

Limitations: Zebrafish cartilage development differs architecturally from the mammalian endochondral growth plate, and the primary readouts are pharyngeal arch patterning and skull and vertebral ossification rather than long-bone metaphyseal growth; ossification effects are directionally mixed, being inhibited in skull and promoted in vertebrae, which has no clean human counterpart.

Readouts

Chondrogenesis and bone ossification

Direction: ALTERED

Interpretation: Whole-organism correlate of the cartilage differentiation node; ALTERED rather than DECREASED because ossification changed in opposite directions in different skeletal elements.

Show evidence (1 reference)

PMID:31237961 SUPPORT Model Organism

"Rmrp mutation inhibits the intramembranous ossification of skull bones and promotes vertebrae ossification. The abnormalities of endochondral bone ossification are variable, depending on the degree of dysregulated chondrogenesis."

Reports the cartilage and ossification phenotype, including its direction-dependence by skeletal element.

Show evidence (1 reference)

PMID:31237961 SUPPORT Model Organism

"We also demonstrate that rmrp mutation upregulates canonical Wnt/β-catenin signaling; the pharmacological inhibition of Wnt/β-catenin could partially alleviate the chondrodysplasia and increased vertebrae mineralization in rmrp mutants."

Pharmacological rescue supports the model being mechanistically informative rather than merely phenotypically similar.

Delayed G2-to-M Progression partially recapitulates fidelity: moderate Shows reduced proliferation and increased apoptosis, but does not resolve the G2-to-M delay measured in patient fibroblasts.

Limitations: Gene-expression-level evidence in a whole zebrafish embryo; it does not resolve the specific G2-to-M step identified in human patient cells.

Readouts

Reduced cell proliferation

Direction: DECREASED

Interpretation: A related proliferation phenotype, not a direct measurement of G2 transit time.

Show evidence (1 reference)

PMID:31237961 SUPPORT Model Organism

"Moreover, rmrp mutation inhibits cell proliferation and promotes apoptosis through dysregulating the expressions of cell-cycle- and apoptosis-related genes."

Reports the proliferation and apoptosis readouts in the model.

Increased apoptosis

Direction: INCREASED

Interpretation: A separate cell-death phenotype accompanying reduced proliferation; it does not directly establish G2 delay.

Show evidence (1 reference)

PMID:31237961 SUPPORT Model Organism

"Moreover, rmrp mutation inhibits cell proliferation and promotes apoptosis through dysregulating the expressions of cell-cycle- and apoptosis-related genes."

Reports the proliferation and apoptosis readouts in the model.

Show evidence (1 reference)

PMID:31237961 SUPPORT Model Organism

"Moreover, rmrp mutation inhibits cell proliferation and promotes apoptosis through dysregulating the expressions of cell-cycle- and apoptosis-related genes."

Supports treating the model as informative for the proliferation arm.

Show evidence (2 references)

PMID:31237961 SUPPORT Model Organism

"Currently, the pathogenesis of osteochondrodysplasia and extraskeletal manifestations in CHH patients remains incompletely understood; in addition, there are no viable animal models for CHH. We generated an rmrp KO zebrafish model to study the developmental mechanisms of CHH."

Describes generation of the model. The statement about absent viable models refers to the background preceding this experiment.

url:https://ern-ithaca.eu/wp-content/uploads/2020/12/Vakkilainen_CH_immnuo_ScandJImmuno2020.pdf SUPPORT REVIEW SYNTHESIS Model Organism

"The absence of RMRP expression was detrimental also in zebrafish as mu- tants survived only for 12-14 days; however, early develop - mental stages could be examined."

The review describes death in the larval period, limiting the developmental model to early stages. Full-text PDF of the management review, PMID:32506568.

{ }

Source YAML

click to show

name: Cartilage-hair hypoplasia
creation_date: "2026-08-14T00:00:00Z"
description: Cartilage-hair hypoplasia (CHH) is an autosomal recessive immuno-osseous dysplasia caused by biallelic variants in the noncoding RNA gene RMRP. Its variable manifestations include metaphyseal chondrodysplasia, disproportionate short stature, fine or sparse hair, immune dysfunction, anemia, Hirschsprung disease and increased malignancy risk. Promoter variants can reduce RNA expression, while transcribed-region variants can impair RNase MRP complex function. Studies demonstrate defective pre-rRNA processing, altered ribosome abundance and cell-proliferation defects; the contributions of mRNA turnover, small-RNA regulation and telomere homeostasis to individual tissues remain incompletely resolved. Immune dysfunction may become clinically apparent in adulthood, and malignancy can occur without preceding clinical immune symptoms.
category: Mendelian
parents:
- osteochondrodysplasia
- immuno-osseous dysplasia
- autosomal recessive disease
synonyms:
- CHH
- metaphyseal chondrodysplasia, McKusick type
- McKusick Type Metaphyseal Chondrodysplasia
- autosomal recessive metaphyseal chondrodysplasia
disease_term:
  preferred_term: cartilage-hair hypoplasia
  term:
    id: MONDO:0009595
    label: cartilage-hair hypoplasia
classifications:
  iuis_category:
    classification_value: combined immunodeficiency with syndromic features
    notes: >-
      IUIS phenotypic classification of inborn errors of immunity; CHH is a
      syndromic combined immunodeficiency, grouped with the immuno-osseous
      dysplasias rather than with the isolated combined immunodeficiencies.
    evidence:
    - reference: PMID:42170584
      reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Cartilage-hair hypoplasia (CHH) is a rare syndromic inborn error of immunity, caused by variants in the noncoding RNA gene RMRP."
      explanation: >-
        Names CHH as a syndromic inborn error of immunity, the basis for the
        syndromic-features assignment.
  isds_skeletal_category:
  - classification_value: metaphyseal_dysplasias
    notes: >-
      ISDS Nosology and Classification of Genetic Skeletal Disorders, 2019
      revision (Mortier et al., PMID:31633310), Table 1 group 11 "Metaphyseal
      dysplasias"; listed as cartilage-hair hypoplasia, the McKusick type
      metaphyseal chondrodysplasia.
inheritance:
- name: Autosomal recessive inheritance
  description: >-
    CHH is autosomal recessive, arising from biallelic variants in RMRP.
    Heterozygous carriers are asymptomatic and do not show the cellular
    proliferation defect, although telomerase activity is reduced in carriers in
    a gene-dose-dependent manner, so the carrier state is not entirely silent at
    every molecular level. Each sib of an affected individual has a 25%
    recurrence risk.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:32506568
    reference_title: "Immunodeficiency in cartilage-hair hypoplasia: Pathogenesis, clinical course and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cartilage-hair hypoplasia (CHH) is an autosomal recessive syndromic immunodeficiency with skeletal dysplasia, short stature, hypotrichosis, variable degree of immune dysfunction and increased incidence of anaemia, Hirschsprung disease and malignancy."
    explanation: >-
      States the autosomal recessive mode of inheritance alongside the defining
      multisystem phenotype.
  - reference: PMID:22420014
    reference_title: "Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "If both parents are known to be heterozygous for an RMRP pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier."
    explanation: >-
      GeneReviews recurrence risks used in counselling families.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "humans carrying pathogenic variants in a single allele remain asymptomatic (8, 64) and do not demonstrate cell proliferation defects (42)"
    explanation: >-
      Establishes that heterozygous carriers are unaffected at both the clinical
      and the cellular proliferation level.
  - reference: PMID:28126377
    reference_title: "Defects in lymphocyte telomere homeostasis contribute to cellular immune phenotype in patients with cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Notably, telomerase activity is affected in a gene dose-dependent manner when comparing heterozygote RMRP carriers with patients with CHH."
    explanation: >-
      Shows a measurable intermediate molecular phenotype in carriers who remain clinically well, qualifying the clinical recessive pattern.
prevalence:
- population: Old Order Amish
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_5_PER_10000
  rate_per_100000: 74.6
  notes: >-
    Estimated incidence of 1 in 1,340 births, the highest reported for any
    population; CHH is one of the classic Amish founder disorders, described by
    McKusick in the Old Order Amish of Lancaster County.
  evidence:
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "with an estimated incidence of 1 in 1,340 in Amish and 1 in 23,000 births in Finnish"
    explanation: >-
      Direct source for the Amish birth incidence converted to the rate here.
- population: Finland
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 4.35
  notes: >-
    Estimated incidence of 1 in 23,000 births. CHH belongs to the Finnish
    disease heritage, and almost all Finnish patients carry the founder variant,
    which is why the Finnish cohort dominates the literature and why its figures
    should be read as founder-population figures rather than universal ones.
  evidence:
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "with an estimated incidence of 1 in 1,340 in Amish and 1 in 23,000 births in Finnish"
    explanation: >-
      Direct source for the Finnish birth incidence converted to the rate here.
- population: Old Order Amish
  measure_type: CARRIER_FREQUENCY
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 5263.0
  notes: >-
    Founder variant carrier rate of 1 in 19, reported alongside a Finnish
    carrier rate of 1 in 76.
  evidence:
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The carrier rates of the founder variant are 1:19 and 1:76 among Amish and Finnish individuals, respectively"
    explanation: >-
      Direct source for the Amish founder-variant carrier frequency.
pathophysiology:
- name: RMRP Promoter Expansion
  biological_scale: MOLECULAR
  description: Insertions, duplications, and triplications between the RMRP TATA box and transcription start site can impair promoter function. These are regulatory alleles of a noncoding RNA gene. CHH requires an affected second allele; a promoter allele may be paired with a transcribed-region allele, and surviving patients with biallelic promoter variants have been reported.
  evidence:
  - reference: PMID:11207361
    reference_title: Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Insertion mutations immediately upstream of the coding sequence silence transcription while mutations in the transcribed region do not.
    explanation: The original functional study distinguished upstream insertion effects on transcription from the tested transcribed-region variants. Its reference to coding sequence means the transcribed noncoding RNA, not a protein-coding region.
  - reference: PMID:37115363
    reference_title: Homozygous RMRP Promoter Duplications Cause Severely Reduced Transcript Abundance and SCID Associated with Cartilage Hair Hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This study provides further evidence that homozygous RMRP promoter duplications reduce but do not abrogate transcript expression and are not universally embryonically lethal.
    explanation: The homozygous promoter-duplication case refutes universal embryonic lethality of this allele class.
  genes:
  - preferred_term: RMRP
    term:
      id: hgnc:10031
      label: RMRP
  genetic_context:
    gene:
      preferred_term: RMRP
      term:
        id: hgnc:10031
        label: RMRP
    allele_type: promoter insertions, duplications, or triplications
    affected_regions:
    - name: RMRP promoter between TATA box and transcription start site
      regulatory_element_type: PROMOTER
    functional_impact_category: LOSS_OF_FUNCTION
    description: One or both disease-associated alleles affect promoter spacing; an isolated heterozygous carrier state is not sufficient for CHH.
  downstream:
  - target: Reduced RMRP Transcript Abundance
    causal_link_type: DIRECT
    description: Promoter spacing alterations impair transcription in functional assays; reduced transcript abundance was also observed in a homozygous promoter-duplication patient.
    evidence:
    - reference: PMID:11207361
      reference_title: Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Insertion mutations immediately upstream of the coding sequence silence transcription while mutations in the transcribed region do not.
      explanation: The original functional study distinguished upstream insertion effects on transcription from the tested transcribed-region variants. Its reference to coding sequence means the transcribed noncoding RNA, not a protein-coding region.
    - reference: PMID:37115363
      reference_title: Homozygous RMRP Promoter Duplications Cause Severely Reduced Transcript Abundance and SCID Associated with Cartilage Hair Hypoplasia.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The patient was found to have severely reduced RMRP transcript abundance (P < 0.01)
      explanation: Transcript quantification in a patient with a homozygous promoter duplication supports reduced RNA abundance. A single blood-derived measurement does not establish the expression pattern in every tissue.
- name: Reduced RMRP Transcript Abundance
  biological_scale: MOLECULAR
  description: Reduced availability of the RMRP RNA is one route to functional deficiency, particularly for promoter expansion alleles. The measured reduction in a promoter-duplication patient does not distinguish expression changes across all tissues from cell-type-specific effects. Transcribed-region variants need not reduce total RNA abundance.
  evidence:
  - reference: PMID:37115363
    reference_title: Homozygous RMRP Promoter Duplications Cause Severely Reduced Transcript Abundance and SCID Associated with Cartilage Hair Hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The patient was found to have severely reduced RMRP transcript abundance (P < 0.01)
    explanation: Transcript quantification in a patient with a homozygous promoter duplication supports reduced RNA abundance. A single blood-derived measurement does not establish the expression pattern in every tissue.
  genes:
  - preferred_term: RMRP
    term:
      id: hgnc:10031
      label: RMRP
  downstream:
  - target: RMRP Non-Coding RNA Loss of Function
    causal_link_type: DIRECT
    description: Reduced availability of the RNA component limits RMRP-dependent activity. The amount of residual RNA and the consequences in individual tissues depend on the alleles.
    evidence:
    - reference: PMID:11207361
      reference_title: Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Insertion mutations immediately upstream of the coding sequence silence transcription while mutations in the transcribed region do not.
      explanation: The original functional study distinguished upstream insertion effects on transcription from the tested transcribed-region variants. Its reference to coding sequence means the transcribed noncoding RNA, not a protein-coding region.
- name: RMRP Transcribed-Region Variants
  biological_scale: MOLECULAR
  description: Pathogenic substitutions and small sequence alterations affect the transcribed noncoding RNA. They may alter RNA structure or interactions rather than change a protein sequence. The founder variant is n.71A>G on NR_003051.3, termed 70AG in older functional literature. The consequences of this experimentally studied allele should not be assigned to all transcribed-region variants.
  evidence:
  - reference: PMID:17701897
    reference_title: Type and level of RMRP functional impairment predicts phenotype in the cartilage hair hypoplasia-anauxetic dysplasia spectrum.
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: Mapping of nucleotide conservation to the two-dimensional structure of the RMRP gene revealed that disease-causing mutations either affect evolutionarily conserved nucleotides or are likely to alter secondary structure through mispairing in stem regions.
    explanation: Sequence and structural analysis supports disruption of conserved RNA features; it does not demonstrate the same molecular defect for every allele.
  - reference: PMID:35115551
    reference_title: A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Moreover, the 70AG mutation caused a reduction in intact RNase MRP complexes.
    explanation: Engineered K562 cells carrying the founder substitution showed reduced intact complex abundance; this result is not assumed for every RMRP allele.
  genes:
  - preferred_term: RMRP
    term:
      id: hgnc:10031
      label: RMRP
  genetic_context:
    gene:
      preferred_term: RMRP
      term:
        id: hgnc:10031
        label: RMRP
    allele_type: pathogenic substitutions and small alterations of the RMRP transcript
    genomic_contexts:
    - noncoding exon
    functional_impact_category: LOSS_OF_FUNCTION
    description: Homozygous or compound-heterozygous disease genotypes affect a noncoding RNA; protein missense terminology does not apply.
  downstream:
  - target: Reduced Intact RNase MRP Complex
    causal_link_type: DIRECT
    description: The founder substitution reduces intact complex abundance in engineered cells despite preserved total RMRP levels.
    evidence:
    - reference: PMID:35115551
      reference_title: A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Moreover, the 70AG mutation caused a reduction in intact RNase MRP complexes.
      explanation: Engineered K562 cells carrying the founder substitution showed reduced intact complex abundance; this result is not assumed for every RMRP allele.
- name: Reduced Intact RNase MRP Complex
  biological_scale: MOLECULAR
  description: Engineered K562 cells homozygous for the founder substitution have less intact RNase MRP complex and reduced RNA association of POP1 and RPP38. Total RMRP abundance is preserved, and SHAPE probing shows subtle local flexibility changes rather than extensive RNA refolding. Impaired complex stability is supported for this allele and cell system; the exact structural mechanism remains unresolved.
  evidence:
  - reference: PMID:35115551
    reference_title: A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Moreover, the 70AG mutation caused a reduction in intact RNase MRP complexes.
    explanation: Engineered K562 cells carrying the founder substitution showed reduced intact complex abundance; this result is not assumed for every RMRP allele.
  - reference: PMID:35115551
    reference_title: A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Levels of POP1 and RMRP are maintained in 70AG cells, so the reduced POP1 recovery in TRAPP indicates that the mutation likely destabilizes the POP1:RMRP interaction.
    explanation: RNA-associated proteomics with preserved total RNA and protein levels supports impaired complex stability. The precise structural change remains an interpretation of the assays.
    directness: INDIRECT
  genes:
  - preferred_term: RMRP
    term:
      id: hgnc:10031
      label: RMRP
  downstream:
  - target: RMRP Non-Coding RNA Loss of Function
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Reduced intact complex abundance provides a proximal explanation for impaired RNase MRP activity in the founder-variant model.
    evidence:
    - reference: PMID:35115551
      reference_title: A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Levels of POP1 and RMRP are maintained in 70AG cells, so the reduced POP1 recovery in TRAPP indicates that the mutation likely destabilizes the POP1:RMRP interaction.
      explanation: RNA-associated proteomics with preserved total RNA and protein levels supports impaired complex stability. The precise structural change remains an interpretation of the assays.
      directness: INDIRECT
- name: RMRP Non-Coding RNA Loss of Function
  biological_scale: MOLECULAR
  description: RMRP encodes the untranslated RNA component of RNase MRP. Disease-associated alleles reduce RNA availability or impair RNA-dependent function by allele-specific mechanisms. Promoter effects and impaired complex stability are distinct routes. Complete RMRP deficiency is lethal in experimental models, but these observations do not establish that every human disease allele retains activity or that all biallelic promoter variants are lethal.
  genes:
  - preferred_term: RMRP
    term:
      id: hgnc:10031
      label: RMRP
  evidence:
  - reference: PMID:11207361
    reference_title: Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We describe numerous mutations in the untranslated RMRP gene that cosegregate with the CHH phenotype.
    explanation: The original identification of RMRP as the CHH gene and of the gene product as an untranslated RNA.
  - reference: PMID:35115551
    reference_title: A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Moreover, the 70AG mutation caused a reduction in intact RNase MRP complexes.
    explanation: Engineered K562 cells carrying the founder substitution showed reduced intact complex abundance; this result is not assumed for every RMRP allele.
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: This, together with failure to produce RMRP knockout yeast or mice, suggests that RMRP expression might exhibit a dose-dependent phenotype correlation and that complete RMRP deficiency is lethal.
    explanation: Reviews model-organism evidence for essentiality. This is indirect evidence about the viability of complete deficiency in humans.
    quote_role: REVIEW_SYNTHESIS
    directness: INDIRECT
  downstream:
  - target: Impaired Pre-rRNA Processing
    description: RMRP dysfunction delays pre-rRNA processing in engineered cells and patient-derived fibroblasts.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:35115551
      reference_title: A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Patient-derived human fibroblasts with CHH-linked mutations showed similar pre-rRNA processing delay.
      explanation: Links CHH-associated RMRP dysfunction to a measured pre-rRNA processing defect in primary patient cells.
  - target: Delayed G2-to-M Progression
    description: Founder-variant patient fibroblasts show delayed mitotic entry. The experiments did not isolate a single causal transcript or demonstrate rescue by restoring RMRP.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:31551465
      reference_title: The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Cell-cycle studies indicated that the CHH cells were delayed specifically in the passage from G2 phase to mitosis.
      explanation: Measures G2 delay in patient-derived fibroblasts; intermediates between the genotype and this cellular phenotype remain incompletely defined.
      directness: INDIRECT
  - target: Impaired Telomere Maintenance
    description: Patient lymphocytes exhibit impaired telomere homeostasis, but the mechanism linking RMRP variants to telomerase deficiency is unresolved. The TERT-RMRP complex has RNA-dependent RNA polymerase activity and is not the telomerase holoenzyme.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:28126377
      reference_title: Defects in lymphocyte telomere homeostasis contribute to cellular immune phenotype in patients with cartilage-hair hypoplasia.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Here we show that telomere length and telomerase activity are impaired in primary lymphocyte subsets from patients with CHH.
      explanation: Links the CHH genotype to the measured phenotype without establishing the molecular route.
      directness: INDIRECT
  - target: Reduced RMRP-Derived Small RNA Abundance
    description: Patient-derived cell lines have reduced RMRP-derived small RNAs; how different alleles affect their production or stability remains uncertain.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:24009312
      reference_title: Small RNAs derived from lncRNA RNase MRP have gene-silencing activity relevant to human cartilage-hair hypoplasia.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: RMRP-S1 and -S2 are significantly reduced in two fibroblast cell lines and a B-cell line derived from CHH patients.
      explanation: Demonstrates reduced small-RNA abundance in patient cells, without resolving the allele-specific mechanism.
      directness: INDIRECT
  - target: Intestinal Enteropathy
    description: Gastrointestinal manifestations are associated with biallelic RMRP disease; the intervening mechanisms have not been demonstrated.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:30410491
      reference_title: A Wide Spectrum of Autoimmune Manifestations and Other Symptoms Suggesting Immune Dysregulation in Patients With Cartilage-Hair Hypoplasia.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The presence of DVA in three subjects with negative celiac screen underscores the necessity for systematic endoscopic evaluation of CHH individuals with gastrointestinal complaints.
      explanation: A small number of patients had duodenal villous atrophy without positive celiac testing; this does not establish autoimmune enteropathy in all patients with diarrhea.
  - target: Impaired RNase MRP-Dependent mRNA Turnover
    description: Reduced Rmrp activity alters the abundance of mRNA substrates in experimental cells; the effects depend on allele and cellular context.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:28743979
      reference_title: Expression of RMRP RNA is regulated in chondrocyte hypertrophy and determines chondrogenic differentiation.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Reduced Rmrp RNA levels indeed resulted in elevated levels of RNase MRP substrates Clb2 and Viperin mRNAs, as well as an accumulation of an ITS1 pre-rRNA processing intermediate.
      explanation: Rmrp knockdown in mouse ATDC5 cultures increased substrate transcript abundance. Transcript abundance supports impaired turnover but does not by itself measure direct cleavage kinetics.
  - target: Reduced Thymic T-Cell Output
    description: CHH is associated with reduced thymic output; the intervening molecular steps are incompletely defined.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:21570718
      reference_title: Reduced thymic output, cell cycle abnormalities, and increased apoptosis of T lymphocytes in patients with cartilage-hair hypoplasia.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: As shown in Fig 2, both the absolute and relative numbers of RTEs were significantly reduced in the patients with CHH, regardless of their age, compared with published normal values.
      explanation: Reduced recent thymic emigrants support decreased thymic output, including in patients without significant clinical infections.
  - target: Increased Activation-Induced T-Cell Death
    description: Patient RMRP genotypes are associated with increased activation-induced lymphocyte death; the responsible molecular mediator is unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:21570718
      reference_title: Reduced thymic output, cell cycle abnormalities, and increased apoptosis of T lymphocytes in patients with cartilage-hair hypoplasia.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: As shown in Fig 6, the percentage of both early and late apoptotic cells was increased in patients with CHH versus healthy controls, reaching a statistically significant difference for late apoptotic/necrotic cells on culture with anti-CD3 mAb 1 IL-2
      explanation: Annexin-V/7-AAD assays measured increased activation-associated cell death in patient lymphocyte cultures; significance depended on the assay condition.
  - target: Malignancy Predisposition
    description: Biallelic RMRP disease is associated with increased cancer risk, through unresolved immune and cell-intrinsic pathways.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:18698627
      reference_title: Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confirms high incidence of non-Hodgkin lymphoma and basal cell carcinoma.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: During the follow-up (2,365 person-years; mean 19.2 years), 14 cases of cancer were diagnosed in the CHH cohort (expected number 2.0; SIR 7.0, CI 3.8-12). Non-Hodgkin lymphoma was the most frequent cancer type (n = 9; SIR 90.2, CI 39.0-180)
      explanation: Registry-based quantification of the overall and lymphoma-specific excess risk against population expectation.
    - reference: PMID:36211439
      reference_title: Lymphomas in cartilage-hair hypoplasia - A case series of 16 patients reveals advanced stage DLBCL as the most common form.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The mechanism by which the RMRP variants in CHH predispose to malignancies is unknown.
      explanation: The lymphoma series explicitly retains uncertainty about the molecular mechanism.
      directness: INDIRECT
      quote_role: BACKGROUND
  - target: Enteric Aganglionosis
    description: Hirschsprung disease is associated with CHH, with no established sequence of molecular intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:42170584
      reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Hirschsprung’s disease (HD) is a well-known comorbidity of CHH, although the pathogenetic link between RMRP deficiency and HD remains unknown.
      explanation: The association is established, while the mechanistic link is unresolved.
      quote_role: REVIEW_SYNTHESIS
  - target: Multilineage Bone Marrow Progenitor Failure
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Functional marrow progenitor impairment is observed in CHH; its molecular intermediates and relationship to peripheral blood counts remain unresolved.
    evidence:
    - reference: PMID:7895753
      reference_title: Defective in-vitro colony formation of haematopoietic progenitors in patients with cartilage-hair hypoplasia and history of anaemia.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: The present study shows defective in vitro colony formation in all myeloid lineages in patients with CHH, which is in accordance with the suggestion of a common cell proliferation defect in CHH.
      explanation: Establishes that the marrow defect spans lineages and is read by the authors as the same proliferation defect seen elsewhere.
- name: Impaired Pre-rRNA Processing
  biological_scale: MOLECULAR
  description: RNase MRP dysfunction delays processing of pre-rRNA in ITS1. Patient-derived fibroblasts and engineered founder-variant K562 cells show altered precursor ratios consistent with reduced site-2 cleavage. In the engineered cells, the ratio of mature short to long 5.8S rRNA is unchanged; older qPCR findings of extended species may instead reflect accumulated precursors. The findings support a processing defect without requiring the same precursor profile in every cell type.
  biological_processes:
  - preferred_term: rRNA processing
    term:
      id: GO:0006364
      label: rRNA processing
    modifier: DECREASED
  evidence:
  - reference: PMID:35115551
    reference_title: A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Human cells engineered with the most common CHH mutation (70AG in RMRP) show specifically impaired pre-rRNA processing, resulting in reduced mature rRNA and a reduced ratio of cytosolic to mitochondrial ribosomes.
    explanation: Engineered founder-variant cells show impaired processing and a reduced cytosolic-to-mitochondrial ribosome ratio; this does not demonstrate altered composition of individual ribosomes.
  - reference: PMID:35115551
    reference_title: A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Patient-derived human fibroblasts with CHH-linked mutations showed similar pre-rRNA processing delay.
    explanation: Confirms the processing delay in primary patient cells rather than only in engineered or cancer-derived lines.
  - reference: PMID:35115551
    reference_title: A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: However, the 5.8SS to 5.8SL ratio was the same in parental and 70AG cells, at approximately 1.25
    explanation: The mature 5.8S isoform ratio was unchanged in this model, qualifying extrapolation from yeast or older precursor assays.
  downstream:
  - target: Reduced Cytosolic Ribosome Abundance
    causal_link_type: DIRECT
    description: Impaired precursor maturation reduces ribosome production in the founder-variant cell model.
    evidence:
    - reference: PMID:35115551
      reference_title: A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Human cells engineered with the most common CHH mutation (70AG in RMRP) show specifically impaired pre-rRNA processing, resulting in reduced mature rRNA and a reduced ratio of cytosolic to mitochondrial ribosomes.
      explanation: Connects the processing defect to lower mature rRNA and a reduced cytosolic-to-mitochondrial ribosome ratio in engineered cells.
- name: Reduced Cytosolic Ribosome Abundance
  biological_scale: MOLECULAR
  description: Founder-variant K562 cells have reduced per-cell mature rRNA and a reduced ratio of cytosolic to mitochondrial ribosomes. RNA-associated proteomics and total-proteome measurements support this finding. These are measurements of abundance and relative pools, not proof of a changed protein composition of each ribosome. High biosynthetic demand is a candidate explanation for tissue vulnerability rather than an established account of all CHH manifestations.
  evidence:
  - reference: PMID:35115551
    reference_title: A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Human cells engineered with the most common CHH mutation (70AG in RMRP) show specifically impaired pre-rRNA processing, resulting in reduced mature rRNA and a reduced ratio of cytosolic to mitochondrial ribosomes.
    explanation: Connects the processing defect to lower mature rRNA and a reduced cytosolic-to-mitochondrial ribosome ratio in engineered cells.
  biological_processes:
  - preferred_term: ribosome biogenesis
    term:
      id: GO:0042254
      label: ribosome biogenesis
    modifier: DECREASED
  downstream:
  - target: Impaired T-Lymphocyte Proliferation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Reduced ribosome production may restrict expansion of activated T cells. Ex vivo Rmrp disruption shows both defects; the study did not perform an isolated ribosome rescue.
    evidence:
    - reference: PMID:35115551
      reference_title: A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Overall, these results support the model that disruption of RMRP impairs T cell proliferation by slowing pre-rRNA processing.
      explanation: Evidence comes from CRISPR-treated primary mouse T-cell cultures, not a whole-animal CHH model.
      directness: INDIRECT
  - target: Growth Plate Chondrocyte Differentiation Failure
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Allele-level correlations between rRNA cleavage impairment and skeletal severity support a role for ribosome dysfunction, while tissue-specific intermediates remain unresolved.
    evidence:
    - reference: PMID:17701897
      reference_title: Type and level of RMRP functional impairment predicts phenotype in the cartilage hair hypoplasia-anauxetic dysplasia spectrum.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: In vitro testing of RNase MRP multiprotein-specific mRNA and rRNA cleavage of different mutations revealed a strong correlation between the decrease in rRNA cleavage in ribosomal assembly and the degree of bone dysplasia
      explanation: Correlates functional assay results with skeletal severity across alleles; it is not a direct demonstration of the intervening chondrocyte mechanism.
      directness: INDIRECT
- name: Impaired RNase MRP-Dependent mRNA Turnover
  biological_scale: MOLECULAR
  description: RNase MRP has reported mRNA-processing functions in addition to pre-rRNA processing. Rmrp knockdown increases cyclin B2 and viperin transcript abundance in ATDC5 cells. Functional studies across RMRP alleles associate impaired mRNA cleavage with extraskeletal features. The contribution of individual substrates to patient lymphocyte, marrow, and hair abnormalities remains unresolved; these findings do not identify cyclin B2 as the proven cause of the separately measured G2 delay in patient fibroblasts.
  evidence:
  - reference: PMID:28743979
    reference_title: Expression of RMRP RNA is regulated in chondrocyte hypertrophy and determines chondrogenic differentiation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Reduced Rmrp RNA levels indeed resulted in elevated levels of RNase MRP substrates Clb2 and Viperin mRNAs, as well as an accumulation of an ITS1 pre-rRNA processing intermediate.
    explanation: Rmrp knockdown in mouse ATDC5 cultures increased substrate transcript abundance. Transcript abundance supports impaired turnover but does not by itself measure direct cleavage kinetics.
  - reference: PMID:17701897
    reference_title: Type and level of RMRP functional impairment predicts phenotype in the cartilage hair hypoplasia-anauxetic dysplasia spectrum.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: We recently demonstrated that mutations may affect both messenger RNA (mRNA) and ribosomal RNA (rRNA) cleavage and thus cell-cycle regulation and protein synthesis.
    explanation: The functional study distinguishes mRNA and rRNA processing effects across the CHH-anauxetic dysplasia spectrum.
- name: Delayed G2-to-M Progression
  biological_scale: CELLULAR
  description: Fibroblasts from five adults homozygous for the founder RMRP variant proliferate slowly and are delayed before mitotic entry. EdU labeling and time-lapse imaging localized the delay to G2; S-phase and mitotic duration were largely preserved, without excess cell death. Transcriptomics implicates multiple cell-cycle regulators. These observations do not establish impaired cyclin B2 RNA cleavage as the specific cause of the G2 delay.
  biological_processes:
  - preferred_term: G2/M transition of mitotic cell cycle
    term:
      id: GO:0000086
      label: G2/M transition of mitotic cell cycle
    modifier: DECREASED
  evidence:
  - reference: PMID:31551465
    reference_title: The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Cell-cycle studies indicated that the CHH cells were delayed specifically in the passage from G2 phase to mitosis.
    explanation: Direct measurement in patient-derived cells localizing the block to the G2-to-M transition, which is what this node asserts.
  - reference: PMID:31551465
    reference_title: The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Transcriptome analysis identified 35 significantly upregulated and 130 downregulated genes in CHH fibroblasts. The downregulated genes were significantly connected to the cell cycle.
    explanation: Differential expression analysis of patient fibroblast RNA sequencing supports cell-cycle dysregulation; enrichment does not prove a specific causal step.
  - reference: PMID:31551465
    reference_title: The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2.
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: Multiple other pathways, involving regulation of apoptosis, bone and cartilage formation, and lymphocyte function, were also affected, as well as PI3K-Akt signaling.
    explanation: Pathway enrichment generates hypotheses about affected programs rather than demonstrating their functional activation in each clinical tissue.
  downstream:
  - target: Impaired T-Lymphocyte Proliferation
    description: Reduced proliferation is a proposed contributor to this manifestation, but the fibroblast G2 experiment does not establish the causal chain in the affected tissue.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:31551465
      reference_title: The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: A generalized defect in cell proliferation has been speculated to explain several of the clinical manifestations, including disorganized growth-plate chondrocyte maturation, hair hypoplasia, immunodeficiency and impaired spermatogenesis
      explanation: The source explicitly presents this tissue-level extension as a hypothesis.
      quote_role: BACKGROUND
      directness: INDIRECT
  - target: Abnormal Hair Production
    description: Reduced proliferation is a proposed contributor to this manifestation, but the fibroblast G2 experiment does not establish the causal chain in the affected tissue.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:31551465
      reference_title: The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: A generalized defect in cell proliferation has been speculated to explain several of the clinical manifestations, including disorganized growth-plate chondrocyte maturation, hair hypoplasia, immunodeficiency and impaired spermatogenesis
      explanation: The source explicitly presents this tissue-level extension as a hypothesis.
      quote_role: BACKGROUND
      directness: INDIRECT
  - target: Growth Plate Chondrocyte Differentiation Failure
    description: Reduced proliferation is a proposed contributor to this manifestation, but the fibroblast G2 experiment does not establish the causal chain in the affected tissue.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:31551465
      reference_title: The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: A generalized defect in cell proliferation has been speculated to explain several of the clinical manifestations, including disorganized growth-plate chondrocyte maturation, hair hypoplasia, immunodeficiency and impaired spermatogenesis
      explanation: The source explicitly presents this tissue-level extension as a hypothesis.
      quote_role: BACKGROUND
      directness: INDIRECT
  - target: Abnormal spermatogenesis
    description: Reduced proliferation is a proposed contributor to this manifestation, but the fibroblast G2 experiment does not establish the causal chain in the affected tissue.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:31551465
      reference_title: The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: A generalized defect in cell proliferation has been speculated to explain several of the clinical manifestations, including disorganized growth-plate chondrocyte maturation, hair hypoplasia, immunodeficiency and impaired spermatogenesis
      explanation: The source explicitly presents this tissue-level extension as a hypothesis.
      quote_role: BACKGROUND
      directness: INDIRECT
- name: Impaired Telomere Maintenance
  biological_scale: MOLECULAR
  description: Patient lymphocyte subsets show shortened telomeres and reduced telomerase activity. Normal relative transcript levels for telomerase components did not explain the activity defect. The mechanism remains unidentified. RMRP binding to TERT in some cell lines forms an RNA-dependent RNA polymerase complex and does not establish a direct role in the telomerase holoenzyme. A separate case-control study found shorter telomeres particularly in children, without an association between relative telomere length and clinical or laboratory features within CHH.
  biological_processes:
  - preferred_term: telomere maintenance
    term:
      id: GO:0000723
      label: telomere maintenance
    modifier: DECREASED
  evidence:
  - reference: PMID:28126377
    reference_title: Defects in lymphocyte telomere homeostasis contribute to cellular immune phenotype in patients with cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Here we show that telomere length and telomerase activity are impaired in primary lymphocyte subsets from patients with CHH.
    explanation: Direct measurement of both telomere length and telomerase activity in patient lymphocytes.
  - reference: PMID:28126377
    reference_title: Defects in lymphocyte telomere homeostasis contribute to cellular immune phenotype in patients with cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Telomerase deficiency in patients with CHH is not mediated by abnormal telomerase gene transcript levels relative to those of endogenous genes.
    explanation: The measured relative transcript levels did not explain the activity defect; the result does not identify its mechanism.
  - reference: PMID:27986801
    reference_title: Decreased telomere length in children with cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Compared with age-matched and sex-matched healthy controls, median RTL was significantly shorter in patients with CHH (n=40 pairs, 1.05 vs 1.21, p=0.017), but not in mutation carriers (n=48 pairs, 1.16 vs 1.10, p=0.224).
    explanation: Independent quantification of telomere shortening in a larger patient cohort.
  - reference: PMID:27986801
    reference_title: Decreased telomere length in children with cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In patients with CHH, RTL showed no correlation with genotype, clinical or laboratory characteristics.
    explanation: 'Retained negative result: the telomere arm is real at the population level but does not explain individual clinical variation.'
  downstream:
  - target: Short telomere length
    description: Connects the molecular arm to its directly measured clinical correlate.
    evidence:
    - reference: PMID:27986801
      reference_title: Decreased telomere length in children with cartilage-hair hypoplasia.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: In particular children (<18 years) with CHH had shorter telomeres than controls (median RTL 1.12 vs 1.26, p=0.008).
      explanation: The clinical measurement supports the shortened-telomere outcome; it does not identify the molecular cause of impaired maintenance.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Impaired T-Lymphocyte Proliferation
    description: Impaired telomere homeostasis is a candidate contributor to lymphocyte growth defects, but association does not establish this direction of causality.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:28126377
      reference_title: Defects in lymphocyte telomere homeostasis contribute to cellular immune phenotype in patients with cartilage-hair hypoplasia.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: These findings suggest that telomere deficiency is implicated in the CHH disease phenotype through an as yet unidentified mechanism.
      explanation: The authors interpret a possible contribution while explicitly retaining mechanistic uncertainty.
      directness: INDIRECT
      quote_role: BACKGROUND
- name: Reduced RMRP-Derived Small RNA Abundance
  biological_scale: MOLECULAR
  description: RMRP produces the short RNAs RMRP-S1 and RMRP-S2. Their steady-state levels were reduced in two founder-variant patient fibroblast lines and one patient-derived B-cell line. Production is Dicer-dependent in HEK293 cells, but the route from each disease allele to reduced small-RNA abundance is unresolved. Abundance changes in these cell lines do not establish loss of silencing activity in hair follicles or growth plates.
  evidence:
  - reference: PMID:24009312
    reference_title: Small RNAs derived from lncRNA RNase MRP have gene-silencing activity relevant to human cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: RMRP-S1 and -S2 are significantly reduced in two fibroblast cell lines and a B-cell line derived from CHH patients.
    explanation: Measured small-RNA reduction in patient-derived cultured cells.
  - reference: PMID:24009312
    reference_title: Small RNAs derived from lncRNA RNase MRP have gene-silencing activity relevant to human cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Thus, the reduction in RMRP-S1 and -S2 was dependent upon complete knockdown of Dicer for 24 h, suggesting that their mechanism of biogenesis is Dicer dependent.
    explanation: Dicer depletion in HEK293 cells supports a role in small-RNA biogenesis; it is not an experiment in patient hair follicles.
  downstream:
  - target: Altered Small RNA-Mediated Gene Regulation
    description: Reduced small-RNA abundance may affect target regulation if functional thresholds are crossed; that step has not been measured in patient growth plates or hair follicles.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:24009312
      reference_title: Small RNAs derived from lncRNA RNase MRP have gene-silencing activity relevant to human cartilage-hair hypoplasia.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Knowing the importance of thresholds in determining the effectiveness of miRNAs in RISC (60), the functional consequences of the reductions in RMRP-S1 and -S2 must be determined by further investigations in appropriate stem and differentiated somatic cells associated with CHH phenotypes.
      explanation: The authors explicitly leave the functional consequences of patient-cell small-RNA reductions for future tissue-relevant experiments.
      directness: INDIRECT
      quote_role: BACKGROUND
    hypothesis_groups:
    - small_rna_regulatory_model
- name: Altered Small RNA-Mediated Gene Regulation
  biological_scale: MOLECULAR
  mechanism_confidence: HYPOTHETICAL
  description: Reduced RMRP-S1 and RMRP-S2 may alter developmental gene regulation. Mimic/inhibitor experiments in HEK293 cells identified regulated transcripts and confirmed effects on PTCH2 and SOX4 RNA and protein. Pathway enrichment suggested relevance to skeletal, hair, and hematopoietic features. These perturbation experiments support a candidate mechanism; they do not demonstrate that reduced endogenous small RNAs cause those manifestations in patients.
  evidence:
  - reference: PMID:24009312
    reference_title: Small RNAs derived from lncRNA RNase MRP have gene-silencing activity relevant to human cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: QRT-PCR assays revealed a significant rise of both PTCH2 and SOX4 RNA after transfection of RMRP-S1 and -S2 inhibitors, compared with mock-transfected cells (Fig. 10A).
    explanation: Inhibitor experiments in HEK293 cells support regulation of these transcripts. The direction and effect size in patient tissues were not established.
  - reference: PMID:24009312
    reference_title: Small RNAs derived from lncRNA RNase MRP have gene-silencing activity relevant to human cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Knowing the importance of thresholds in determining the effectiveness of miRNAs in RISC (60), the functional consequences of the reductions in RMRP-S1 and -S2 must be determined by further investigations in appropriate stem and differentiated somatic cells associated with CHH phenotypes.
    explanation: The authors explicitly leave the functional consequences of patient-cell small-RNA reductions for future tissue-relevant experiments.
    directness: INDIRECT
    quote_role: BACKGROUND
  downstream:
  - target: Abnormal Hair Production
    description: A proposed consequence of altered developmental gene regulation; tissue-specific causality has not been demonstrated.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:24009312
      reference_title: Small RNAs derived from lncRNA RNase MRP have gene-silencing activity relevant to human cartilage-hair hypoplasia.
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: Pathway analysis identified regulated genes that function in skeletal development, hair development and hematopoietic cell differentiation including PTCH2 and SOX4 among others, linked to major CHH phenotypes.
      explanation: Pathway enrichment after cultured-cell perturbation motivates this proposed tissue link, rather than demonstrating causality in the tissue.
      directness: INDIRECT
      quote_role: BACKGROUND
    hypothesis_groups:
    - small_rna_regulatory_model
  - target: Growth Plate Chondrocyte Differentiation Failure
    description: A proposed consequence of altered developmental gene regulation; tissue-specific causality has not been demonstrated.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:24009312
      reference_title: Small RNAs derived from lncRNA RNase MRP have gene-silencing activity relevant to human cartilage-hair hypoplasia.
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: Pathway analysis identified regulated genes that function in skeletal development, hair development and hematopoietic cell differentiation including PTCH2 and SOX4 among others, linked to major CHH phenotypes.
      explanation: Pathway enrichment after cultured-cell perturbation motivates this proposed tissue link, rather than demonstrating causality in the tissue.
      directness: INDIRECT
      quote_role: BACKGROUND
    hypothesis_groups:
    - small_rna_regulatory_model
- name: Growth Plate Chondrocyte Differentiation Failure
  biological_scale: TISSUE
  description: RMRP expression rises during hypertrophic chondrocyte differentiation in mouse growth plates and ATDC5 cultures. Rmrp knockdown impairs hypertrophic markers, matrix accumulation, and mineralization in vitro. Patient fibroblasts induced toward a chondrocyte-like state also show reduced hypertrophic differentiation. These models support a role for RMRP in cartilage maturation, consistent with the paucity and disorganization of growth-plate chondrocytes in CHH. The responsible RNA substrates and relative contributions of ribosome synthesis, cell-cycle regulation, and small RNAs remain unresolved. Wnt/beta-catenin activation and partial pharmacological rescue are findings from the zebrafish model, not established human mechanisms.
  cell_types:
  - preferred_term: chondrocyte
    term:
      id: CL:0000138
      label: chondrocyte
  biological_processes:
  - preferred_term: chondrocyte differentiation
    term:
      id: GO:0002062
      label: chondrocyte differentiation
    modifier: DECREASED
  - preferred_term: chondrocyte hypertrophy
    term:
      id: GO:0003415
      label: chondrocyte hypertrophy
    modifier: DECREASED
  - preferred_term: endochondral ossification
    term:
      id: GO:0001958
      label: endochondral ossification
    modifier: DECREASED
  evidence:
  - reference: PMID:28743979
    reference_title: Expression of RMRP RNA is regulated in chondrocyte hypertrophy and determines chondrogenic differentiation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Genetic interference with Rmrp RNA expression in ATDC5 cultures caused a deregulation of chondrogenic differentiation, with a prominent impact on hypertrophy and changes in pre-rRNA processing and rRNA levels.
    explanation: Direct chondrocyte evidence coupling impaired pre-rRNA processing to deranged differentiation in the same experiment.
  - reference: PMID:28743979
    reference_title: Expression of RMRP RNA is regulated in chondrocyte hypertrophy and determines chondrogenic differentiation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Expression of Rmrp RNA and RNase MRP protein subunits was detected in the murine growth plate and during the course of chondrogenic differentiation of ATDC5 cultures, where Rmrp RNA expression was found to be correlated with chondrocyte hypertrophy.
    explanation: Shows expression in normal mouse growth plates and during cultured-cell differentiation; it does not establish exclusive tissue-specific expression.
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Histological examination of the patient's bone back in 1960s demonstrated the paucity of cartilage cells and disturbed columnar tissue organization
    explanation: 'Human histological correlate: the growth plate is hypocellular and loses its columnar architecture.'
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Short stature in CHH is mostly prenatal, with birth length corrected for gestational age being -2.9 standard deviation score (SDS) for boys and -3.0 SDS for girls
    explanation: Establishes that the growth deficit is largely established before birth, consistent with a developmental growth-plate lesion.
  - reference: PMID:31237961
    reference_title: Rmrp Mutation Disrupts Chondrogenesis and Bone Ossification in Zebrafish Model of Cartilage-Hair Hypoplasia via Enhanced Wnt/β-Catenin Signaling.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: We also demonstrate that rmrp mutation upregulates canonical Wnt/β-catenin signaling; the pharmacological inhibition of Wnt/β-catenin could partially alleviate the chondrodysplasia and increased vertebrae mineralization in rmrp mutants.
    explanation: Wnt activation and partial pharmacological reversal were demonstrated in zebrafish. This source does not establish the same mediator in human cartilage.
  - reference: PMID:28743979
    reference_title: Expression of RMRP RNA is regulated in chondrocyte hypertrophy and determines chondrogenic differentiation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: As long as the substrate(s) of RNase MRP that are involved in the molecular mechanisms of chondrogenic differentiation has/have not been identified, we can only speculate how induction of RMRP RNA expression is associated with chondrocyte hypertrophy.
    explanation: The primary study does not isolate a single RNA substrate as the mediator of impaired chondrogenesis.
    directness: INDIRECT
    quote_role: BACKGROUND
  - reference: PMID:28743979
    reference_title: Expression of RMRP RNA is regulated in chondrocyte hypertrophy and determines chondrogenic differentiation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Together, data show that in CHH fibroblasts chondrogenic trans-differentiation is impaired with a major impact on hypertrophic development of these cultures.
    explanation: Patient fibroblast trans-differentiation provides a human cell model; these are not primary patient growth-plate biopsies.
  downstream:
  - target: Metaphyseal chondrodysplasia
    description: Growth-plate disorganization produces the metaphyseal dysplasia that names the disease.
  - target: Disproportionate short-limb short stature
    description: Failure of endochondral elongation in the limbs produces disproportionate short stature.
  - target: Genu varum
    description: A skeletal manifestation associated with CHH; the precise route from altered chondrocyte differentiation to this finding is not established.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Limited elbow extension
    description: A skeletal manifestation associated with CHH; the precise route from altered chondrocyte differentiation to this finding is not established.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Joint hypermobility
    description: A skeletal manifestation associated with CHH; the precise route from altered chondrocyte differentiation to this finding is not established.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Lumbar hyperlordosis
    description: A skeletal manifestation associated with CHH; the precise route from altered chondrocyte differentiation to this finding is not established.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Short metacarpal
    description: The same failure of endochondral growth shortens the short tubular bones of the hands and feet.
  - target: Coxa vara
    description: A skeletal manifestation associated with CHH; the precise route from altered chondrocyte differentiation to this finding is not established.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Scoliosis
    description: A skeletal manifestation associated with CHH; the precise route from altered chondrocyte differentiation to this finding is not established.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Impaired T-Lymphocyte Proliferation
  biological_scale: CELLULAR
  description: Peripheral T cells from patients with CHH can proliferate poorly after stimulation. Experiments demonstrate altered cell-cycle distribution and increased activation-induced death; Rmrp disruption in primary mouse T-cell cultures also impairs expansion and pre-rRNA processing. These findings support cell-intrinsic dysfunction, but the relative contributions of RNA processing, telomere homeostasis, and other pathways remain unresolved.
  cell_types:
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  biological_processes:
  - preferred_term: T cell proliferation
    term:
      id: GO:0042098
      label: T cell proliferation
    modifier: DECREASED
  evidence:
  - reference: PMID:21570718
    reference_title: Reduced thymic output, cell cycle abnormalities, and increased apoptosis of T lymphocytes in patients with cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: As shown in Fig 4, proliferation of CD3+ lymphocytes from patients with CHH was impaired.
    explanation: Patient PBMC cultures stimulated with anti-CD3, with or without IL-2, showed impaired T-cell proliferation.
  - reference: PMID:35115551
    reference_title: A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: This showed that disruption of RMRP markedly impaired T cell proliferation.
    explanation: CRISPR perturbation of activated primary mouse T cells provides ex vivo evidence; it is classified as an in-vitro experiment.
  downstream:
  - target: Cellular and Humoral Immune Dysfunction
    description: Defective T-cell expansion contributes to variable cellular immune dysfunction; laboratory severity does not precisely predict an individual clinical course.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:21570718
      reference_title: Reduced thymic output, cell cycle abnormalities, and increased apoptosis of T lymphocytes in patients with cartilage-hair hypoplasia.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: As shown in Fig 4, proliferation of CD3+ lymphocytes from patients with CHH was impaired.
      explanation: Patient PBMC cultures stimulated with anti-CD3, with or without IL-2, showed impaired T-cell proliferation.
    - reference: PMID:31379817
      reference_title: A 30-Year Prospective Follow-Up Study Reveals Risk Factors for Early Death in Cartilage-Hair Hypoplasia.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Half of the patients (57%, n = 46) manifested no symptoms of immunodeficiency during follow-up while 19% (n = 15) and 24% (n = 19) demonstrated symptoms of humoral or combined immunodeficiency, including six cases of adult-onset immunodeficiency.
      explanation: These categories were assigned from clinical symptoms, not solely laboratory results. Absence of infections does not imply normal immune testing.
- name: Reduced Thymic T-Cell Output
  biological_scale: TISSUE
  description: Reduced numbers of recent thymic emigrants indicate impaired thymic T-cell generation. This phenotype can occur even without clinically significant immunodeficiency and need not imply a uniform thymic architectural defect in all patients.
  evidence:
  - reference: PMID:21570718
    reference_title: Reduced thymic output, cell cycle abnormalities, and increased apoptosis of T lymphocytes in patients with cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: As shown in Fig 2, both the absolute and relative numbers of RTEs were significantly reduced in the patients with CHH, regardless of their age, compared with published normal values.
    explanation: Reduced recent thymic emigrants support decreased thymic output, including in patients without significant clinical infections.
  downstream:
  - target: Decreased total T cell count
    description: Reduced thymic production can contribute to low peripheral T-cell numbers, together with peripheral proliferation and survival defects.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:21570718
      reference_title: Reduced thymic output, cell cycle abnormalities, and increased apoptosis of T lymphocytes in patients with cartilage-hair hypoplasia.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: As shown in Fig 2, both the absolute and relative numbers of RTEs were significantly reduced in the patients with CHH, regardless of their age, compared with published normal values.
      explanation: Reduced recent thymic emigrants support decreased thymic output, including in patients without significant clinical infections.
  - target: Cellular and Humoral Immune Dysfunction
    description: Reduced replenishment of naive T cells may contribute to immune dysfunction; its clinical impact is variable.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:21570718
      reference_title: Reduced thymic output, cell cycle abnormalities, and increased apoptosis of T lymphocytes in patients with cartilage-hair hypoplasia.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: As shown in Fig 2, both the absolute and relative numbers of RTEs were significantly reduced in the patients with CHH, regardless of their age, compared with published normal values.
      explanation: Reduced recent thymic emigrants support decreased thymic output, including in patients without significant clinical infections.
- name: Increased Activation-Induced T-Cell Death
  biological_scale: CELLULAR
  description: Activated patient lymphocyte cultures show increased apoptosis or late apoptotic/necrotic cell fractions. This contributes to reduced expansion alongside cell-cycle abnormalities. The result is specific to stimulated lymphocytes and should not be generalized to patient fibroblasts, where increased death was not detected.
  evidence:
  - reference: PMID:21570718
    reference_title: Reduced thymic output, cell cycle abnormalities, and increased apoptosis of T lymphocytes in patients with cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: As shown in Fig 6, the percentage of both early and late apoptotic cells was increased in patients with CHH versus healthy controls, reaching a statistically significant difference for late apoptotic/necrotic cells on culture with anti-CD3 mAb 1 IL-2
    explanation: Annexin-V/7-AAD assays measured increased activation-associated cell death in patient lymphocyte cultures; significance depended on the assay condition.
  downstream:
  - target: Impaired T-Lymphocyte Proliferation
    description: Increased loss of activated T cells contributes to poor culture expansion.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:21570718
      reference_title: Reduced thymic output, cell cycle abnormalities, and increased apoptosis of T lymphocytes in patients with cartilage-hair hypoplasia.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: As shown in Fig 6, the percentage of both early and late apoptotic cells was increased in patients with CHH versus healthy controls, reaching a statistically significant difference for late apoptotic/necrotic cells on culture with anti-CD3 mAb 1 IL-2
      explanation: Annexin-V/7-AAD assays measured increased activation-associated cell death in patient lymphocyte cultures; significance depended on the assay condition.
- name: Cellular and Humoral Immune Dysfunction
  biological_scale: ORGANISM
  description: Immune dysfunction ranges from laboratory abnormalities without frequent infections to symptomatic humoral or combined immunodeficiency, including SCID in some patients. T-cell counts, naive subsets, and recent thymic emigrants can be reduced; B-cell and antibody defects are variable. Clinical progression, including adult-onset disease, occurs in a subset rather than universally. Clinical history, function testing, and serial assessment are needed together.
  evidence:
  - reference: PMID:31379817
    reference_title: A 30-Year Prospective Follow-Up Study Reveals Risk Factors for Early Death in Cartilage-Hair Hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Half of the patients (57%, n = 46) manifested no symptoms of immunodeficiency during follow-up while 19% (n = 15) and 24% (n = 19) demonstrated symptoms of humoral or combined immunodeficiency, including six cases of adult-onset immunodeficiency.
    explanation: These categories were assigned from clinical symptoms, not solely laboratory results. Absence of infections does not imply normal immune testing.
  - reference: PMID:31379817
    reference_title: A 30-Year Prospective Follow-Up Study Reveals Risk Factors for Early Death in Cartilage-Hair Hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In a significant proportion of patients (17/79, 22%), clinical features of immunodeficiency progressed over time.
    explanation: The longitudinal cohort demonstrates progression in a minority of participants, not inevitable deterioration.
  downstream:
  - target: Combined immunodeficiency
    description: Cellular and humoral defects can combine into clinically significant immunodeficiency.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Recurrent respiratory infections
    description: Impaired host defense predisposes to recurrent infections, although some patients remain clinically asymptomatic.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Severe varicella zoster infection
    description: Impaired cellular defense can permit severe varicella.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Decreased specific antibody response to vaccination
    description: Some patients have impaired specific antibody responses despite preserved total immunoglobulin levels.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Chronic Airway Injury
    description: Recurrent respiratory infections can contribute to airway damage, with substantial variation in progression.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Immune Dysregulation and Autoimmunity
    description: Immune abnormalities may also affect tolerance, although the responsible mechanisms remain unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Malignancy Predisposition
    description: Defective immune surveillance is a proposed contributor to malignancy risk, rather than a demonstrated sole mechanism.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Multilineage Bone Marrow Progenitor Failure
  biological_scale: CELLULAR
  description: A study of eight patients with a history of anemia found reduced erythroid, megakaryocyte, and usually granulocyte-macrophage colony formation. Stronger stimulation revealed normal or increased erythroid progenitor numbers, supporting functional impairment rather than simple depletion. The culture defect did not correlate with peripheral blood counts. Clinical anemia is often macrocytic and more severe in early childhood, but persistent transfusion dependence occurs in a severe subgroup.
  cell_types:
  - preferred_term: erythroid progenitor cell
    term:
      id: CL:0000038
      label: erythroid progenitor cell
  biological_processes:
  - preferred_term: erythrocyte differentiation
    term:
      id: GO:0030218
      label: erythrocyte differentiation
    modifier: DECREASED
  evidence:
  - reference: PMID:7895753
    reference_title: Defective in-vitro colony formation of haematopoietic progenitors in patients with cartilage-hair hypoplasia and history of anaemia.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: The present study shows defective in vitro colony formation in all myeloid lineages in patients with CHH, which is in accordance with the suggestion of a common cell proliferation defect in CHH.
    explanation: Establishes that the marrow defect spans lineages and is read by the authors as the same proliferation defect seen elsewhere.
  - reference: PMID:7895753
    reference_title: Defective in-vitro colony formation of haematopoietic progenitors in patients with cartilage-hair hypoplasia and history of anaemia.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: The impaired growth was not caused by a decreased number of progenitors as shown by erythroid cultures. The erythroid progenitors were incapable of colony formation in culture conditions sufficient for colony formation by normal progenitors.
    explanation: Distinguishes a functional proliferation defect from progenitor depletion, which is the specific claim this node makes.
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Bone marrow erythroid hypoplasia and poor growth of erythroid precursors have been demonstrated in all CHH patients with severe anemia who underwent bone marrow examinations
    explanation: In-patient marrow correlate of the culture findings for the severely anemic subgroup.
  - reference: PMID:10690856
    reference_title: Anemia in children with cartilage-hair hypoplasia is related to body growth and to the insulin-like growth factor system.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Retrospective analysis of hematological data of 114 patients showed that the severity of the anemia and macrocytosis in CHH varies with age. The anemia was most severe in early childhood.
    explanation: Anemia and macrocytosis vary with age and were most severe in early childhood; this does not exclude persistent severe anemia.
  downstream:
  - target: Macrocytic anemia
    description: Failure of erythroid colony formation produces a macrocytic anemia.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Anemia
    description: Connects the progenitor defect to the general clinical phenotype.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Decreased total neutrophil count
    description: The granulocyte-macrophage arm of the colony-formation defect can decompensate into clinical neutropenia, though it usually does not.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Immune Dysregulation and Autoimmunity
  biological_scale: ORGANISM
  description: Clinical autoimmune manifestations occurred in 11 of 104 Finnish patients and were associated with higher mortality and recurrent serious infections. Autoantibody positivity can occur without corresponding clinical disease. The mechanisms of impaired tolerance remain uncertain; normal regulatory T-cell counts do not exclude functional defects. Asthma and rhinitis diagnoses are common, but not all reported respiratory symptoms have demonstrated allergic mechanisms.
  evidence:
  - reference: PMID:30410491
    reference_title: A Wide Spectrum of Autoimmune Manifestations and Other Symptoms Suggesting Immune Dysregulation in Patients With Cartilage-Hair Hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Clinical autoimmunity was common (11/104, 10.6%) and included conditions previously undescribed in subjects with CHH (narcolepsy, psoriasis, idiopathic thrombocytopenic purpura, and multifocal motor axonal neuropathy).
    explanation: Quantifies clinical autoimmunity and establishes the breadth of the spectrum.
  - reference: PMID:30410491
    reference_title: A Wide Spectrum of Autoimmune Manifestations and Other Symptoms Suggesting Immune Dysregulation in Patients With Cartilage-Hair Hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: AI diseases are common in Finnish patients with CHH and are associated with higher mortality, recurrent pneumonia, sepsis, high IgE and/or undetectable IgA levels.
    explanation: Establishes the mortality association that makes this arm clinically consequential.
  - reference: PMID:30410491
    reference_title: A Wide Spectrum of Autoimmune Manifestations and Other Symptoms Suggesting Immune Dysregulation in Patients With Cartilage-Hair Hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Several patients demonstrated serum autoantibody positivity without compatible symptoms.
    explanation: Autoantibody positivity without compatible symptoms does not establish clinical autoimmune disease.
  - reference: PMID:31379817
    reference_title: A 30-Year Prospective Follow-Up Study Reveals Risk Factors for Early Death in Cartilage-Hair Hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: autoimmunity in adulthood (OR = 39, 95%CI = 3.5-430)
    explanation: Quantifies adult autoimmunity as a mortality risk factor; the very wide confidence interval is itself informative about the precision available in a cohort this size.
  downstream:
  - target: Autoimmunity
    description: Loss of tolerance manifests as clinical autoimmune disease.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Autoimmune hemolytic anemia
    description: Autoimmune destruction of red cells is one reported manifestation.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Asthma
    description: These clinical diagnoses are reported in CHH; their relationship to immune dysregulation and the contribution of true allergy remain incompletely established.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Allergic rhinitis
    description: These clinical diagnoses are reported in CHH; their relationship to immune dysregulation and the contribution of true allergy remain incompletely established.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Malignancy Predisposition
  biological_scale: ORGANISM
  description: CHH confers increased risk of lymphoma and basal cell carcinoma. Both defective immune surveillance and cell-intrinsic consequences of RMRP dysfunction are proposed contributors, but neither explains all cases. Malignancy can develop without preceding clinical immunodeficiency. Normal cancer incidence among unaffected relatives supports a disease association without ruling out environmental contributions, including the contribution of sun exposure to skin cancer risk.
  evidence:
  - reference: PMID:18698627
    reference_title: Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confirms high incidence of non-Hodgkin lymphoma and basal cell carcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: During the follow-up (2,365 person-years; mean 19.2 years), 14 cases of cancer were diagnosed in the CHH cohort (expected number 2.0; SIR 7.0, CI 3.8-12). Non-Hodgkin lymphoma was the most frequent cancer type (n = 9; SIR 90.2, CI 39.0-180)
    explanation: Registry-based quantification of the overall and lymphoma-specific excess risk against population expectation.
  - reference: PMID:18698627
    reference_title: Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confirms high incidence of non-Hodgkin lymphoma and basal cell carcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In addition, ten patients had basal cell carcinoma of the skin (expected number 0.3; SIR 33.2, CI 16-61).
    explanation: Quantifies the second component of the cancer excess.
  - reference: PMID:10064668
    reference_title: Increased incidence of cancer in patients with cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The cancer incidence among the siblings or the parents did not differ from the average cancer incidence in the Finnish population.
    explanation: No excess was detected in unaffected relatives; this comparison does not exclude environmental effects or gene-environment interactions in affected patients.
  - reference: PMID:10064668
    reference_title: Increased incidence of cancer in patients with cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This study confirms an increased risk of cancer, especially non-Hodgkin's lymphoma, probably attributable to defective immunity, among patients with CHH.
    explanation: The attribution to defective immunity is explicitly probable rather than experimentally established.
  - reference: PMID:36211439
    reference_title: Lymphomas in cartilage-hair hypoplasia - A case series of 16 patients reveals advanced stage DLBCL as the most common form.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The most common lymphoma type was diffuse large cell B-cell lymphoma (DLBCL) (6/16, 38%). Eight patients received chemotherapy (8/16, 50%), and two of them survived.
    explanation: Characterizes the dominant lymphoma subtype and the poor treatment outcome.
  - reference: PMID:31379817
    reference_title: A 30-Year Prospective Follow-Up Study Reveals Risk Factors for Early Death in Cartilage-Hair Hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Of the 15 patients with non-skin cancer, eight had no preceding clinical symptoms of immunodeficiency.
    explanation: 'The key surveillance-relevant observation: over half of cancers arose in patients with no clinical immune symptoms, which is why screening is universal rather than risk-stratified.'
  - reference: PMID:36211439
    reference_title: Lymphomas in cartilage-hair hypoplasia - A case series of 16 patients reveals advanced stage DLBCL as the most common form.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The mechanism by which the RMRP variants in CHH predispose to malignancies is unknown.
    explanation: The lymphoma series explicitly retains uncertainty about the molecular mechanism.
    directness: INDIRECT
    quote_role: BACKGROUND
  downstream:
  - target: Non-Hodgkin lymphoma
    description: This malignancy is observed at increased frequency in CHH; the molecular route from RMRP dysfunction is incompletely resolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Basal cell carcinoma
    description: This malignancy is observed at increased frequency in CHH; the molecular route from RMRP dysfunction is incompletely resolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Neoplasm
    description: This malignancy is observed at increased frequency in CHH; the molecular route from RMRP dysfunction is incompletely resolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Chronic Airway Injury
  biological_scale: TISSUE
  description: Recurrent infection and inflammation can contribute to structural lung disease in CHH. Bronchiectasis can occur without hypogammaglobulinemia and its course is variable. The follow-up MRI study found stable or improved imaging in 14 participants over a median 6.8 years, but two of the three participants with established bronchiectasis lacked repeat imaging. This selected cohort cannot establish the course of advanced bronchiectasis. Lung disease is an important cause of mortality, without having the highest cause-specific standardized mortality ratio in the longitudinal mortality study.
  evidence:
  - reference: PMID:33675005
    reference_title: 'Pulmonary Follow-Up Imaging in Cartilage-Hair Hypoplasia: a Prospective Cohort Study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Patients with cartilage-hair hypoplasia are prone to recurrent respiratory tract infections, and the prevalence of bronchiectasis ranges from 29 to 52%.
    explanation: Reports bronchiectasis prevalence across differently selected cohorts; this sentence alone does not prove the direction of causality between infections and airway damage.
  - reference: PMID:31379817
    reference_title: A 30-Year Prospective Follow-Up Study Reveals Risk Factors for Early Death in Cartilage-Hair Hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Altogether 20 patients had deceased (SMR = 7.0, 95%CI = 4.3-11); most commonly from malignancy (n = 7, SMR = 10, 95%CI = 4.1-21) and lung disease (n = 4, SMR = 46, 95%CI = 9.5-130).
    explanation: Quantifies overall and lung-disease mortality; the full paper reports a higher standardized mortality ratio for lymphoid neoplasms.
  - reference: PMID:33675005
    reference_title: 'Pulmonary Follow-Up Imaging in Cartilage-Hair Hypoplasia: a Prospective Cohort Study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In conclusion, our results suggest slow if any development of bronchiectasis in selected subjects with cartilage-hair hypoplasia.
    explanation: The follow-up evidence is from a selected cohort with limited repeat imaging in participants with established bronchiectasis.
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hypogammaglobulinemia is present in some, but not all, of these patients, and immunoglobulin replacement therapy (IGRT) is often insufficient to prevent deterioration.
    explanation: Establishes the dissociation between measurable antibody deficiency and lung disease, and the limits of replacement therapy.
  - reference: PMID:33675005
    reference_title: 'Pulmonary Follow-Up Imaging in Cartilage-Hair Hypoplasia: a Prospective Cohort Study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Of three patients with bron-

      chiectasis (bronchiectasis score≥ 7 points) detected already in

      their initial MRI, two did not undergo repeated imaging while

      the third cleared inflammatory changes (score dropped to <7).'
    explanation: Loss of follow-up among participants with established bronchiectasis limits inference about progression.
  downstream:
  - target: Bronchiectasis
    description: Repeated airway infection and inflammation produce irreversible bronchial dilatation.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Recurrent pneumonia
    description: Impaired clearance and damaged airways predispose to repeated pneumonia.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Abnormal Hair Production
  biological_scale: TISSUE
  description: An incompletely resolved defect of hair production underlies the fine or sparse hair typical of CHH. Functional allele comparisons associate hair hypoplasia with reduced mRNA cleavage, and small-RNA perturbation studies identify a candidate regulatory route. Neither result establishes a unique molecular cause in patient follicles. Hair appearance is variable, including normal hair in some patients; direct follicular histology is not established by the cited clinical descriptions.
  evidence:
  - reference: PMID:22420014
    reference_title: Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Other findings include joint hypermobility, fine, silky hair, immunodeficiency, anemia, increased risk for malignancy, gastrointestinal dysfunction, and impaired spermatogenesis.
    explanation: Establishes fine silky hair as a characteristic feature of the spectrum.
  - reference: PMID:17701897
    reference_title: Type and level of RMRP functional impairment predicts phenotype in the cartilage hair hypoplasia-anauxetic dysplasia spectrum.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: reduced mRNA cleavage, and thus cell-cycle impairment, predicts the presence of hair hypoplasia, immunodeficiency, and hematological abnormalities and thus increased cancer risk
    explanation: An association across tested alleles supports an mRNA-processing hypothesis, without demonstrating a unique causal route in patient follicles.
  - reference: PMID:24009312
    reference_title: Small RNAs derived from lncRNA RNase MRP have gene-silencing activity relevant to human cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: Pathway analysis identified regulated genes that function in skeletal development, hair development and hematopoietic cell differentiation including PTCH2 and SOX4 among others, linked to major CHH phenotypes.
    explanation: Pathway enrichment motivates a small-RNA regulatory hypothesis; it does not directly demonstrate defective hair development.
  downstream:
  - target: Fine hair
    description: Hair-production dysfunction is a proposed tissue-level route to this clinical feature; the specific follicular lesion remains unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Sparse hair
    description: Hair-production dysfunction is a proposed tissue-level route to this clinical feature; the specific follicular lesion remains unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  mechanism_confidence: HYPOTHETICAL
- name: Intestinal Enteropathy
  biological_scale: TISSUE
  description: Persistent or recurrent diarrhea in CHH may accompany malabsorption or enteropathy. In the Finnish cohort, duodenal villous atrophy occurred in some patients despite negative celiac testing. Infection and immune dysregulation are possible contributors; systematic histology was limited and a single mechanism has not been established. This process is distinct from congenital enteric aganglionosis.
  evidence:
  - reference: PMID:30410491
    reference_title: A Wide Spectrum of Autoimmune Manifestations and Other Symptoms Suggesting Immune Dysregulation in Patients With Cartilage-Hair Hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The presence of DVA in three subjects with negative celiac screen underscores the necessity for systematic endoscopic evaluation of CHH individuals with gastrointestinal complaints.
    explanation: A small number of patients had duodenal villous atrophy without positive celiac testing; this does not establish autoimmune enteropathy in all patients with diarrhea.
  downstream:
  - target: Chronic diarrhea
    description: Enteropathy is one potential cause of chronic diarrhea; infectious and other causes also require evaluation.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:30410491
      reference_title: A Wide Spectrum of Autoimmune Manifestations and Other Symptoms Suggesting Immune Dysregulation in Patients With Cartilage-Hair Hypoplasia.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The presence of DVA in three subjects with negative celiac screen underscores the necessity for systematic endoscopic evaluation of CHH individuals with gastrointestinal complaints.
      explanation: A small number of patients had duodenal villous atrophy without positive celiac testing; this does not establish autoimmune enteropathy in all patients with diarrhea.
- name: Enteric Aganglionosis
  biological_scale: TISSUE
  description: Hirschsprung disease occurs at increased frequency in CHH. The developmental link between RMRP dysfunction and absent enteric ganglion cells is unknown; intestinal epithelial abnormalities in zebrafish do not establish the cause of human aganglionosis.
  evidence:
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hirschsprung’s disease (HD) is a well-known comorbidity of CHH, although the pathogenetic link between RMRP deficiency and HD remains unknown.
    explanation: The association is established, while the mechanistic link is unresolved.
    quote_role: REVIEW_SYNTHESIS
  downstream:
  - target: Aganglionic megacolon
    description: Absence of enteric ganglion cells produces the Hirschsprung phenotype.
    causal_link_type: DIRECT
phenotypes:
- name: Disproportionate short-limb short stature
  category: Growth
  description: Disproportionate short stature with short extremities, largely established before birth and progressive during infancy and puberty. Median adult height is 131 cm for men and 123 cm for women. Individuals of normal height with genetically confirmed CHH have been reported, so short stature is characteristic but not obligatory.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Disproportionate short-limb short stature
    term:
      id: HP:0008873
      label: Disproportionate short-limb short stature
  evidence:
  - reference: PMID:22420014
    reference_title: Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: CHH-AD spectrum disorders are characterized by severe disproportionate (short-limb) short stature that is usually recognized in the newborn, and occasionally prenatally because of the short extremities.
    explanation: Establishes short-limb disproportionate short stature as a defining and near-universal feature of the spectrum, supporting the VERY_FREQUENT band.
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The growth failure is progressive, particularly during the first year of life and during puberty, resulting in the median adult height of 131 cm for males and 123 cm for females
    explanation: Quantifies the adult height outcome described here.
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: While short stature was first thought to be invariably present in CHH patients, individuals with normal height have since been reported
    explanation: 'Retained qualification: short stature is characteristic but not obligatory, which is why the band is VERY_FREQUENT rather than obligate.'
  - reference: PMID:42063088
    reference_title: Perinatal outcomes in 35 children with cartilage hair hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In the whole cohort 27/32 (84%) had a Z-score below −2.0.
    explanation: Birth length was often short in the Finnish neonatal cohort, but normal birth length did not exclude CHH.
- name: Metaphyseal chondrodysplasia
  category: Skeletal
  description: Metaphyseal dysplasia with flaring, cupping, widening, cysts, fragmentation and scalloping of the metaphyses, most marked at the knee. Changes may not be apparent in the first two years of life and some patients never show them, so normal radiographs do not exclude the diagnosis.
  phenotype_term:
    preferred_term: Metaphyseal chondrodysplasia
    term:
      id: HP:0005871
      label: Metaphyseal chondrodysplasia
  evidence:
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Radiologically, metaphyseal abnormalities included flaring, cupping, widening, cysts, fragmentation, and scalloping of metaphyses in the tubular bones, particularly at the knee.
    explanation: Describes the specific radiographic metaphyseal changes of CHH.
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Importantly, metaphyseal changes may not be apparent in the first 2 years of life
    explanation: Supports the diagnostic caveat that early radiographs may be uninformative.
- name: Joint hypermobility
  category: Musculoskeletal
  description: Generalized ligamentous laxity, present in the large majority of patients and coexisting paradoxically with restricted elbow extension.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Joint hypermobility
    term:
      id: HP:0001382
      label: Joint hypermobility
  evidence:
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: incomplete extension of elbows (present in 92%, 79/86 patients) despite overall ligamentous laxity (95%, 81/85)
    explanation: Reports ligamentous laxity in 95% (81/85), which maps to the VERY_FREQUENT band (80-100%).
- name: Limited elbow extension
  category: Musculoskeletal
  description: Incomplete extension of the elbows, present in the great majority of patients despite generalized laxity elsewhere.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Limited elbow extension
    term:
      id: HP:0001377
      label: Limited elbow extension
  evidence:
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: incomplete extension of elbows (present in 92%, 79/86 patients) despite overall ligamentous laxity (95%, 81/85)
    explanation: Reports incomplete elbow extension in 92% (79/86), which maps to the VERY_FREQUENT band (80-100%).
- name: Genu varum
  category: Skeletal
  description: Varus deformity of the lower limbs, frequently progressive and a common indication for corrective realignment surgery.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Genu varum
    term:
      id: HP:0002970
      label: Genu varum
  evidence:
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: lower limbs varus deformity (63%, 54/86), chest deformity (68%, 57/84), as well as lumbar lordosis (85%, 72/85) and scoliosis (21%, 18/86)
    explanation: Reports lower-limb varus deformity in 63% (54/86), which maps to the FREQUENT band (30-79%).
  - reference: PMID:25764362
    reference_title: 'Cartilage hair hypoplasia: characteristics and orthopaedic manifestations.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Of the cases reviewed, 32 patients had undergone surgery, most commonly to correct genu varum.
    explanation: The primary report supplies the number operated; its text and conclusion use inconsistent percentage denominators.
- name: Lumbar hyperlordosis
  category: Skeletal
  description: Exaggerated lumbar lordosis, part of the characteristic skeletal habitus.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Lumbar hyperlordosis
    term:
      id: HP:0002938
      label: Lumbar hyperlordosis
  evidence:
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: lower limbs varus deformity (63%, 54/86), chest deformity (68%, 57/84), as well as lumbar lordosis (85%, 72/85) and scoliosis (21%, 18/86)
    explanation: Reports lumbar lordosis in 85% (72/85), which maps to the VERY_FREQUENT band (80-100%).
- name: Scoliosis
  category: Skeletal
  description: Lateral spinal curvature, present in a minority of patients.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: lower limbs varus deformity (63%, 54/86), chest deformity (68%, 57/84), as well as lumbar lordosis (85%, 72/85) and scoliosis (21%, 18/86)
    explanation: Reports scoliosis in 21% (18/86), which maps to the OCCASIONAL band (5-29%).
- name: Short metacarpal
  category: Skeletal
  description: Marked shortening of the metacarpals, metatarsals and phalanges with metaphyseal cupping and cone-shaped epiphyses, giving the characteristically short, pudgy hands with striking laxity of the small joints. No frequency band is assigned because the orthopaedic series describes the finding qualitatively rather than counting it.
  phenotype_term:
    preferred_term: Short metacarpal
    term:
      id: HP:0010049
      label: Short metacarpal
  evidence:
  - reference: PMID:25764362
    reference_title: 'Cartilage hair hypoplasia: characteristics and orthopaedic manifestations.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: There is marked shortening of the metacarpals, metatarsals, and phalanges, with metaphyseal cupping
    explanation: Directly describes the shortened metacarpals this phenotype records, in the largest reported orthopaedic series of CHH patients.
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Typical features in addition to short limbs include short hands
    explanation: Independent confirmation that short hands are a typical feature, though stated clinically rather than at the level of the individual bone.
- name: Coxa vara
  category: Skeletal
  description: Reduced femoral neck-shaft angle on radiography, present in about a quarter of patients whose films were reviewed. Occasionally severe enough to warrant corrective osteotomy alongside the more common varus knee.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Coxa vara
    term:
      id: HP:0002812
      label: Coxa vara
  evidence:
  - reference: PMID:25764362
    reference_title: 'Cartilage hair hypoplasia: characteristics and orthopaedic manifestations.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In our series, 27 % of the cases where radiographs were reviewed (19/71) showed coxa vara radiographically.
    explanation: Reports coxa vara in 27% (19/71), which maps to the OCCASIONAL band (5-29%).
- name: Decreased specific antibody response to vaccination
  category: Immunologic
  description: Specific antibody deficiency can occur despite normal total immunoglobulin levels. Seven of eight selected patients tested after pneumococcal polysaccharide vaccination had deficient responses. This small tested subgroup supports functional assessment but does not establish a population-wide frequency or a validated prognostic marker.
  phenotype_term:
    preferred_term: Decreased specific antibody response to vaccination
    term:
      id: HP:0032140
      label: Decreased specific antibody response to vaccination
  evidence:
  - reference: PMID:28284971
    reference_title: Analysis of clinical and immunologic phenotype in a large cohort of children and adults with cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Seven out of eight (88%) patients who agreed to receive Pneumovax® vaccine demonstrated specific antibody deficiency (SAD)
    explanation: 'Reports the vaccine-challenge result: seven of eight participants demonstrated specific antibody deficiency. No frequency band is assigned because only eight patients consented, so the proportion is not a population estimate.'
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: While B cell counts are often decreased, hypogammaglobulinemia is rare in patients with CHH; moreover, some individuals have hypergammaglobulinemia
    explanation: Establishes that total immunoglobulin concentration is usually preserved in CHH, which is why the humoral defect is curated here as an impaired specific antibody response rather than as decreased circulating immunoglobulin.
- name: Decreased total neutrophil count
  category: Hematologic
  description: Neutropenia occurs in single patients and may be intrinsic to the marrow defect or autoimmune in origin. It is reported alongside the anemia rather than instead of it, consistent with the multilineage colony-formation defect, but it is not a characteristic feature and no frequency band is assigned.
  phenotype_term:
    preferred_term: Decreased total neutrophil count
    term:
      id: HP:0001875
      label: Decreased total neutrophil count
  evidence:
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Single patients also have neutropenia, either intrinsic or autoimmune
    explanation: Establishes neutropenia as an occasional feature and names both candidate mechanisms; the single-patient framing is why no frequency is assigned.
  - reference: PMID:25764362
    reference_title: 'Cartilage hair hypoplasia: characteristics and orthopaedic manifestations.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: CHH is associated with a broad spectrum of mild-to-moderate, cell-mediated immunodysfunction, including occasionally severe combined immune deficiency, neutropenia, lymphopenia, disordered erythrogenesis, and a predisposition to lymphoma
    explanation: Independent listing of neutropenia among the recognized haematologic features of CHH.
- name: Fine hair
  category: Dermatologic
  description: Fine, silky hair, one of the two features that name the disease.
  phenotype_term:
    preferred_term: Fine hair
    term:
      id: HP:0002213
      label: Fine hair
  evidence:
  - reference: PMID:22420014
    reference_title: Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Other findings include joint hypermobility, fine, silky hair, immunodeficiency, anemia, increased risk for malignancy, gastrointestinal dysfunction, and impaired spermatogenesis.
    explanation: Establishes fine silky hair as a characteristic feature.
- name: Sparse hair
  category: Dermatologic
  description: Hypoplastic, sparse scalp and body hair, ranging in severity up to complete alopecia in the most severely affected individuals.
  phenotype_term:
    preferred_term: Sparse hair
    term:
      id: HP:0008070
      label: Sparse hair
  evidence:
  - reference: PMID:32506568
    reference_title: 'Immunodeficiency in cartilage-hair hypoplasia: Pathogenesis, clinical course and management.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Cartilage-hair hypoplasia (CHH) is an autosomal recessive syndromic immunodeficiency with skeletal dysplasia, short stature, hypotrichosis, variable degree of immune dysfunction and increased incidence of anaemia, Hirschsprung disease and malignancy.
    explanation: Names hypotrichosis as a defining feature of the syndrome.
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Historically, CHH-HD has been associated with more severe growth failure, complete alopecia, and severe anemia
    explanation: Supports the severe end of the hair phenotype; the evidence is limited because complete alopecia is described in the Hirschsprung subgroup rather than of CHH generally.
- name: Combined immunodeficiency
  category: Immunologic
  description: Clinical combined immunodeficiency, affecting roughly a quarter of patients in prospective follow-up. More than half manifest no symptoms of immunodeficiency at all, and a further fifth show humoral features only, so the label describes one end of a continuum rather than the disease as a whole. Onset may be in adulthood.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Combined immunodeficiency
    term:
      id: HP:0005387
      label: Combined immunodeficiency
  evidence:
  - reference: PMID:31379817
    reference_title: A 30-Year Prospective Follow-Up Study Reveals Risk Factors for Early Death in Cartilage-Hair Hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Half of the patients (57%, n = 46) manifested no symptoms of immunodeficiency during follow-up while 19% (n = 15) and 24% (n = 19) demonstrated symptoms of humoral or combined immunodeficiency, including six cases of adult-onset immunodeficiency.
    explanation: Reports symptomatic combined immunodeficiency in 24% of an 80-patient prospective cohort, which maps to the OCCASIONAL band (5-29%).
  - reference: PMID:28284971
    reference_title: Analysis of clinical and immunologic phenotype in a large cohort of children and adults with cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'We grouped patients as having: 1) no symptoms/signs of immunodeficiency (n=15, 27%), 2) features of humoral immunodeficiency only (n=26, 46%) and 3) features of combined immunodeficiency (CID, n=15, 27%)'
    explanation: Independent cohort reporting 27%, consistent with the same band.
  - reference: PMID:28284971
    reference_title: Analysis of clinical and immunologic phenotype in a large cohort of children and adults with cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: As mortality due to infections and malignancies is increased in CHH4, patients surviving into adulthood represent individuals with milder disease.
    explanation: 'Ascertainment caveat retained: cohorts of living patients probably understate severity in the disease as a whole.'
- name: Decreased total T cell count
  category: Laboratory
  description: Reduced circulating T cells, with the deficit concentrated in recent thymic emigrants and naive subsets. Patients with clinically suggested combined immunodeficiency show lower CD3, CD8 and recent thymic emigrant counts.
  phenotype_term:
    preferred_term: Decreased total T cell count
    term:
      id: HP:0005403
      label: Decreased total T cell count
  evidence:
  - reference: PMID:28284971
    reference_title: Analysis of clinical and immunologic phenotype in a large cohort of children and adults with cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Patients with clinically suggested CID showed decreased median CD3+, CD8+ and RTE counts
    explanation: Directly reports reduced T cell counts in the clinically affected subgroup.
- name: Recurrent respiratory infections
  category: Immunologic
  description: Recurrent sinopulmonary infection including rhinosinusitis, otitis media and pneumonia. A substantial share of patients nonetheless have a normal infection history, which is why no frequency band is assigned.
  phenotype_term:
    preferred_term: Recurrent respiratory infections
    term:
      id: HP:0002205
      label: Recurrent respiratory infections
  evidence:
  - reference: PMID:33675005
    reference_title: 'Pulmonary Follow-Up Imaging in Cartilage-Hair Hypoplasia: a Prospective Cohort Study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Patients with cartilage-hair hypoplasia are prone to recurrent respiratory tract infections, and the prevalence of bronchiectasis ranges from 29 to 52%.
    explanation: Establishes the recurrent respiratory infection phenotype.
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In the clinical cohorts, 33-78% of the patients have normal infection history
    explanation: 'Retained counterweight: a large fraction of patients are not clinically infection-prone, so no frequency band is assigned.'
- name: Recurrent pneumonia
  category: Respiratory
  description: Repeated episodes of pneumonia. Pneumonia in the first year of life, or recurrently in adulthood, is a reported risk factor for early death.
  phenotype_term:
    preferred_term: Recurrent pneumonia
    term:
      id: HP:0006532
      label: Recurrent pneumonia
  evidence:
  - reference: PMID:31379817
    reference_title: A 30-Year Prospective Follow-Up Study Reveals Risk Factors for Early Death in Cartilage-Hair Hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: pneumonia in the first year of life or recurrently in adulthood (OR = 7.6/19, 95%CI = 1.3-43/2.6-140)
    explanation: Establishes recurrent pneumonia as a prognostic risk factor rather than merely a manifestation.
  - reference: PMID:33675005
    reference_title: 'Pulmonary Follow-Up Imaging in Cartilage-Hair Hypoplasia: a Prospective Cohort Study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Patients with subtle signs of bronchiectasis on imaging tended to have low immunoglobulin M levels, as well as suffered from pneumonia during the follow-up.
    explanation: Links pneumonia during follow-up to the imaging changes in the same cohort.
- name: Bronchiectasis
  category: Respiratory
  description: Irreversible bronchial dilatation from recurrent airway infection, reported in 29% of an unselected cohort aged 13-68 years and more often in selected symptomatic cohorts. Reported cohort frequencies cross the OCCASIONAL and FREQUENT bands and do not establish a single population frequency. Bronchiectasis can be detected in the first decade.
  phenotype_term:
    preferred_term: Bronchiectasis
    term:
      id: HP:0002110
      label: Bronchiectasis
  evidence:
  - reference: PMID:33675005
    reference_title: 'Pulmonary Follow-Up Imaging in Cartilage-Hair Hypoplasia: a Prospective Cohort Study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Patients with cartilage-hair hypoplasia are prone to recurrent respiratory tract infections, and the prevalence of bronchiectasis ranges from 29 to 52%.
    explanation: Summarizes a range across cohorts that spans two frequency bands; ascertainment differences prevent assigning one frequency category.
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In an unselected cohort of 34 Finnish patients, aged 13-68 years, 10 (29%) had bronchiectasis on chest HRCT imaging
    explanation: Gives the unselected-cohort figure anchoring the lower end of the range.
- name: Anemia
  category: Hematologic
  description: Anemia is often macrocytic and more severe in childhood, with improvement by adulthood in many patients. Persistent or recurrent transfusion-dependent disease occurs in a subgroup. Functional erythroid progenitor defects are documented, but peripheral counts do not track colony formation directly; autoimmune anemia is a distinct possible contributor.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Anemia
    term:
      id: HP:0001903
      label: Anemia
  evidence:
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In a cohort of 88 Finnish patients, low hemoglobin levels were common in childhood (54/74, 73%), in addition to macrocytosis (in 47%), but were not seen in adult subjects
    explanation: Reports low haemoglobin in 73% (54/74) of children, which maps to the FREQUENT band (30-79%); the same source notes its absence in adults, which is why the description is age-qualified.
  - reference: PMID:10690856
    reference_title: Anemia in children with cartilage-hair hypoplasia is related to body growth and to the insulin-like growth factor system.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Retrospective analysis of hematological data of 114 patients showed that the severity of the anemia and macrocytosis in CHH varies with age. The anemia was most severe in early childhood.
    explanation: Independent confirmation of the age dependence of the anemia.
- name: Macrocytic anemia
  category: Hematologic
  description: The anemia of CHH is characteristically macrocytic, and macrocytosis occurs even in patients without anemia. Iron studies, vitamin B12 and folate are normal, so this is not a nutritional macrocytosis.
  phenotype_term:
    preferred_term: Macrocytic anemia
    term:
      id: HP:0001972
      label: Macrocytic anemia
  evidence:
  - reference: PMID:39321258
    reference_title: 'Anemia in patients with cartilage hair hypoplasia: a narrative review and recommendations.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Most authors have reported macrocytic anemia and blood transfusion as a common treatment approach in this patient group.
    explanation: Establishes the macrocytic character of the anemia across the published literature.
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Reticulocyte index and haptoglobin, iron and transferrin concentrations, as well as vitamin B12 and folate levels were normal.
    explanation: Excludes nutritional and haemolytic causes for the macrocytosis, which is what makes it a marker of the intrinsic marrow defect.
- name: Autoimmunity
  category: Immunologic
  description: Clinical autoimmune disease occurred in 11/104 Finnish patients and included diverse manifestations. It was associated with recurrent serious infections and higher mortality in observational follow-up; these associations do not establish causality.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Autoimmunity
    term:
      id: HP:0002960
      label: Autoimmunity
  evidence:
  - reference: PMID:30410491
    reference_title: A Wide Spectrum of Autoimmune Manifestations and Other Symptoms Suggesting Immune Dysregulation in Patients With Cartilage-Hair Hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Clinical autoimmunity was common (11/104, 10.6%) and included conditions previously undescribed in subjects with CHH (narcolepsy, psoriasis, idiopathic thrombocytopenic purpura, and multifocal motor axonal neuropathy).
    explanation: Reports clinical autoimmunity in 10.6% (11/104), which maps to the OCCASIONAL band (5-29%).
- name: Autoimmune hemolytic anemia
  category: Immunologic
  description: Autoimmune haemolytic anemia is the most common autoimmune manifestation of CHH and is mechanistically distinct from the hypoplastic anemia of marrow origin.
  phenotype_term:
    preferred_term: Autoimmune hemolytic anemia
    term:
      id: HP:0001890
      label: Autoimmune hemolytic anemia
  evidence:
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Apart from hypoplastic anemia, autoimmune hemolytic anemia (AIHA) has also been described in multiple patients and is the most common autoimmune phenomenon in CHH.
    explanation: Establishes AIHA as the leading autoimmune feature and distinguishes it from the hypoplastic anemia.
- name: Asthma
  category: Respiratory
  description: Physician-diagnosed asthma was reported in 24/104 Finnish patients (23%). The diagnosis can overlap with other respiratory manifestations, and the mechanism and comparability with general-population estimates are uncertain.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Asthma
    term:
      id: HP:0002099
      label: Asthma
  evidence:
  - reference: PMID:30410491
    reference_title: A Wide Spectrum of Autoimmune Manifestations and Other Symptoms Suggesting Immune Dysregulation in Patients With Cartilage-Hair Hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We confirmed the high prevalence of asthma (23%) and allergic rhinoconjunctivitis (39%).
    explanation: Reports asthma in 23%, which maps to the OCCASIONAL band (5-29%).
- name: Allergic rhinitis
  category: Immunologic
  description: Allergic rhinoconjunctivitis was reported in 39% of the Finnish cohort. Some patients lacked allergen-specific sensitization, and five nasal cytology samples showed no eosinophils. These small and partly inconclusive tests do not establish a single mechanism for all reported symptoms.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Allergic rhinitis
    term:
      id: HP:0003193
      label: Allergic rhinitis
  evidence:
  - reference: PMID:30410491
    reference_title: A Wide Spectrum of Autoimmune Manifestations and Other Symptoms Suggesting Immune Dysregulation in Patients With Cartilage-Hair Hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We confirmed the high prevalence of asthma (23%) and allergic rhinoconjunctivitis (39%).
    explanation: Reports allergic rhinoconjunctivitis in 39%, which maps to the FREQUENT band (30-79%).
  - reference: PMID:30410491
    reference_title: A Wide Spectrum of Autoimmune Manifestations and Other Symptoms Suggesting Immune Dysregulation in Patients With Cartilage-Hair Hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Despite the history of allergic rhinitis, no eosinophils were observed in nasal cytology in five tested patients.
    explanation: Retained negative finding qualifying the atopic interpretation; the evidence is limited because only five patients were tested.
- name: Chronic diarrhea
  category: Gastrointestinal
  description: Persistent or recurrent diarrhea is common. The Finnish cohort reported gastrointestinal complaints in 32/104 patients and compared 23 patients with diarrhea against 81 without it, implying approximately 22% with diarrhea. Infectious, inflammatory and malabsorptive causes require evaluation; available endoscopy findings included villous atrophy in some patients.
  phenotype_term:
    preferred_term: Chronic diarrhea
    term:
      id: HP:0002028
      label: Chronic diarrhea
  evidence:
  - reference: PMID:30410491
    reference_title: A Wide Spectrum of Autoimmune Manifestations and Other Symptoms Suggesting Immune Dysregulation in Patients With Cartilage-Hair Hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Gastrointestinal complaints, mostly persistent diarrhea, were also frequently reported (32/104, 31%).
    explanation: Reports gastrointestinal complaints in 31% (32/104), mostly persistent diarrhoea. This denominator does not establish a diarrhoea-specific frequency.
  - reference: PMID:30410491
    reference_title: A Wide Spectrum of Autoimmune Manifestations and Other Symptoms Suggesting Immune Dysregulation in Patients With Cartilage-Hair Hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Significantly more patients with diarrhea reported arthralgia (18/23, 78% vs. 38/81, 47%, p = 0.011, B coefficient 1.41), as compared with those without diarrhea.
    explanation: The comparison gives 23 patients with diarrhea and 81 without it; 23/104 is approximately 22%, distinct from the 31% with any gastrointestinal complaint.
  frequency: OCCASIONAL
- name: Aganglionic megacolon
  category: Gastrointestinal
  description: Hirschsprung disease, reported in 9% of a historical Finnish cohort and 25% of patients born in the 2000s, the rise probably reflecting earlier fatal cases going undiagnosed rather than a true increase.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Aganglionic megacolon
    term:
      id: HP:0002251
      label: Aganglionic megacolon
  evidence:
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The prevalence of HD in the Finnish CHH cohort has increased from 9% (13/142) in the 20th century to 25% (8/32) in the 2000s
    explanation: Both reported figures, 9% and 25%, fall within the OCCASIONAL band (5-29%).
- name: Non-Hodgkin lymphoma
  category: Oncologic
  description: Non-Hodgkin lymphoma is the dominant malignancy of CHH, with a standardized incidence ratio around 90, presenting in young adulthood, usually at advanced stage, and with high mortality. Diffuse large B-cell lymphoma is the most common subtype.
  phenotype_term:
    preferred_term: Non-Hodgkin lymphoma
    term:
      id: HP:0012539
      label: Non-Hodgkin lymphoma
  evidence:
  - reference: PMID:18698627
    reference_title: Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confirms high incidence of non-Hodgkin lymphoma and basal cell carcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Non-Hodgkin lymphoma was the most frequent cancer type (n = 9; SIR 90.2, CI 39.0-180) followed by squamous cell carcinoma (3), leukemia (1) and Hodgkin lymphoma (1).
    explanation: Quantifies the non-Hodgkin lymphoma excess against population expectation.
  - reference: PMID:36211439
    reference_title: Lymphomas in cartilage-hair hypoplasia - A case series of 16 patients reveals advanced stage DLBCL as the most common form.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Lymphoma was diagnosed in young adulthood (median age 26.4 years, range from 6.4 to 69.5 years), mostly in advanced stage.
    explanation: Establishes the age at presentation and the advanced stage driving the poor outcome.
  - reference: PMID:36211439
    reference_title: Lymphomas in cartilage-hair hypoplasia - A case series of 16 patients reveals advanced stage DLBCL as the most common form.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Altogether, eleven CHH patients died due to lymphomas (11/16, 69%).
    explanation: Quantifies lymphoma mortality within the case series.
- name: Basal cell carcinoma
  category: Oncologic
  description: Basal cell carcinoma occurs at greatly elevated frequency and only on sun-exposed skin, which is why sun protection is emphasized in management.
  phenotype_term:
    preferred_term: Basal cell carcinoma
    term:
      id: HP:0002671
      label: Basal cell carcinoma
  evidence:
  - reference: PMID:18698627
    reference_title: Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confirms high incidence of non-Hodgkin lymphoma and basal cell carcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In addition, ten patients had basal cell carcinoma of the skin (expected number 0.3; SIR 33.2, CI 16-61).
    explanation: Quantifies the basal cell carcinoma excess against population expectation.
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Skin cancer in CHH develops only on sun-exposed areas (95); therefore, enhanced sun protection should be emphasized.
    explanation: Supports the anatomical restriction to sun-exposed skin and the resulting management advice.
- name: Neoplasm
  category: Oncologic
  description: Overall malignancy risk is elevated roughly sevenfold over population expectation, concentrated in young adults, and is not confined to patients with clinically apparent immunodeficiency.
  phenotype_term:
    preferred_term: Neoplasm
    term:
      id: HP:0002664
      label: Neoplasm
  evidence:
  - reference: PMID:18698627
    reference_title: Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confirms high incidence of non-Hodgkin lymphoma and basal cell carcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: During the follow-up (2,365 person-years; mean 19.2 years), 14 cases of cancer were diagnosed in the CHH cohort (expected number 2.0; SIR 7.0, CI 3.8-12).
    explanation: Quantifies the overall cancer excess.
  - reference: PMID:18698627
    reference_title: Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confirms high incidence of non-Hodgkin lymphoma and basal cell carcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Nine of the 14 cancers were diagnosed in patients less than 45 years of age.
    explanation: Supports the concentration of malignancy in younger patients.
- name: Severe varicella zoster infection
  category: Immunologic
  description: Severe primary varicella was described as fatal in the original Amish series and remains a recognized risk, although most patients now clear varicella without complication. Low IgG2 has been associated with hospitalization for varicella.
  phenotype_term:
    preferred_term: Severe varicella zoster infection
    term:
      id: HP:0032170
      label: Severe varicella zoster infection
  evidence:
  - reference: PMID:22420014
    reference_title: Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: immediate high-dose intravenous acyclovir for varicella infection
    explanation: The management recommendation presupposes varicella as a recognized severe risk in this population.
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This has not been reported in later case series; vice versa, the majority of patients with CHH clear varicella without antiviral medications or any complications
    explanation: 'Retained counterweight: severe varicella is a real but uncommon outcome, so no frequency band is assigned and the historical framing is qualified.'
  - reference: PMID:28284971
    reference_title: Analysis of clinical and immunologic phenotype in a large cohort of children and adults with cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Lower median IgG2 concentrations (1.08 vs 1.96 g/l, p=0.016) were observed in patients who required hospitalization for VZV infection.
    explanation: Supports the IgG2 association described here.
- name: Short telomere length
  category: Laboratory
  description: Shorter telomeres have been reported in patient lymphocytes, with reduced telomerase activity. In one case-control study, the difference was clearest in children; within that CHH cohort, relative telomere length did not associate with clinical or laboratory features. These results do not establish telomere length as a severity predictor.
  phenotype_term:
    preferred_term: Short telomere length
    term:
      id: HP:0031413
      label: Short telomere length
  evidence:
  - reference: PMID:27986801
    reference_title: Decreased telomere length in children with cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In particular children (<18 years) with CHH had shorter telomeres than controls (median RTL 1.12 vs 1.26, p=0.008).
    explanation: Directly measures the shortened telomere phenotype in children.
  - reference: PMID:28126377
    reference_title: Defects in lymphocyte telomere homeostasis contribute to cellular immune phenotype in patients with cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Here we show that telomere length and telomerase activity are impaired in primary lymphocyte subsets from patients with CHH.
    explanation: Independent measurement in lymphocyte subsets, adding the telomerase activity deficit.
- name: Abnormal spermatogenesis
  category: Genitourinary
  description: Impaired spermatogenesis is a recognized feature of the spectrum, and pubertal maturation may require hormonal induction.
  phenotype_term:
    preferred_term: Abnormal spermatogenesis
    term:
      id: HP:0008669
      label: Abnormal spermatogenesis
  evidence:
  - reference: PMID:22420014
    reference_title: Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Other findings include joint hypermobility, fine, silky hair, immunodeficiency, anemia, increased risk for malignancy, gastrointestinal dysfunction, and impaired spermatogenesis.
    explanation: Names impaired spermatogenesis as a feature of the spectrum.
  - reference: PMID:31551465
    reference_title: The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: A generalized defect in cell proliferation has been speculated to explain several of the clinical manifestations, including disorganized growth-plate chondrocyte maturation, hair hypoplasia, immunodeficiency and impaired spermatogenesis
    explanation: The authors propose a proliferation-based explanation; this sentence does not establish the mechanism of impaired spermatogenesis.
    quote_role: BACKGROUND
    directness: INDIRECT
- name: Arthralgia
  category: Musculoskeletal
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Arthralgia
    term:
      id: HP:0002829
      label: Arthralgia
  description: Joint pain or morning stiffness affected 56/104 Finnish patients. Most did not have diagnosed inflammatory arthritis, and osteoarthritis was common among older symptomatic patients. The combined pain/stiffness measure should not be interpreted as a prevalence of autoimmune arthritis.
  evidence:
  - reference: PMID:30410491
    reference_title: A Wide Spectrum of Autoimmune Manifestations and Other Symptoms Suggesting Immune Dysregulation in Patients With Cartilage-Hair Hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: More than half of our patients (56/104, 54%) suffered from arthralgia or morning joint stiffness, but only one was diagnosed with genuine seronegative juvenile polyarthritis.
    explanation: Documents the combined symptom measure and the distinction from inflammatory arthritis.
- name: Neonatal respiratory insufficiency
  category: Respiratory
  phenotype_term:
    preferred_term: Respiratory insufficiency
    term:
      id: HP:0002093
      label: Respiratory insufficiency
  description: Seven of 19 Finnish neonates with available neonatal records required respiratory support; four were premature. Hypoventilation and pulmonary hypertension were reported indications. The selected denominator and contribution of prematurity preclude a universal CHH frequency or a single established mechanism.
  evidence:
  - reference: PMID:42063088
    reference_title: Perinatal outcomes in 35 children with cartilage hair hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Seven (37%) children needed respiratory support, including intubation and continuous positive airway pressure (CPAP), in the immediate newborn period.
    explanation: Respiratory support was documented in 7/19 infants with additional neonatal information, not all 35 children in the cohort.
genetic:
- name: RMRP
  gene_term:
    preferred_term: RMRP
    term:
      id: hgnc:10031
      label: RMRP
  association: Pathogenic Variants
  relationship_type: CAUSATIVE
  notes: RMRP encodes the untranslated RNA component of RNase MRP. Biallelic promoter and transcribed-region variants cause the CHH-anauxetic dysplasia spectrum. Experimental substrate-specific functional differences have been associated with spectrum phenotypes, but genotype does not reliably predict individual clinical severity. The Finnish and Amish founder allele has been reported as n.70A>G, n.71A>G and n.72A>G under different reference sequences. In a Brazilian series, n.197C>T occurred in 21/30 unrelated probands in compound heterozygosity; haplotype data supported a founder effect. These are cohort findings, not population carrier frequencies. Because RMRP is noncoding, exome coverage must be checked explicitly; promoter analysis may also be necessary. Variant interpretation requires evidence appropriate to a functional RNA rather than protein-coding consequence rules.
  evidence:
  - reference: PMID:11207361
    reference_title: Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We describe numerous mutations in the untranslated RMRP gene that cosegregate with the CHH phenotype.
    explanation: The original cosegregation evidence establishing RMRP as the CHH gene.
  - reference: PMID:31551465
    reference_title: The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: RMRP was the first non-coding nuclear RNA gene implicated in a disease.
    explanation: Supports the historical significance noted here.
  - reference: PMID:31551465
    reference_title: The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'The founder mutation n.71 A > G (NCBI reference sequence: NR_003051.3) has been detected in almost all previously reported Finnish patients with CHH either in homozygous or heterozygous state3.'
    explanation: Specifies the founder allele and its reference sequence, and its dominance in the Finnish population.
  - reference: PMID:28284971
    reference_title: Analysis of clinical and immunologic phenotype in a large cohort of children and adults with cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: All patients were homozygous (n=43) or compound heterozygous (n=13) for the RMRP g.70A>G mutation.
    explanation: Demonstrates the dominance of the founder allele in a genetically confirmed cohort, using the older nomenclature noted above.
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: For example, the founder variant in the Finnish and Amish populations (n.71A>G) has been previously reported as n.70A>G and most recently as n.72A>G.
    explanation: Documents the nomenclature drift for the founder allele that this note warns about.
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Importantly, pathogenic variants in RMRP may be missed on whole-exome sequencing; therefore, RMRP coverage should be specifically inquired for
    explanation: Supports the diagnostic caveat that exome sequencing may not cover this non-coding gene.
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: As an example, of the four criteria of strong evidence of pathogenicity (PS1-4), none is applicable to RMRP variants
    explanation: Supports the variant-interpretation difficulty specific to a non-coding disease gene.
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Genotype-phenotype correlation has not been consistently demonstrated in CHH. Siblings with identical pathogenic variants can exhibit dramatically different clinical course of immunodeficiency
    explanation: 'Important limit on the substrate-dissociation model: the in vitro correlation does not translate into individual prediction, and identical genotypes diverge clinically.'
  - reference: PMID:38862721
    reference_title: Identification of a founder effect involving n.197C>T variant in RMRP gene associated to cartilage-hair hypoplasia syndrome in Brazilian patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: It is noteworthy that 70% of the cohort (21/30), considering only one propositus in familial cases, present the n.197C>T variant in compound heterozygosity.
    explanation: Documents enrichment in the Brazilian cohort, without inferring a population frequency.
  - reference: PMID:38862721
    reference_title: Identification of a founder effect involving n.197C>T variant in RMRP gene associated to cartilage-hair hypoplasia syndrome in Brazilian patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: A common haplotype to the n.197C>T variant carriers was identified.
    explanation: Haplotype sharing supports a founder effect; geographic origin remains an inference.
diagnosis:
- name: Clinical and radiographic diagnosis
  description: Diagnosis is established in a proband with characteristic clinical and radiographic findings. Metaphyseal changes may be absent in the first two years of life and some patients never show them, so normal radiographs do not exclude CHH.
  diagnosis_term:
    preferred_term: skeletal radiography
    term:
      id: NCIT:C38101
      label: X-Ray Imaging
  evidence:
  - reference: PMID:22420014
    reference_title: Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Diagnosis of a CHH-AD spectrum disorder is established in a proband with characteristic clinical and radiographic findings.
    explanation: States the clinical and radiographic basis of diagnosis.
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Some patients' radiographs show no signs of metaphyseal dysplasia despite evident short stature (19) or severe immunodeficiency
    explanation: Supports the caveat that radiographic normality does not exclude the diagnosis.
- name: Molecular genetic testing
  description: Identification of biallelic RMRP variants confirms the diagnosis and enables family studies, carrier testing and prenatal or preimplantation testing. Testing must specifically cover the non-coding gene including its promoter region, since standard exome capture may miss it; whole-genome sequencing, targeted panels fully covering RMRP, or copy-number assessment are the reliable options.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: NCIT:C19770
      label: Molecular Analysis
  evidence:
  - reference: PMID:22420014
    reference_title: Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: identification of biallelic pathogenic variants in RMRP by molecular genetic testing can confirm the diagnosis and allow for family studies
    explanation: Specifies the role of molecular testing relative to clinical diagnosis.
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: diagnostic approach can include whole-genome sequencing or targeted panels that fully capture the RMRP gene, including the promoter region, as well as copy number variation assessment
    explanation: Specifies the testing strategies that reliably cover a non-coding gene and its promoter.
- name: Immunological assessment and surveillance
  description: Baseline and serial assessment includes lymphocyte subsets and function, immunoglobulins, and age-appropriate vaccine responses. Immunophenotyping is one component of this broader evaluation. Laboratory abnormalities and clinical severity do not always align; progression can occur, including in adulthood, but is not universal.
  diagnosis_term:
    preferred_term: Immunological Flow Cytometry
    term:
      id: NCIT:C113003
      label: Immunological Flow Cytometry
  evidence:
  - reference: PMID:32506568
    reference_title: 'Immunodeficiency in cartilage-hair hypoplasia: Pathogenesis, clinical course and management.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Regular follow-up by a multidisciplinary team should be implemented to address immune dysfunction in all patients with CHH, also in asymptomatic cases.
    explanation: Directly supports assessing asymptomatic patients rather than testing on symptoms alone.
  - reference: PMID:31379817
    reference_title: A 30-Year Prospective Follow-Up Study Reveals Risk Factors for Early Death in Cartilage-Hair Hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In conclusion, patients with CHH may develop adult-onset immunodeficiency or malignancy without preceding clinical symptoms of immune defect, warranting careful follow-up.
    explanation: The prospective-cohort conclusion that makes lifelong surveillance the recommended model rather than symptom-triggered testing.
  - reference: PMID:28284971
    reference_title: Analysis of clinical and immunologic phenotype in a large cohort of children and adults with cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: SAD may therefore be a marker of more severe disease and vaccine responses should be routinely studied after infancy.
    explanation: Supports routine vaccine-response testing as part of immunological assessment.
  notes: The ontology binding represents flow-cytometric immunophenotyping; proliferation, immunoglobulin and vaccine-response tests complement it.
- name: Malignancy surveillance
  description: Regular malignancy surveillance includes clinical and laboratory assessment and appropriate imaging. GeneReviews specifies annual examination and abdominal ultrasound every one to two years in children, with adult evaluation according to clinical needs. Follow-up continues beyond childhood because malignancy can develop without preceding clinical immune symptoms. Cohort observations support early detection but do not quantify the independent benefit of a particular screening schedule.
  evidence:
  - reference: PMID:22420014
    reference_title: Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Clinical and laboratory examination for manifestations of malignancy annually in children and as needed in adults; abdominal ultrasound every one to two years in children and as needed in adults.
    explanation: States the surveillance schedule recorded here.
  - reference: PMID:36211439
    reference_title: Lymphomas in cartilage-hair hypoplasia - A case series of 16 patients reveals advanced stage DLBCL as the most common form.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In almost all surviving lymphoma patients, the diagnosis was made either during routine follow-up or after evaluation for non-specific mild symptoms.
    explanation: Survivors were often diagnosed during follow-up or evaluation of mild symptoms. This uncontrolled observation supports vigilance but does not estimate the survival benefit of screening.
  - reference: PMID:36211439
    reference_title: Lymphomas in cartilage-hair hypoplasia - A case series of 16 patients reveals advanced stage DLBCL as the most common form.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Other CHH-related manifestations poorly predicted lymphoma development, implying that all CHH patients should be regularly screened for malignancy.
    explanation: Supports universal rather than risk-stratified screening.
  - reference: PMID:18698627
    reference_title: Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confirms high incidence of non-Hodgkin lymphoma and basal cell carcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Careful follow-up, extending beyond pediatric age, is warranted for early diagnosis of malignancies.
    explanation: Supports continuing surveillance into adulthood.
  diagnosis_term:
    preferred_term: cancer screening
    term:
      id: NCIT:C15406
      label: Cancer Screening
- name: Growth and musculoskeletal surveillance
  diagnosis_term:
    preferred_term: X-Ray Imaging
    term:
      id: NCIT:C38101
      label: X-Ray Imaging
  description: Follow linear growth using CHH-specific curves and assess lower-limb joints and the spine clinically, with radiographs when indicated. The separate recommendation for routine annual spine radiography in anauxetic dysplasia should not be generalized to all patients with CHH.
  evidence:
  - reference: PMID:22420014
    reference_title: Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Monitor growth using CHH-specific growth curves; clinical and (if warranted) radiographic examination of joints of the lower extremities and spine annually in childhood and as required in adulthood;
    explanation: Clinical monitoring and conditional radiography are recommended for the CHH spectrum.
- name: Pregnancy and neonatal assessment
  description: For an affected mother, GeneReviews advises considering planned cesarean delivery because of cephalopelvic disproportion. This differs from an unaffected mother carrying an affected fetus, for whom fetal CHH alone does not establish a cesarean indication. Prenatal short long bones can prompt genetic evaluation. Neonates require assessment for respiratory compromise, anemia, immune dysfunction and Hirschsprung disease; available neonatal frequencies come from a small retrospective Finnish cohort with incomplete records.
  evidence:
  - reference: PMID:22420014
    reference_title: Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Pregnancy management: Fetal growth is generally unaffected;

      therefore, planned cesarean section should be considered in term pregnancies in

      affected women due to cephalopelvic disproportion.'
    explanation: This recommendation concerns mothers who themselves have CHH, not all pregnancies with an affected fetus.
  - reference: PMID:42063088
    reference_title: Perinatal outcomes in 35 children with cartilage hair hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Abnormal growth was observed in prenatal ultrasound in 26/30 (87%) children.
    explanation: Prenatal growth findings were frequent among children with available ultrasound records.
  - reference: PMID:42063088
    reference_title: Perinatal outcomes in 35 children with cartilage hair hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Indications for respiratory support included hypoventilation and pulmonary hypertension.
    explanation: Supports planning for respiratory assessment; prematurity and other factors may contribute.
treatments:
- name: Hematopoietic stem cell transplantation
  description: Allogeneic HSCT can correct severe immune dysfunction and transfusion-dependent anemia. In a historical European series of 16 transplanted patients, 10 were long-term survivors, with normalization of T-cell numbers and function and resolution of autoimmunity. Skeletal dysplasia is not established as corrected by HSCT, although catch-up growth has been reported, possibly because infections decrease. Indications in mildly symptomatic patients remain debated; timing should account for severe infections, organ damage, and malignancy.
  therapeutic_modality: CELL_THERAPY
  treatment_term:
    preferred_term: hematopoietic cell transplantation
    term:
      id: NCIT:C15431
      label: Hematopoietic Cell Transplantation
  target_mechanisms:
  - target: Impaired T-Lymphocyte Proliferation
    treatment_effect: RESTORES
    description: Replacing the haematopoietic compartment with donor cells carrying functional RMRP restores lymphocyte numbers and function.
    evidence:
    - reference: PMID:20375313
      reference_title: Clinical and immunologic outcome of patients with cartilage hair hypoplasia after hematopoietic stem cell transplantation.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: T-lymphocyte numbers and function have normalized, and autoimmunity has resolved in all survivors.
      explanation: Direct evidence that transplantation corrects the lymphoid arm modeled by this node.
  - target: Multilineage Bone Marrow Progenitor Failure
    treatment_effect: RESTORES
    description: Donor progenitors restore erythropoiesis, curing transfusion-dependent anemia.
    evidence:
    - reference: PMID:42170584
      reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The only curative option for severe anemia in CHH remains HSCT, with multiple case reports of successful resolution
      explanation: Direct evidence that transplantation corrects the marrow arm modeled by this node.
  - target: Immune Dysregulation and Autoimmunity
    treatment_effect: RESTORES
    description: Autoimmunity resolved in all long-term survivors of transplantation, consistent with the dysregulation being intrinsic to the haematopoietic compartment.
    evidence:
    - reference: PMID:20375313
      reference_title: Clinical and immunologic outcome of patients with cartilage hair hypoplasia after hematopoietic stem cell transplantation.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: T-lymphocyte numbers and function have normalized, and autoimmunity has resolved in all survivors.
      explanation: Direct evidence of resolution of the autoimmune arm after transplantation.
  evidence:
  - reference: PMID:20375313
    reference_title: Clinical and immunologic outcome of patients with cartilage hair hypoplasia after hematopoietic stem cell transplantation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Previous reports in single CHH patients with significant immunodeficiencies have demonstrated that allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment for the severe immunodeficiency, while growth failure remains unaffected.
    explanation: The abstract summarizes older reports of persistent growth failure. This does not exclude the catch-up growth reported in later clinical synthesis and does not prove chondrocyte autonomy.
  - reference: PMID:20375313
    reference_title: Clinical and immunologic outcome of patients with cartilage hair hypoplasia after hematopoietic stem cell transplantation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Of 16 patients, 10 (62.5%) were long-term survivors, with a median follow-up of 7 years.
    explanation: Quantifies long-term survival in the largest reported transplanted cohort.
  - reference: PMID:20375313
    reference_title: Clinical and immunologic outcome of patients with cartilage hair hypoplasia after hematopoietic stem cell transplantation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: HSCT should be considered in CHH patients with severe immunodeficiency/autoimmunity, before the development of severe infections, major organ damage, or malignancy might jeopardize the outcome of HSCT and the quality of life in these patients.
    explanation: Supports the timing argument for earlier transplantation.
  - reference: PMID:32506568
    reference_title: 'Immunodeficiency in cartilage-hair hypoplasia: Pathogenesis, clinical course and management.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Haematopoietic stem cell transplantation can cure immune dysfunction, but its benefits in mildly symptomatic patients with CHH remain debatable.
    explanation: Retained qualification on patient selection; the evidence is limited because it supports the curative claim while explicitly contesting the indication in mild disease.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK84550/pdf/Bookshelf_NBK84550.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/sites/books/NBK84550/pdf/Bookshelf_NBK84550.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "HSCT has resulted in normalization of \nT lymphocyte numbers & function, \nresolution of autoimmune \nmanifestations, & catch-up growth, \nprobably due to ↓ infections."
    explanation: GeneReviews reports catch-up growth after transplantation; improved growth does not demonstrate reversal of skeletal dysplasia. Full-text PDF of the GeneReviews chapter, PMID:22420014.
    quote_role: REVIEW_SYNTHESIS
- name: Immunoglobulin replacement therapy
  description: Immunoglobulin replacement is considered for clinically relevant antibody deficiency, including low immunoglobulin or IgG subclass levels or inadequate vaccine responses. It supplies passive antibody but does not correct the underlying cellular defect; lung disease can progress despite treatment.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: immunoglobulin therapy
    term:
      id: NCIT:C62710
      label: Immunoglobulin Therapy
  target_mechanisms:
  - target: Cellular and Humoral Immune Dysfunction
    treatment_effect: BYPASSES
    description: Passive antibody supplements inadequate humoral immunity without correcting the underlying RMRP-related defect.
    evidence:
    - reference: PMID:22420014
      reference_title: Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: consideration of prophylactic antibiotic therapy and/or immunoglobulin replacement therapy
      explanation: Establishes immunoglobulin replacement as recommended management for the immune defect.
  evidence:
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hypogammaglobulinemia is present in some, but not all, of these patients, and immunoglobulin replacement therapy (IGRT) is often insufficient to prevent deterioration.
    explanation: The evidence is limited because it establishes the therapy's use while limiting the claim of benefit against progressive lung disease.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK84550/pdf/Bookshelf_NBK84550.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/sites/books/NBK84550/pdf/Bookshelf_NBK84550.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Consider IVIG if immunoglobulin or IgG \nsubclass levels are low, or if vaccine responses \nare inadequate."
    explanation: The indication includes functional antibody deficiency even when total IgG is preserved. Full-text PDF of the GeneReviews chapter, PMID:22420014.
    quote_role: REVIEW_SYNTHESIS
- name: Antimicrobial prophylaxis and treatment of infection
  description: Infections are treated according to type, location and severity, with prophylactic antibiotics considered in selected patients. Antimicrobial management is directed at the consequences of the immune defect rather than at the defect itself.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: antibiotic therapy
    term:
      id: NCIT:C15620
      label: Antibiotic Therapy
  target_mechanisms:
  - target: Chronic Airway Injury
    treatment_effect: INHIBITS
    description: Suppressing recurrent airway infection is the available lever on the infection-to-structural-damage sequence.
    evidence:
    - reference: PMID:22420014
      reference_title: Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: treatment of underlying infections based on their type, location, and severity; immediate high-dose intravenous acyclovir for varicella infection; consideration of prophylactic antibiotic therapy and/or immunoglobulin replacement therapy
      explanation: Establishes both treatment of infection and prophylaxis as recommended management.
  evidence:
  - reference: PMID:22420014
    reference_title: Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: physiotherapy and other acute and long-term medical management for bronchiectasis per pulmonologist
    explanation: Supports the specialist respiratory management arm alongside antimicrobials.
- name: High-dose intravenous acyclovir for varicella
  description: GeneReviews recommends prompt high-dose intravenous acyclovir when varicella develops in CHH to prevent severe complications. The recommendation addresses the risk of severe viral disease despite many patients having an uncomplicated course.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: antiviral therapy
    term:
      id: NCIT:C16119
      label: Antiviral Therapy
    therapeutic_agent:
    - preferred_term: acyclovir
      term:
        id: CHEBI:2453
        label: acyclovir
  target_mechanisms:
  - target: Severe varicella zoster infection
    treatment_effect: INHIBITS
    description: Antiviral treatment suppresses viral replication and is intended to prevent or limit severe varicella complications.
    evidence:
    - reference: PMID:22420014
      reference_title: Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: immediate high-dose intravenous acyclovir for varicella infection
      explanation: States the specific antiviral recommendation for this population.
  evidence:
  - reference: PMID:22420014
    reference_title: Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: immediate high-dose intravenous acyclovir for varicella infection
    explanation: The GeneReviews management recommendation this treatment records.
- name: Live viral vaccination after specialist immune assessment
  description: Live vaccines require individualized specialist assessment and are avoided in severe or clinically significant combined immunodeficiency. The Finnish study supports consideration in selected patients with no or mild clinical immune dysfunction. All five prospective varicella vaccine recipients had normal mitogen responses and normal IgG, although three were lymphopenic. One developed self-limited rash and knee swelling. This small, selected trial does not establish safety across the CHH spectrum; mild lymphopenia alone was not an absolute exclusion in the study.
  therapeutic_modality: VACCINE
  treatment_term:
    preferred_term: vaccination
    term:
      id: NCIT:C15346
      label: Vaccination
  evidence:
  - reference: PMID:22420014
    reference_title: Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Agents/circumstances to avoid: Administration of live vaccines when signs of abnormal immunologic function or SCID are present.'
    explanation: The explicit GeneReviews agents-to-avoid warning, recorded verbatim.
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: as well as vaccine-strain rubella virus-induced skin granulomas
    explanation: Documents a realized live-vaccine complication in CHH, the concrete basis for the warning.
  - reference: PMID:32849667
    reference_title: The Safety and Efficacy of Live Viral Vaccines in Patients With Cartilage-Hair Hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: No serious adverse events have been recorded after immunization with live viral vaccines in Finnish patients with CHH. Patients generate humoral and cellular immune response to live viral vaccines.
    explanation: The retrospective series and five-subject trial support selected use, but do not establish safety in severe clinical combined immunodeficiency or outside the studied population.
  - reference: PMID:32849667
    reference_title: The Safety and Efficacy of Live Viral Vaccines in Patients With Cartilage-Hair Hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Immunization with live vaccines may be considered in selected CHH patients with no or clinically mild immunodeficiency.
    explanation: The authors' own scoped conclusion, which is the position this entry adopts.
  - reference: PMID:22420014
    reference_title: Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Early diagnosis of relatives at risk for the CHH-AD spectrum disorders allows for early management of manifestations that can be associated with significant morbidity (e.g., infections, immunization with live vaccines, malignancies).
    explanation: Supports extending the same precaution to at-risk relatives before formal diagnosis.
  - reference: PMID:32849667
    reference_title: The Safety and Efficacy of Live Viral Vaccines in Patients With Cartilage-Hair Hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Three patients were lymphopenic, with various abnormalities in lymphocyte subpopulations. Lymphocyte responses to stimulation with mitogens were normal in all patients. All five patients had normal levels of immunoglobulin G.
    explanation: The trial population had preserved tested function despite some low cell counts, limiting generalization.
  - reference: PMID:32849667
    reference_title: The Safety and Efficacy of Live Viral Vaccines in Patients With Cartilage-Hair Hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Even though several patients with clinical features of combined immunodeficiency have been immunized with MMR successfully, we advise against live vaccine administration to these patients.
    explanation: The study itself limits its favorable conclusion and advises against live vaccines in clinical combined immunodeficiency.
    quote_role: BACKGROUND
- name: Red blood cell transfusion with iron chelation
  description: Severe anemia is managed with red cell transfusion, and iron chelation is recommended for those requiring repeated transfusion. Transfusion dependency typically presents in the first months of life and may remit spontaneously or recur after prolonged remission, so the requirement should be reassessed rather than assumed permanent.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: blood transfusion
    term:
      id: NCIT:C15192
      label: Blood Transfusion
  target_mechanisms:
  - target: Multilineage Bone Marrow Progenitor Failure
    treatment_effect: BYPASSES
    description: Transfused red cells substitute for the erythropoiesis the marrow cannot sustain, without correcting the progenitor defect.
    evidence:
    - reference: PMID:39321258
      reference_title: 'Anemia in patients with cartilage hair hypoplasia: a narrative review and recommendations.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Most authors have reported macrocytic anemia and blood transfusion as a common treatment approach in this patient group.
      explanation: Establishes transfusion as the standard supportive approach to the anemia.
  evidence:
  - reference: PMID:39321258
    reference_title: 'Anemia in patients with cartilage hair hypoplasia: a narrative review and recommendations.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Recommended guidelines for managing anemia in CHH patients include iron chelation therapy for those requiring multiple blood transfusions, regular assessment of anemia symptoms, red blood cell parameters, and immune system function.
    explanation: States the chelation and monitoring recommendations recorded here.
  - reference: PMID:22420014
    reference_title: Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: red blood cell transfusions for severe anemia with iron chelation as needed
    explanation: Independent statement of the same management pairing.
- name: Orthopedic surgical management
  description: Corrective osteotomy may be required for progressive varus deformity of the lower extremities. The North American review reported 32 patients who had undergone surgery, most often for genu varum. Published surgical percentages use inconsistent denominators, so a single population-wide percentage is not assigned.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: orthopedic surgical procedure
    term:
      id: NCIT:C16186
      label: Orthopedic Surgical Procedure
  target_mechanisms:
  - target: Genu varum
    treatment_effect: INHIBITS
    description: Realignment osteotomy corrects the varus deformity produced by asymmetric metaphyseal growth.
    evidence:
    - reference: PMID:22420014
      reference_title: Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: corrective osteotomies may be required for progressive varus deformity of the lower extremities
      explanation: States the surgical indication for the deformity targeted here.
  evidence:
  - reference: PMID:25764362
    reference_title: 'Cartilage hair hypoplasia: characteristics and orthopaedic manifestations.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Of the cases reviewed, 32 patients had undergone surgery, most commonly to correct genu varum.
    explanation: The primary report supplies the number operated; its text and conclusion use inconsistent percentage denominators.
- name: Growth hormone therapy, generally not recommended
  description: Routine growth hormone treatment is not recommended because sustained benefit has not been established. A review describes eight patients with ineffective or temporary responses, but also reports improvement in a child without growth hormone deficiency. A later case report describes improved growth during approximately two years of treatment without final-height follow-up. Coexisting growth hormone deficiency warrants endocrine assessment, although replacement does not guarantee a growth response. These heterogeneous observations do not demonstrate correction of the underlying chondrocyte defect. Growth hormone did not improve erythroid colony formation in the cited anemia study.
  therapeutic_modality: PEPTIDE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Several case reports (altogether, of eight patients) have described GH therapy as ineffective or, at most, with temporary benefit
    explanation: Summarizes limited or absent benefit in reported cases, supporting the recommendation against routine use without proving universal futility.
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: However, GH deficiency has also been reported in CHH patients, and for them, GH treatment might be beneficial
    explanation: Supports assessment for a potentially treatable endocrine contribution; benefit in an individual patient is not assured.
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: In addition, in a single patient with genetically confirmed CHH and no GH deficiency, GH treatment improved height from −4.2 SDS prior to treatment at 3 years of age to −2.6 SDS at 6 years
    explanation: Records an exception without growth hormone deficiency. This single child's response does not establish sustained final-height benefit.
  - reference: PMID:39886981
    reference_title: RMRP variants inhibit the cell cycle checkpoints pathway in cartilage‑hair hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Notably, treatment with GH for ~2 years resulted in a gradual improvement; however, the patient should be tracked for a longer period to observe the final effect.
    explanation: A later single-patient report describes improvement over limited follow-up and explicitly leaves the final effect unresolved.
  - reference: PMID:35663969
    reference_title: 'Sirolimus Restores Erythropoiesis and Controls Immune Dysregulation in a Child With Cartilage-Hair Hypoplasia: A Case Report.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Progressive growth delay associated with growth hormone de ﬁciency poorly responding to replacement therapy also developed
    explanation: Describes poor response despite growth hormone deficiency in a patient with a clinical CHH diagnosis. The reported RMRP variants lacked functional confirmation, limiting molecular attribution.
  - reference: PMID:10690856
    reference_title: Anemia in children with cartilage-hair hypoplasia is related to body growth and to the insulin-like growth factor system.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Bone marrow cultures obtained from six patients with CHH showed reduced or totally absent erythroid colony formation, which was not influenced by GH or IGF-I in vitro or by GH treatment in vivo.
    explanation: Supports the absence of an erythroid response in this study; it does not establish the skeletal response in all patients.
- name: Pulmonary physiotherapy and bronchiectasis care
  treatment_term:
    preferred_term: Respiratory Therapy
    term:
      id: NCIT:C15322
      label: Respiratory Therapy
  description: Pulmonology-led care includes airway-clearance physiotherapy and individualized acute and long-term management of bronchiectasis. Imaging and clinical follow-up should reflect symptoms and existing disease severity.
  evidence:
  - reference: PMID:22420014
    reference_title: Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: physiotherapy and other acute and long-term medical management for bronchiectasis per pulmonologist
    explanation: GeneReviews explicitly includes pulmonary physiotherapy and specialist management.
- name: Nutritional support for gastrointestinal disease
  treatment_term:
    preferred_term: Nutritional Support
    term:
      id: NCIT:C15433
      label: Nutritional Support
  description: Assess nutrition in patients with short bowel syndrome or malabsorption and address the underlying gastrointestinal condition. Hirschsprung disease and congenital megacolon require standard specialist management; persistent diarrhea warrants evaluation of infectious, inflammatory, and malabsorptive causes.
  evidence:
  - reference: PMID:22420014
    reference_title: Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: standard treatments for malignancies, congenital megacolon, Hirschsprung disease, and intestinal malabsorption; nutritional evaluation in those with short bowel syndrome;
    explanation: Supports gastrointestinal care and nutritional evaluation, without assuming a single cause of diarrhea.
- name: Hormonal induction for delayed puberty
  treatment_term:
    preferred_term: Hormone Replacement Therapy
    term:
      id: NCIT:C15599
      label: Hormone Replacement Therapy
  description: Assess pubertal development and investigate hypogonadism when puberty is delayed. Hormonal induction may be needed for pubertal maturation, according to endocrine evaluation.
  evidence:
  - reference: PMID:22420014
    reference_title: Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: hormonal induction as needed for pubertal maturation;
    explanation: GeneReviews describes conditional hormonal treatment, not universal therapy.
- name: Sirolimus for anemia, single-case evidence
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Sirolimus
      term:
        id: NCIT:C1212
        label: Sirolimus
  description: One patient with a clinical CHH diagnosis and ALPS-like immune dysregulation had improved anemia and erythroid colony growth during sirolimus treatment, deterioration after withdrawal, and improvement after restarting. Immune deficiency nevertheless progressed and ultimately required HSCT after cryptococcal meningoencephalitis. Both RMRP variants remained formally uncertain without functional validation, and somatic FAS disease was not excluded. This report is exploratory evidence, not an established CHH treatment or demonstration of a specific mTOR-mediated rescue mechanism.
  evidence:
  - reference: PMID:35663969
    reference_title: 'Sirolimus Restores Erythropoiesis and Controls Immune Dysregulation in a Child With Cartilage-Hair Hypoplasia: A Case Report.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We report the case of a young girl presenting with transfusion-dependent erythropoietic failure and immunological features resembling autoimmune lymphoproliferative syndrome who responded well to empirical sirolimus.
    explanation: A single uncontrolled case supports a possible treatment effect with substantial diagnostic and mechanistic limitations.
  - reference: PMID:35663969
    reference_title: 'Sirolimus Restores Erythropoiesis and Controls Immune Dysregulation in a Child With Cartilage-Hair Hypoplasia: A Case Report.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The patient eventually underwent a haploidentical bone marrow transplant due to progressive combined immunodeficiency manifested as cryptococcal meningoencephalitis.
    explanation: The anemia response did not prevent progression of immune deficiency.
clinical_trials:
- name: NCT02383797
  status: UNKNOWN
  description: >-
    Phase 4, open-label, single-group VZV immunization study with five
    participants. Selection by disease severity and immune function limits
    applicability to patients without clinical immunodeficiency. The registry
    status was UNKNOWN on 2026-10-04; the last known status was active, not
    recruiting, with the last registry update in October 2019. Published
    results describe humoral and cellular responses, and one participant's
    rash and knee swelling that resolved without treatment. Publication of
    these results does not establish a current COMPLETED registry status.
  target_phenotypes:
  - preferred_term: Severe varicella zoster infection
    term:
      id: HP:0032170
      label: Severe varicella zoster infection
  - preferred_term: Decreased specific antibody response to vaccination
    term:
      id: HP:0032140
      label: Decreased specific antibody response to vaccination
  evidence:
  - reference: clinicaltrials:NCT02383797
    reference_title: "Immunodeficiency in Cartilage-hair Hypoplasia: Correlation With Pulmonary Disease, Infections and Malignancy"
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: BACKGROUND
    snippet: "The investigators will verify the development of immune response to vaccination by testing for VZV antibodies and cell-mediated immunity."
    explanation: >-
      The registered protocol's stated objective, matching the immunization
      question this entry curates under live viral vaccination.
  - reference: PMID:32849667
    reference_title: "The Safety and Efficacy of Live Viral Vaccines in Patients With Cartilage-Hair Hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We conducted a clinical trial (ClinicalTrials.gov identifier: NCT02383797) of live VZV vaccine on five subjects with CHH who lacked varicella history, had no clinical symptoms of immunodeficiency, and were seronegative for VZV"
    explanation: >-
      Ties the registered trial to its publication and states the enrolment
      criteria that scope its conclusion to mildly affected patients.
  - reference: PMID:32849667
    reference_title: "The Safety and Efficacy of Live Viral Vaccines in Patients With Cartilage-Hair Hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical trial participants developed humoral and cellular responses to VZV vaccine. One trial participant developed post-immunization rash and knee swelling, both resolved without treatment."
    explanation: >-
      Reports the trial outcome including its single adverse event; the evidence is limited because five participants cannot establish safety across the full CHH immune-deficiency spectrum.
differential_diagnoses:
- name: Anauxetic dysplasia
  disease_term:
    preferred_term: anauxetic dysplasia
    term:
      id: MONDO:0011773
      label: anauxetic dysplasia
  description: The severe end of the same RMRP spectrum, reached by allele combinations producing the greatest loss of rRNA cleavage activity. It shares the molecular lesion but is skeletally far more severe and may include atlantoaxial subluxation and cognitive deficiency, while the hair, immune and haematologic features characteristic of CHH are not assumed to be present.
  distinguishing_features:
  - Markedly more severe skeletal dysplasia, with the most pronounced short stature of the spectrum.
  - Atlantoaxial subluxation may be present in the newborn, which is not characteristic of CHH.
  - Cognitive deficiency may occur, which is not a feature of CHH.
  - Hair, immune and haematologic involvement is conditional rather than characteristic.
  evidence:
  - reference: PMID:17701897
    reference_title: Type and level of RMRP functional impairment predicts phenotype in the cartilage hair hypoplasia-anauxetic dysplasia spectrum.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Mutations in the RMRP gene lead to a wide spectrum of autosomal recessive skeletal dysplasias, ranging from the milder phenotypes metaphyseal dysplasia without hypotrichosis and cartilage hair hypoplasia (CHH) to the severe anauxetic dysplasia (AD).
    explanation: Places CHH and anauxetic dysplasia at different points of one allelic spectrum.
  - reference: PMID:22420014
    reference_title: Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The most severe phenotype, AD, has the most pronounced skeletal phenotype, may be associated with atlantoaxial subluxation in the newborn, and may include cognitive deficiency.
    explanation: Names the features that separate anauxetic dysplasia from CHH clinically.
- name: Metaphyseal dysplasia without hypotrichosis
  disease_term:
    preferred_term: metaphyseal dysplasia without hypotrichosis
    term:
      id: MONDO:0009601
      label: metaphyseal dysplasia without hypotrichosis
  description: 'The mild end of the same RMRP spectrum, distinguished from CHH by absence of hair involvement. Its status as a separate entity is doubtful: longitudinal follow-up of such individuals has revealed late-onset immune abnormalities typical of CHH, so the distinction may reflect age at assessment rather than a different disease.'
  distinguishing_features:
  - Absence of hypotrichosis, as reflected in the disease name.
  - Milder skeletal phenotype than CHH.
  - May be reclassified as CHH on longer follow-up once immune features emerge.
  evidence:
  - reference: PMID:17701897
    reference_title: Type and level of RMRP functional impairment predicts phenotype in the cartilage hair hypoplasia-anauxetic dysplasia spectrum.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Mutations in the RMRP gene lead to a wide spectrum of autosomal recessive skeletal dysplasias, ranging from the milder phenotypes metaphyseal dysplasia without hypotrichosis and cartilage hair hypoplasia (CHH) to the severe anauxetic dysplasia (AD).
    explanation: Places metaphyseal dysplasia without hypotrichosis at the mild end of the same spectrum as CHH.
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: However, the longitudinal follow-up of such individuals has revealed late-onset development of immune abnormalities typical for CHH.
    explanation: Supports treating the distinction as provisional rather than a firm diagnostic boundary.
- name: Schmid metaphyseal chondrodysplasia
  disease_term:
    preferred_term: metaphyseal chondrodysplasia, Schmid type
    term:
      id: MONDO:0007983
      label: Schmid metaphyseal chondrodysplasia
  description: Autosomal dominant COL10A1-related metaphyseal dysplasia shares short stature and radiographic metaphyseal abnormalities with CHH. The absence of the characteristic extraskeletal manifestations of CHH helps distinguish it.
  distinguishing_features:
  - Autosomal dominant COL10A1-related disease rather than autosomal recessive RMRP-related disease.
  - Metaphyseal dysplasia, especially of the proximal femur, without the characteristic extraskeletal manifestations of CHH.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK84550/pdf/Bookshelf_NBK84550.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/sites/books/NBK84550/pdf/Bookshelf_NBK84550.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "COL10A1\nCOL10A1-related metaphyseal \ndysplasia Schmid (See Schmid \nMetaphyseal Chondrodysplasia.)\nAD\nShort stature & radiographic \nmetaphyseal abnormalities \n(metaphyseal dysplasia esp in \nproximal femur) resembling \nCHH\nNo extraskeletal manifestations"
    explanation: The GeneReviews differential table directly identifies the gene, inheritance, overlap and distinguishing features. Full-text PDF of the GeneReviews chapter, PMID:22420014.
    quote_role: REVIEW_SYNTHESIS
- name: Shwachman-Diamond syndrome
  disease_term:
    preferred_term: Shwachman-Diamond syndrome
    term:
      id: MONDO:0009833
      label: Shwachman-Diamond syndrome
  description: Shwachman-Diamond syndrome overlaps with CHH through short stature, metaphyseal abnormalities, infections and anemia. Exocrine pancreatic insufficiency, neutropenia and poor weight gain are prominent distinguishing features; skeletal changes are usually milder.
  distinguishing_features:
  - Exocrine pancreatic insufficiency and poor weight gain are principal manifestations.
  - Neutropenia is a principal hematologic feature.
  - Skeletal features are usually milder than in CHH.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK84550/pdf/Bookshelf_NBK84550.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/sites/books/NBK84550/pdf/Bookshelf_NBK84550.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "• Milder skeletal features \n(usually)\n• Principal manifestations: \nexocrine pancreatic \ninsufficiency, neutropenia, \npoor weight gain, & growth \ndeficiency"
    explanation: The Shwachman-Diamond row in the GeneReviews differential table directly supports these distinctions. Full-text PDF of the GeneReviews chapter, PMID:22420014.
    quote_role: REVIEW_SYNTHESIS
- name: Dyskeratosis congenita
  disease_term:
    preferred_term: dyskeratosis congenita
    term:
      id: MONDO:0015780
      label: dyskeratosis congenita
  description: Dyskeratosis congenita and related telomere biology disorders overlap with CHH through marrow failure, immune abnormalities, malignancy susceptibility and short telomeres. The classic mucocutaneous triad favors dyskeratosis congenita, whereas metaphyseal dysplasia and disproportionate short-limb stature favor CHH; neither diagnosis requires every characteristic finding.
  distinguishing_features:
  - Classic mucocutaneous triad of dysplastic nails, reticular skin pigmentation and oral leukoplakia, which is not present in every patient.
  - Metaphyseal dysplasia and disproportionate short-limb stature favor CHH.
  - Caused by telomere maintenance genes rather than by RMRP.
  evidence:
  - reference: PMID:28126377
    reference_title: Defects in lymphocyte telomere homeostasis contribute to cellular immune phenotype in patients with cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The CHH disease phenotype has some overlap with dyskeratosis congenita, a well-known "telomere disorder."
    explanation: Explicitly names the phenotypic overlap that makes this a mechanistically motivated differential.
  - reference: PMID:20301779
    reference_title: Dyskeratosis Congenita and Related Telomere Biology Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Classic DC is characterized by a triad of dysplastic nails, lacy \nreticular pigmentation of the upper chest and/or neck, and oral leukoplakia, \nalthough this may not be present in all individuals."
    explanation: GeneReviews directly supports the classic distinguishing signs while acknowledging incomplete presentation.
    quote_role: REVIEW_SYNTHESIS
datasets:
- accession: arrayexpress:E-MTAB-10996
  title: RNA-seq of control and CHH fibroblasts transdifferentiated into chondrocyte-like cells
  description: Bulk transcriptomes from four patient and four control fibroblast donors before and during chondrogenic transdifferentiation. The 24 samples represent repeated day 0, 1, and 3 measurements, not 24 independent donors.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 24
  platform: Illumina NextSeq
  publication: PMID:34988338
  evidence:
  - reference: PMID:34988338
    reference_title: Uncovering pathways regulating chondrogenic differentiation of CHH fibroblasts.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Total RNA was isolated at three different time points during FDC transdifferentiation (Day 0, 1, and 3; in total 24 RNA samples) using the mirVana miRNA Isolation Kit (Thermo Fisher Scientific) according to the manufacturer's protocol.
    explanation: Twenty-four culture samples derive from eight donors measured at three time points.
- accession: bioproject:PRJEB23608
  title: Transcriptomic analysis of CHH patient and control fibroblasts using STRT sequencing
  description: RNA profiles from fibroblasts of five founder-variant patients and five matched controls across culture passages. The study retained 18 patient and 17 control samples after quality exclusions. Despite the STRT method name, each library used 10 ng of total RNA; this is not a single-cell transcriptomic atlas.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  publication: PMID:31551465
  evidence:
  - reference: PMID:31551465
    reference_title: The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Four samples (two case passages and two control passages) were excluded due to low 5′ capture rate, indicative of partial RNA degradation, leaving 18 and 17 acceptable samples for analysis, respectively (see Supplementary Table S3).
    explanation: The analytical sample counts are repeated culture passages from ten donors.
- accession: geo:GSE171019
  title: A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis [human]
  description: Human K562 CRAC experiments identify RNAs interacting with tagged RNase MRP/P protein components after UV crosslinking. This is protein-RNA interaction profiling, not conventional transcript abundance RNA-seq.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  sample_count: 8
  publication: PMID:35115551
  notes: The human CRAC subseries of GSE171021. The same superseries also contains yeast experiments and a separate human RMRP SHAPE subseries.
- accession: geo:GSE190787
  title: A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis [RMRP_SHAPE]
  description: In-cell SHAPE profiling of RMRP in wild-type and founder-variant cells with 1M7 or DMSO control. Targeted sequencing measures RNA modification sites to infer structure, rather than whole-transcriptome expression.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  sample_count: 12
  publication: PMID:35115551
- accession: pride:PXD025029
  title: A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis
  description: Proteomic resource accompanying the engineered RMRP founder-variant cell study, including analyses of ribosome abundance and RNA-associated proteins.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: PROTEOMICS
  publication: PMID:35115551
experimental_models:
- name: Rmrp-deficient ATDC5 chondrogenic cell model
  experimental_model_type: CELL_LINE
  organism:
    preferred_term: mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  cell_types:
  - preferred_term: chondrocyte
    term:
      id: CL:0000138
      label: chondrocyte
  cell_source: Mouse ATDC5 chondrogenic cell line
  culture_system: Monolayer chondrogenic differentiation culture with Rmrp RNA interference
  conditions:
  - Rmrp knockdown
  - Control chondrogenic differentiation
  publication: PMID:28743979
  description: Rmrp RNA interference in mouse ATDC5 cultures impairs hypertrophic differentiation, matrix accumulation, and mineralization, alongside changes in pre-rRNA processing and rRNA abundance. The monolayer model does not reproduce growth-plate architecture or isolate one RNA substrate as the mediator.
  modeled_mechanisms:
  - target: Growth Plate Chondrocyte Differentiation Failure
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: Measures chondrogenic differentiation and hypertrophy after Rmrp interference.
    limitations: A murine immortalized chondrogenic line in monolayer culture; it models the differentiation step but not growth-plate architecture, limb proportion, or any extraskeletal disease.
    readouts:
    - name: Chondrogenic differentiation and hypertrophy
      target: Growth Plate Chondrocyte Differentiation Failure
      direction: DECREASED
      interpretation: Cellular correlate of the growth-plate differentiation node.
      evidence:
      - reference: PMID:28743979
        reference_title: Expression of RMRP RNA is regulated in chondrocyte hypertrophy and determines chondrogenic differentiation.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: Genetic interference with Rmrp RNA expression in ATDC5 cultures caused a deregulation of chondrogenic differentiation, with a prominent impact on hypertrophy and changes in pre-rRNA processing and rRNA levels.
        explanation: Directly demonstrates the differentiation and hypertrophy defect.
    evidence:
    - reference: PMID:28743979
      reference_title: Expression of RMRP RNA is regulated in chondrocyte hypertrophy and determines chondrogenic differentiation.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Genetic interference with Rmrp RNA expression in ATDC5 cultures caused a deregulation of chondrogenic differentiation, with a prominent impact on hypertrophy and changes in pre-rRNA processing and rRNA levels.
      explanation: Supports treating this model as informative for the growth-plate node.
  evidence:
  - reference: PMID:28743979
    reference_title: Expression of RMRP RNA is regulated in chondrocyte hypertrophy and determines chondrogenic differentiation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Genetic interference with Rmrp RNA expression in ATDC5 cultures caused a deregulation of chondrogenic differentiation, with a prominent impact on hypertrophy and changes in pre-rRNA processing and rRNA levels.
    explanation: Establishes the model, perturbation, molecular readout and cellular phenotype.
- name: CHH patient-derived fibroblast cell-cycle and transcriptome model
  experimental_model_type: PRIMARY_CELL_CULTURE
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  cell_source: Primary dermal fibroblasts from patients with cartilage-hair hypoplasia and healthy controls
  culture_system: Monolayer culture with pulse-labeling, time-lapse microscopy and RNA sequencing
  conditions:
  - CHH patient fibroblasts
  - Healthy control fibroblasts
  publication: PMID:31551465
  description: Primary fibroblasts from five Finnish patients homozygous for the founder RMRP variant and five matched controls were assessed by RNA sequencing, pulse labeling, and time-lapse microscopy. Direct tracking localized the proliferation delay to G2-to-mitosis progression. Transcriptomic pathway associations do not establish the mechanism of disease in other tissues.
  modeled_mechanisms:
  - target: Delayed G2-to-M Progression
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: Directly measures cell-cycle progression and transcriptome changes in patient-derived cells carrying the disease genotype.
    limitations: Patient fibroblasts provide an accessible cellular phenotype, but they are not growth-plate, lymphocyte, or marrow cells. The study did not perform RMRP complementation, and multiple passages from each donor are repeated observations rather than independent patients.
    readouts:
    - name: G2-to-mitosis transit time
      target: Delayed G2-to-M Progression
      direction: INCREASED
      interpretation: Delayed passage from G2 into mitosis is the specific cell-cycle lesion this node asserts.
      evidence:
      - reference: PMID:31551465
        reference_title: The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: Cell-cycle studies indicated that the CHH cells were delayed specifically in the passage from G2 phase to mitosis.
        explanation: The direct measurement of the readout in patient cells.
    evidence:
    - reference: PMID:31551465
      reference_title: The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: We combined transcriptome analysis with single-cell analysis using fibroblasts from CHH patients and healthy controls.
      explanation: Establishes the model system and the two orthogonal measurement approaches.
  findings:
  - statement: CHH fibroblasts had 35 significantly upregulated and 130 downregulated genes; the downregulated set was enriched for cell-cycle functions.
    supporting_text: The downregulated genes were significantly connected to the cell cycle.
    evidence:
    - reference: PMID:31551465
      reference_title: The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Transcriptome analysis identified 35 significantly upregulated and 130 downregulated genes in CHH fibroblasts. The downregulated genes were significantly connected to the cell cycle.
      explanation: The experimental result is quoted directly from the publication abstract.
  evidence:
  - reference: PMID:31551465
    reference_title: The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: To directly assess cell cycle progression, we followed CHH fibroblasts by pulse-labeling and time-lapse microscopy.
    explanation: Establishes the direct cell-cycle measurement rather than inference from static assays.
- name: Patient bone marrow progenitor colony-forming assay
  experimental_model_type: PRIMARY_CELL_CULTURE
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  cell_types:
  - preferred_term: erythroid progenitor cell
    term:
      id: CL:0000038
      label: erythroid progenitor cell
  cell_source: Bone marrow and peripheral blood from patients with cartilage-hair hypoplasia
  culture_system: Semi-solid colony-forming assay for erythroid, megakaryocyte and granulocyte-macrophage progenitors
  conditions:
  - Patient-derived progenitors
  - Normal progenitor controls
  - Standard versus more effectively stimulated culture
  publication: PMID:7895753
  description: Colony assays in eight patients with CHH and a history of anemia demonstrate impaired myeloid progenitor function. Erythroid progenitor numbers were normal or increased under stronger stimulation, supporting a functional defect rather than depletion. Colony formation did not correlate with peripheral blood counts.
  modeled_mechanisms:
  - target: Multilineage Bone Marrow Progenitor Failure
    relationship: RECAPITULATES
    fidelity: HIGH
    description: Measures colony formation across erythroid, megakaryocyte and granulocyte-macrophage lineages in patient-derived progenitors.
    limitations: Ex vivo culture in eight patients; the defect did not track peripheral blood counts, so it cannot serve as a severity readout for an individual patient.
    readouts:
    - name: Erythroid, megakaryocyte and granulocyte-macrophage colony formation
      target: Multilineage Bone Marrow Progenitor Failure
      direction: DECREASED
      interpretation: Functional demonstration of the multilineage progenitor defect in patient cells.
      evidence:
      - reference: PMID:7895753
        reference_title: Defective in-vitro colony formation of haematopoietic progenitors in patients with cartilage-hair hypoplasia and history of anaemia.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: All patients showed decreased erythroid and megakaryocyte colony formation. Only one patient had a normal granulocyte-macrophage growth, while the others showed decreased numbers of colonies.
        explanation: Reports the measured colony deficit across all three lineages.
    evidence:
    - reference: PMID:7895753
      reference_title: Defective in-vitro colony formation of haematopoietic progenitors in patients with cartilage-hair hypoplasia and history of anaemia.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: The present study shows defective in vitro colony formation in all myeloid lineages in patients with CHH, which is in accordance with the suggestion of a common cell proliferation defect in CHH.
      explanation: Supports treating this assay as informative for the marrow-failure node.
  findings:
  - statement: Colony formation fails despite normal or increased progenitor numbers, identifying a functional proliferation defect rather than progenitor depletion.
    supporting_text: The impaired growth was not caused by a decreased number of progenitors as shown by erythroid cultures.
    evidence:
    - reference: PMID:7895753
      reference_title: Defective in-vitro colony formation of haematopoietic progenitors in patients with cartilage-hair hypoplasia and history of anaemia.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: The impaired growth was not caused by a decreased number of progenitors as shown by erythroid cultures. The erythroid progenitors were incapable of colony formation in culture conditions sufficient for colony formation by normal progenitors.
      explanation: The experimental result is quoted directly from the publication abstract.
  evidence:
  - reference: PMID:7895753
    reference_title: Defective in-vitro colony formation of haematopoietic progenitors in patients with cartilage-hair hypoplasia and history of anaemia.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: In the present study erythroid, megakaryocyte, and granulocyte-macrophage colony formation in vitro by progenitors from bone marrow and blood was investigated in eight patients with CHH.
    explanation: Establishes the model system, cell source and readout.
- name: Patient fibroblast-derived chondrocyte transdifferentiation
  experimental_model_type: PRIMARY_CELL_CULTURE
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  cell_source: Dermal fibroblasts from four CHH patients and four control donors
  culture_system: High-density plating on aggrecan with TGF-beta3, ITS, and ascorbic acid; days 0, 1, and 3
  publication: PMID:34988338
  description: Patient cells acquire a chondrocyte-like phenotype with impaired commitment to terminal differentiation. RNA sequencing and selected protein assays identify altered BMP, FGF, and IGF-1 pathway components.
  modeled_mechanisms:
  - target: Growth Plate Chondrocyte Differentiation Failure
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: Patient cells acquire a chondrocyte-like phenotype with impaired commitment to terminal differentiation. RNA sequencing and selected protein assays identify altered BMP, FGF, and IGF-1 pathway components.
    limitations: Small donor cohort and short descriptive culture study. These are transdifferentiated fibroblasts, not primary growth-plate chondrocytes. COL10A1 reduction was not significant in this study, unlike the earlier experiment, and COL2A1 was not detected. Pathway causality requires functional perturbation.
    evidence:
    - reference: PMID:34988338
      reference_title: Uncovering pathways regulating chondrogenic differentiation of CHH fibroblasts.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: We demonstrated that CHH fibroblasts are capable of transdifferentiating into chondrocyte-like cells, and show a reduced commitment to terminal differentiation.
      explanation: The model retains chondrogenic capacity but has impaired terminal differentiation; it is not a complete failure to form chondrocytes.
    - reference: PMID:34988338
      reference_title: Uncovering pathways regulating chondrogenic differentiation of CHH fibroblasts.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: The sample size presented in this study is limited to four individuals per group, however, considering the rarity of CHH it is a reasonable number.
      explanation: The study used four patient and four control donors; repeated time points are not additional independent donors.
  evidence:
  - reference: PMID:34988338
    reference_title: Uncovering pathways regulating chondrogenic differentiation of CHH fibroblasts.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: We demonstrated that CHH fibroblasts are capable of transdifferentiating into chondrocyte-like cells, and show a reduced commitment to terminal differentiation.
    explanation: The model retains chondrogenic capacity but has impaired terminal differentiation; it is not a complete failure to form chondrocytes.
  - reference: PMID:34988338
    reference_title: Uncovering pathways regulating chondrogenic differentiation of CHH fibroblasts.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: The sample size presented in this study is limited to four individuals per group, however, considering the rarity of CHH it is a reasonable number.
    explanation: The study used four patient and four control donors; repeated time points are not additional independent donors.
- name: RMRP founder-variant K562 cells
  experimental_model_type: CELL_LINE
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  cell_source: K562 chronic myelogenous leukemia cells with CRISPR-engineered homozygous RMRP 70AG, compared with parental cells
  culture_system: Suspension culture; pre-rRNA analysis, FlowFISH, proteomics, RNA-protein interaction assays, and SHAPE RNA probing
  publication: PMID:35115551
  description: The founder substitution delays pre-rRNA processing and reduces mature rRNA and intact RNase MRP complex abundance. Total RMRP RNA is not significantly reduced, and the mature 5.8S short-to-long ratio is unchanged.
  modeled_mechanisms:
  - target: Impaired Pre-rRNA Processing
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: The founder substitution delays pre-rRNA processing and reduces mature rRNA and intact RNase MRP complex abundance. Total RMRP RNA is not significantly reduced, and the mature 5.8S short-to-long ratio is unchanged.
    limitations: An engineered malignant cell line tests one allele in a tractable system. It does not reproduce patient immune, cartilage, or hair phenotypes; clone-dependent effects were observed.
    evidence:
    - reference: PMID:35115551
      reference_title: A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Human cells engineered with the most common CHH mutation (70AG in RMRP) show specifically impaired pre-rRNA processing, resulting in reduced mature rRNA and a reduced ratio of cytosolic to mitochondrial ribosomes.
      explanation: The engineered K562 founder-variant model links genotype to processing and ribosome abundance.
  evidence:
  - reference: PMID:35115551
    reference_title: A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Human cells engineered with the most common CHH mutation (70AG in RMRP) show specifically impaired pre-rRNA processing, resulting in reduced mature rRNA and a reduced ratio of cytosolic to mitochondrial ribosomes.
    explanation: The engineered K562 founder-variant model links genotype to processing and ribosome abundance.
- name: Rmrp-disrupted primary mouse T-cell cultures
  experimental_model_type: PRIMARY_CELL_CULTURE
  organism:
    preferred_term: mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  cell_source: Naive antigen-specific OT-1 Rag-deficient mouse T cells isolated from peripheral lymph nodes
  culture_system: Ovalbumin-peptide activation followed by CRISPR electroporation at 24 hours and proliferation/pre-rRNA assays 48 hours later
  publication: PMID:35115551
  description: Rmrp disruption impairs expansion of viable activated T cells and changes pre-rRNA precursor abundance.
  modeled_mechanisms:
  - target: Impaired T-Lymphocyte Proliferation
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: Rmrp disruption impairs expansion of viable activated T cells and changes pre-rRNA precursor abundance.
    limitations: Ex vivo cultures contain heterogeneous CRISPR-generated alleles. This is not a whole-animal disease model, and guide-specific effects on proliferation and pre-rRNA accumulation were not fully concordant.
    evidence:
    - reference: PMID:35115551
      reference_title: A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: This showed that disruption of RMRP markedly impaired T cell proliferation.
      explanation: CRISPR perturbation was performed in activated primary mouse T-cell cultures, not in a viable whole-animal Rmrp knockout.
  evidence:
  - reference: PMID:35115551
    reference_title: A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: This showed that disruption of RMRP markedly impaired T cell proliferation.
    explanation: CRISPR perturbation was performed in activated primary mouse T-cell cultures, not in a viable whole-animal Rmrp knockout.
animal_models:
- name: rmrp knockout zebrafish
  species: Zebrafish
  genotype: rmrp knockout
  publication: PMID:31237961
  description: Rmrp knockout zebrafish permit study of early chondrogenesis, ossification, cell proliferation and apoptosis, but survive only 12-14 days. Canonical Wnt/beta-catenin signaling is increased, and pharmacological inhibition partly alleviates skeletal abnormalities. This is preclinical developmental evidence; efficacy in mammalian CHH or patients has not been established.
  modeled_mechanisms:
  - target: Growth Plate Chondrocyte Differentiation Failure
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: Reproduces dysregulated chondrogenesis and abnormal ossification, and implicates Wnt/beta-catenin as a reversible effector.
    limitations: Zebrafish cartilage development differs architecturally from the mammalian endochondral growth plate, and the primary readouts are pharyngeal arch patterning and skull and vertebral ossification rather than long-bone metaphyseal growth; ossification effects are directionally mixed, being inhibited in skull and promoted in vertebrae, which has no clean human counterpart.
    readouts:
    - name: Chondrogenesis and bone ossification
      target: Growth Plate Chondrocyte Differentiation Failure
      direction: ALTERED
      interpretation: Whole-organism correlate of the cartilage differentiation node; ALTERED rather than DECREASED because ossification changed in opposite directions in different skeletal elements.
      evidence:
      - reference: PMID:31237961
        reference_title: Rmrp Mutation Disrupts Chondrogenesis and Bone Ossification in Zebrafish Model of Cartilage-Hair Hypoplasia via Enhanced Wnt/β-Catenin Signaling.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: Rmrp mutation inhibits the intramembranous ossification of skull bones and promotes vertebrae ossification. The abnormalities of endochondral bone ossification are variable, depending on the degree of dysregulated chondrogenesis.
        explanation: Reports the cartilage and ossification phenotype, including its direction-dependence by skeletal element.
    evidence:
    - reference: PMID:31237961
      reference_title: Rmrp Mutation Disrupts Chondrogenesis and Bone Ossification in Zebrafish Model of Cartilage-Hair Hypoplasia via Enhanced Wnt/β-Catenin Signaling.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: We also demonstrate that rmrp mutation upregulates canonical Wnt/β-catenin signaling; the pharmacological inhibition of Wnt/β-catenin could partially alleviate the chondrodysplasia and increased vertebrae mineralization in rmrp mutants.
      explanation: Pharmacological rescue supports the model being mechanistically informative rather than merely phenotypically similar.
  - target: Delayed G2-to-M Progression
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: Shows reduced proliferation and increased apoptosis, but does not resolve the G2-to-M delay measured in patient fibroblasts.
    limitations: Gene-expression-level evidence in a whole zebrafish embryo; it does not resolve the specific G2-to-M step identified in human patient cells.
    readouts:
    - name: Reduced cell proliferation
      target: Delayed G2-to-M Progression
      direction: DECREASED
      interpretation: A related proliferation phenotype, not a direct measurement of G2 transit time.
      evidence:
      - reference: PMID:31237961
        reference_title: Rmrp Mutation Disrupts Chondrogenesis and Bone Ossification in Zebrafish Model of Cartilage-Hair Hypoplasia via Enhanced Wnt/β-Catenin Signaling.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: Moreover, rmrp mutation inhibits cell proliferation and promotes apoptosis through dysregulating the expressions of cell-cycle- and apoptosis-related genes.
        explanation: Reports the proliferation and apoptosis readouts in the model.
    - name: Increased apoptosis
      target: Delayed G2-to-M Progression
      direction: INCREASED
      interpretation: A separate cell-death phenotype accompanying reduced proliferation; it does not directly establish G2 delay.
      evidence:
      - reference: PMID:31237961
        reference_title: Rmrp Mutation Disrupts Chondrogenesis and Bone Ossification in Zebrafish Model of Cartilage-Hair Hypoplasia via Enhanced Wnt/β-Catenin Signaling.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: Moreover, rmrp mutation inhibits cell proliferation and promotes apoptosis through dysregulating the expressions of cell-cycle- and apoptosis-related genes.
        explanation: Reports the proliferation and apoptosis readouts in the model.
    evidence:
    - reference: PMID:31237961
      reference_title: Rmrp Mutation Disrupts Chondrogenesis and Bone Ossification in Zebrafish Model of Cartilage-Hair Hypoplasia via Enhanced Wnt/β-Catenin Signaling.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Moreover, rmrp mutation inhibits cell proliferation and promotes apoptosis through dysregulating the expressions of cell-cycle- and apoptosis-related genes.
      explanation: Supports treating the model as informative for the proliferation arm.
  evidence:
  - reference: PMID:31237961
    reference_title: Rmrp Mutation Disrupts Chondrogenesis and Bone Ossification in Zebrafish Model of Cartilage-Hair Hypoplasia via Enhanced Wnt/β-Catenin Signaling.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Currently, the pathogenesis of osteochondrodysplasia and extraskeletal manifestations in CHH patients remains incompletely understood; in addition, there are no viable animal models for CHH. We generated an rmrp KO zebrafish model to study the developmental mechanisms of CHH.
    explanation: Describes generation of the model. The statement about absent viable models refers to the background preceding this experiment.
  - reference: url:https://ern-ithaca.eu/wp-content/uploads/2020/12/Vakkilainen_CH_immnuo_ScandJImmuno2020.pdf
    reference_title: https://ern-ithaca.eu/wp-content/uploads/2020/12/Vakkilainen_CH_immnuo_ScandJImmuno2020.pdf
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The absence \nof RMRP expression was detrimental also in zebrafish as mu-\ntants survived only for 12-14 days; however, early develop -\nmental stages could be examined."
    explanation: The review describes death in the larval period, limiting the developmental model to early stages. Full-text PDF of the management review, PMID:32506568.
    quote_role: REVIEW_SYNTHESIS
discussions:
- discussion_id: gap_chh_hirschsprung_mechanism
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: By what route does deficiency of a ubiquitously expressed non-coding RNA produce failure of enteric neural crest colonization, and why does this manifest as Hirschsprung disease in only a minority of patients?
  attaches_to:
  - pathophysiology#Enteric Aganglionosis
  - pathophysiology#Delayed G2-to-M Progression
  rationale: The association between CHH and Hirschsprung disease is established, but the link from RMRP dysfunction to enteric aganglionosis is unknown. Reduced proliferation or migration of enteric neural crest cells is a testable hypothesis. Existing cell-cycle findings in other cell types do not establish that mechanism or explain incomplete penetrance. Hypoplastic gut in a model must also be distinguished from loss of enteric ganglia.
  proposed_experiments:
  - experiment_id: exp_chh_enteric_crest_colonization
    name: Enteric neural crest colonization under graded RMRP deficiency
    description: Track enteric neural crest cell proliferation, migration velocity and terminal colonization of the distal gut across a graded allelic series of RMRP deficiency, using the zebrafish model and patient-derived enteric neural crest-like cells, and test whether the colonization front fails to reach the hindgut within the developmental window. Measure Cyclin B2 turnover in the migrating population to test the cell-cycle account specifically.
    decision_criterion: A dose-dependent colonization defect accompanied by impaired neural crest proliferation and rescue after RMRP correction would support this mechanism. Normal colonization in one model would limit its applicability but would not exclude effects of other alleles, developmental stages or species.
    supporting_outcome:
    - RMRP-dependent proliferation or migration defects contribute to impaired enteric neural crest colonization.
    refuting_outcome:
    - Colonization remains normal under the tested conditions despite documented RMRP dysfunction, weakening this model-specific hypothesis.
  evidence:
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hirschsprung's disease (HD) is a well-known comorbidity of CHH, although the pathogenetic link between RMRP deficiency and HD remains unknown.
    explanation: Explicit statement in the review literature that this mechanism is unknown, which is what makes it a knowledge gap rather than an omission.
- discussion_id: gap_chh_cancer_surveillance_versus_cell_autonomous
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: What are the relative contributions of immune dysfunction and cell-intrinsic RMRP effects to lymphoma susceptibility in CHH?
  attaches_to:
  - pathophysiology#Malignancy Predisposition
  - pathophysiology#Impaired Telomere Maintenance
  - pathophysiology#Delayed G2-to-M Progression
  rationale: Lymphoma risk is elevated, but its causal basis is unresolved. Malignancy can occur without preceding clinical immune symptoms; this does not demonstrate normal immune function or exclude impaired surveillance. Cell-cycle and telomere abnormalities measured in selected patient cells motivate investigation of intrinsic susceptibility, but have not been established in every tissue or in the malignant clone. Immune and intrinsic mechanisms may coexist, and cancer risk after HSCT is not determined by these observations.
  proposed_experiments:
  - experiment_id: exp_chh_lymphoma_clonal_origin
    name: Genomic and clonal characterization of CHH-associated lymphomas
    description: Sequence CHH-associated lymphomas for mutational signatures of replication stress and telomere crisis, quantify telomere length and cyclin dysregulation within the malignant clone against the patient's own non-malignant lymphocytes, and determine Epstein-Barr virus status systematically rather than opportunistically. Compare against sporadic diffuse large B-cell lymphoma and against lymphomas arising in non-CHH immunodeficiencies.
    decision_criterion: Enrichment of replication-stress or telomere-crisis signatures relative to appropriate lymphoma controls would support an intrinsic contribution, especially with functional validation. Absence of enrichment would be inconclusive about immune surveillance and other intrinsic mechanisms.
    supporting_outcome:
    - CHH-associated lymphomas show functionally supported intrinsic RMRP-related susceptibility in addition to any immune contribution.
    refuting_outcome:
    - The tested genomic signatures are not enriched, weakening those specific intrinsic hypotheses without proving a purely immune mechanism.
  evidence:
  - reference: PMID:10064668
    reference_title: Increased incidence of cancer in patients with cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This study confirms an increased risk of cancer, especially non-Hodgkin's lymphoma, probably attributable to defective immunity, among patients with CHH.
    explanation: The surveillance attribution is offered as probable, not demonstrated, which is the opening this gap addresses.
  - reference: PMID:31379817
    reference_title: A 30-Year Prospective Follow-Up Study Reveals Risk Factors for Early Death in Cartilage-Hair Hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Of the 15 patients with non-skin cancer, eight had no preceding clinical symptoms of immunodeficiency.
    explanation: Absence of prior clinical symptoms limits clinical prediction; it does not establish normal immune function.
- discussion_id: gap_chh_telomerase_post_transcriptional_mechanism
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: How does loss of RMRP reduce telomerase activity when telomerase gene transcript levels are normal?
  attaches_to:
  - pathophysiology#Impaired Telomere Maintenance
  rationale: Reduced telomerase activity was not explained by relative telomerase-gene transcript levels in the studied lymphocytes. Protein abundance, assembly, localization and cell-state effects remain candidates. The reported TERT-RMRP complex has RNA-dependent RNA polymerase activity and should not be equated with the telomerase holoenzyme. A relationship between impaired ribosome production and telomerase function is plausible but has not been demonstrated in CHH.
  proposed_experiments:
  - experiment_id: exp_chh_telomerase_assembly_step
    name: Localizing the post-transcriptional telomerase defect in CHH lymphocytes
    description: In patient lymphocytes across an allelic series, quantify TERT protein abundance, TERC levels, telomerase holoenzyme assembly and trafficking, and TERT-RMRP complex formation, and test whether restoring TERT protein alone rescues telomerase activity. Run the same panel in cells where ribosome synthesis is limited independently of RMRP, to separate a specific TERT-RMRP effect from a general translational ceiling.
    decision_criterion: Identify which protein, assembly or trafficking defect tracks reduced activity and responds to RMRP correction. Reproduction by an independent ribosome perturbation would support a shared route, but specificity and mediation would require rescue experiments and control of cell activation and proliferation.
    supporting_outcome:
    - A specific post-transcriptional RMRP-telomerase mechanism independent of general ribosome limitation
    refuting_outcome:
    - Independent ribosome perturbation reproduces the defect, weakening a uniquely RMRP-specific explanation while leaving the mediating steps unresolved.
  evidence:
  - reference: PMID:28126377
    reference_title: Defects in lymphocyte telomere homeostasis contribute to cellular immune phenotype in patients with cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Telomerase deficiency in patients with CHH is not mediated by abnormal telomerase gene transcript levels relative to those of endogenous genes.
    explanation: The measured relative transcript levels do not explain the activity deficit; the result does not establish one particular post-transcriptional mechanism.
  - reference: PMID:28126377
    reference_title: Defects in lymphocyte telomere homeostasis contribute to cellular immune phenotype in patients with cartilage-hair hypoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: These findings suggest that telomere deficiency is implicated in the CHH disease phenotype through an as yet unidentified mechanism.
    explanation: The authors state directly that the mechanism is unidentified.
- discussion_id: gap_chh_hsct_effect_on_linear_growth
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: Does haematopoietic stem cell transplantation ever rescue linear growth in CHH, and if so, what distinguishes the patients in whom it does?
  attaches_to:
  - pathophysiology#Growth Plate Chondrocyte Differentiation Failure
  - pathophysiology#Multilineage Bone Marrow Progenitor Failure
  rationale: 'Reports of growth after HSCT differ: older summaries describe persistent growth failure, whereas GeneReviews reports catch-up growth, possibly related to fewer infections, and two promoter-variant cases reportedly normalized growth. Improved linear growth does not by itself establish reversal of skeletal dysplasia. Genotype, age, chronic illness, nutrition and conditioning may contribute to differences. These observations do not establish skeletal growth as an indication for HSCT.'
  proposed_experiments:
  - experiment_id: exp_chh_growth_trajectory_after_hsct
    name: Genotype-stratified growth trajectories before and after transplantation
    description: Compare longitudinal height trajectories against CHH-specific curves before and after HSCT, with age- and genotype-matched untransplanted comparators. Record nutrition, infection burden, conditioning, pubertal development and skeletal imaging. Analyze promoter and transcribed-region variants separately where numbers permit, while accounting for indication and survivor bias.
    decision_criterion: A reproducible change in growth trajectory would support an association with HSCT, while accompanying clinical and skeletal findings could distinguish catch-up growth from structural change. Observational comparisons alone would not establish causality or justify transplantation for growth.
    supporting_outcome:
    - A subgroup shows reproducible improvement in linear growth associated with HSCT after adjustment for major measured confounders.
    refuting_outcome:
    - No meaningful trajectory difference is detected within the precision and follow-up of the study.
  evidence:
  - reference: PMID:20375313
    reference_title: Clinical and immunologic outcome of patients with cartilage hair hypoplasia after hematopoietic stem cell transplantation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment for the severe immunodeficiency, while growth failure remains unaffected
    explanation: The abstract summarizes earlier reports of persistent growth failure, which must be read alongside later observations of catch-up growth.
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Skeletal features are not altered by HSCT (68); however, two patients normalized their growth after HSCT, one homozygous and another compound heterozygous for promoter region duplications
    explanation: Carries both sides of the discrepancy in one sentence, including the variant class shared by the two exceptional patients; the evidence is limited because two cases cannot settle the question either way.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK84550/pdf/Bookshelf_NBK84550.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/sites/books/NBK84550/pdf/Bookshelf_NBK84550.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "HSCT has resulted in normalization of \nT lymphocyte numbers & function, \nresolution of autoimmune \nmanifestations, & catch-up growth, \nprobably due to ↓ infections."
    explanation: GeneReviews reports catch-up growth and proposes reduced infections as an explanation. Full-text PDF of the GeneReviews chapter, PMID:22420014.
    quote_role: REVIEW_SYNTHESIS
- discussion_id: mismatch_chh_no_viable_mouse_model
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  prompt: Can conclusions about CHH pathogenesis be validated in a mammalian whole-organism system, given that Rmrp knockout mice die before embryonic day 6.5 while heterozygotes are healthy?
  attaches_to:
  - pathophysiology#RMRP Non-Coding RNA Loss of Function
  - pathophysiology#Growth Plate Chondrocyte Differentiation Failure
  rationale: The reported mouse disruption is lethal before embryonic day 6.5, whereas heterozygotes are healthy despite reduced RMRP expression. This limits that model for studying the viable human disease, but does not exclude future hypomorphic or conditional models. Zebrafish knockouts permit developmental analysis before larval death and show partial pharmacological rescue; whether the same response occurs in a mammalian growth plate is unresolved. Mammalian cell and tissue studies provide complementary evidence without reproducing the complete organismal phenotype.
  proposed_experiments:
  - experiment_id: exp_chh_hypomorphic_mouse_knockin
    name: Hypomorphic and conditional Rmrp mouse alleles reproducing patient variants
    description: Generate knock-in mice carrying the founder n.71A>G variant and a promoter-region insertion allele, plus a chondrocyte-conditional deletion, and characterize growth-plate architecture, limb proportion, immune reconstitution and erythropoiesis. Test whether beta-catenin inhibition rescues the skeletal phenotype in a mammalian growth plate as it partially does in zebrafish.
    decision_criterion: A viable hypomorphic or tissue-specific allele that reproduces relevant patient phenotypes would enable mammalian tests of the proposed pathway. Failure of the selected constructs would limit those designs, not prove that no murine disease model can exist.
    supporting_outcome:
    - A graded mammalian model of RMRP deficiency is achievable and can validate the zebrafish rescue
    refuting_outcome:
    - The tested alleles fail to reproduce the relevant phenotype, requiring alternative dosage, tissue or developmental designs.
  evidence:
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Mouse model for RMRP deficiency has never been established, as Rmrp knockout by insertion of DNA elements upstream the promoter was lethal early in embryonic development before embryonic day (E) 6.5
    explanation: Establishes the absence of a viable mouse null, the core of this mismatch.
  - reference: PMID:42170584
    reference_title: 'Cartilage-hair hypoplasia: A comprehensive review.'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Hemizygous mice missing one RMRP allele showed 50% decrease of RMRP expression in embryonic fibroblasts and were healthy
    explanation: The reported heterozygous mice were unaffected despite reduced expression; this does not establish the effects of all hypomorphic alleles.
references:
- reference: PMID:20301779
  title: "Dyskeratosis Congenita and Related Telomere Biology Disorders."
  tags:
  - GeneReviews
  findings: []
- reference: PMID:22420014
  title: Cartilage-Hair Hypoplasia - Anauxetic Dysplasia Spectrum Disorders
  tags:
  - GeneReviews
- reference: PMID:42170584
  title: 'Cartilage-hair hypoplasia: A comprehensive review'
- reference: PMID:11207361
  title: Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia
- reference: PMID:35115551
  title: A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis
- reference: PMID:31551465
  title: The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2
- reference: PMID:31379817
  title: A 30-Year Prospective Follow-Up Study Reveals Risk Factors for Early Death in Cartilage-Hair Hypoplasia
- reference: PMID:32506568
  title: 'Immunodeficiency in cartilage-hair hypoplasia: Pathogenesis, clinical course and management'
- reference: PMID:39886981
  title: RMRP variants inhibit the cell cycle checkpoints pathway in cartilage‑hair hypoplasia.
- reference: PMID:35663969
  title: 'Sirolimus Restores Erythropoiesis and Controls Immune Dysregulation in a Child With Cartilage-Hair Hypoplasia: A Case Report.'
- reference: PMID:37115363
  title: Homozygous RMRP Promoter Duplications Cause Severely Reduced Transcript Abundance and SCID Associated with Cartilage Hair Hypoplasia.
- reference: PMID:17701897
  title: Type and level of RMRP functional impairment predicts phenotype in the cartilage hair hypoplasia-anauxetic dysplasia spectrum.
- reference: PMID:34988338
  title: Uncovering pathways regulating chondrogenic differentiation of CHH fibroblasts.
- reference: PMID:21570718
  title: Reduced thymic output, cell cycle abnormalities, and increased apoptosis of T lymphocytes in patients with cartilage-hair hypoplasia.
- reference: PMID:38862721
  title: Identification of a founder effect involving n.197C>T variant in RMRP gene associated to cartilage-hair hypoplasia syndrome in Brazilian patients.
- reference: PMID:42063088
  title: Perinatal outcomes in 35 children with cartilage hair hypoplasia.

📚

References & Deep Research

References

PMID:20301779

Dyskeratosis Congenita and Related Telomere Biology Disorders.

No top-level findings curated for this source.

PMID:22420014

Cartilage-Hair Hypoplasia - Anauxetic Dysplasia Spectrum Disorders

No top-level findings curated for this source.

PMID:42170584

Cartilage-hair hypoplasia: A comprehensive review

No top-level findings curated for this source.

PMID:11207361

Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia

No top-level findings curated for this source.

PMID:35115551

A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis

No top-level findings curated for this source.

PMID:31551465

The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2

No top-level findings curated for this source.

PMID:31379817

A 30-Year Prospective Follow-Up Study Reveals Risk Factors for Early Death in Cartilage-Hair Hypoplasia

No top-level findings curated for this source.

PMID:32506568

Immunodeficiency in cartilage-hair hypoplasia: Pathogenesis, clinical course and management

No top-level findings curated for this source.

PMID:39886981

RMRP variants inhibit the cell cycle checkpoints pathway in cartilage‑hair hypoplasia.

No top-level findings curated for this source.

PMID:35663969

Sirolimus Restores Erythropoiesis and Controls Immune Dysregulation in a Child With Cartilage-Hair Hypoplasia: A Case Report.

No top-level findings curated for this source.

PMID:37115363

Homozygous RMRP Promoter Duplications Cause Severely Reduced Transcript Abundance and SCID Associated with Cartilage Hair Hypoplasia.

No top-level findings curated for this source.

PMID:17701897

Type and level of RMRP functional impairment predicts phenotype in the cartilage hair hypoplasia-anauxetic dysplasia spectrum.

No top-level findings curated for this source.

PMID:34988338

Uncovering pathways regulating chondrogenic differentiation of CHH fibroblasts.

No top-level findings curated for this source.

PMID:21570718

Reduced thymic output, cell cycle abnormalities, and increased apoptosis of T lymphocytes in patients with cartilage-hair hypoplasia.

No top-level findings curated for this source.

PMID:38862721

Identification of a founder effect involving n.197C>T variant in RMRP gene associated to cartilage-hair hypoplasia syndrome in Brazilian patients.

No top-level findings curated for this source.

PMID:42063088

Perinatal outcomes in 35 children with cartilage hair hypoplasia.

No top-level findings curated for this source.

Deep Research

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (3)

Review cartilage-hair hypoplasia mechanisms and clinical evidence · 2026-10-04T19:30:49Z · View source

Reviewed the existing entry against its deep-research report, GeneReviews and cached primary literature, reading available full scientific texts, including the RNase MRP complex/ribosome, patient-cell cycle, small-RNA, chondrocyte, immune, lymphoma, lung, vaccine and recent clinical studies. Abstract-only sources remain qualified; supplementary files were not systematically reviewed. Full-text retrieval for PMID17701897 remained inaccessible, so its abstract was not treated as full-text evidence. Separated regulatory promoter effects, RNA abundance, transcribed-region variants and intact RNase MRP complex loss. Distinguished measured pre-rRNA/ribosome, mRNA turnover, G2, telomere and small-RNA findings from hypotheses about tissue consequences. Split thymic output, activated T-cell death and clinical immune dysfunction; qualified lymphoma, autoimmunity, airway, hair and enteric mechanisms. Revised the overview and knowledge-gap experiments to avoid causal conclusions unsupported by the cited experiments. Corrected numeric birth-prevalence bands and phenotype frequency denominators, added joint pain and neonatal respiratory observations, and incorporated the Brazilian founder cohort. Reworked HSCT/growth, GH, vaccination and exploratory sirolimus interpretation; added pulmonary, nutritional, pubertal and pregnancy/neonatal care. Moved malignancy screening to diagnosis, corrected immune testing and antiviral targets, and replaced unsupported differential citations with GeneReviews evidence. Kept anauxetic-dysplasia-specific care distinct from CHH. Added patient-derived chondrocyte, engineered K562 and primary mouse T-cell culture models and five verified datasets. Corrected G2 transit-time direction and zebrafish larval viability/proliferation/apoptosis interpretation. Registry NCT02383797 is UNKNOWN on live API, with last-known ACTIVE_NOT_RECRUITING status from 2019; protocol statements are separate from published clinical outcomes. Completeness cross-check: phenotype, spectrum/differential distinctions, mechanisms, treatment/trial, genetics, diagnostic/surveillance and high-value reference/dataset coverage addressed. No new disease subtype split was warranted. Validation: schema and ontology terms passed; 279 snippets and 296 titles matched cached sources before automatic tagging of the differential GeneReviews citation. All five datasets verified; all 477 snippets in six other consumers of refreshed shared references matched. Pathograph target check passed. Cache changes are fetcher-generated or validator normalization; no reference markdown was manually created or edited.

Address PR #8500 review findings · 2026-08-14T19:28:21Z · View source

Addressed the ai4c-reviewer CHANGES_REQUESTED findings on PR #8500. Finding 1 (missing high-frequency phenotypes): added Short metacarpal (HP:0010049) and Coxa vara (HP:0002812, OCCASIONAL from 27 percent, 19/71) sourced to PMID:25764362, which was fetched for this purpose because the deep-research report flagged it as paraphrase-only; and Decreased total neutrophil count (HP:0001875) with no frequency band, since the sources describe single patients. The reviewer's fourth suggestion, Decreased circulating immunoglobulin concentration (HP:0004313) at 19 percent, was NOT added: the proposed supporting sentence describes symptoms of humoral immunodeficiency, a clinical category, not measured immunoglobulin concentration, and PMID:42170584 states directly that hypogammaglobulinemia is rare in CHH and that some individuals are hypergammaglobulinemic. Curated the supported phenotype instead, Decreased specific antibody response to vaccination (HP:0032140), carrying the contradicting quote as evidence so the distinction is recorded in the entry rather than only in the PR thread. Finding 2: added a clinical_trials block for NCT02383797 with the trial record fetched via just fetch-reference. Finding 3: added a negative growth-hormone treatment entry, but sourced to PMID:42170584 rather than to GeneReviews as the reviewer stated, because the cached GeneReviews record contains no growth-hormone statement; included the coexisting-GH-deficiency carve-out and the independent negative erythroid result from PMID:10690856. Suggestion 4 accepted: added gap_chh_hsct_effect_on_linear_growth, sourced to the reviewer-unmentioned but quotable sentence in PMID:42170584 recording two promoter-variant patients who normalized growth after transplant, rather than to the deep-research report's GeneReviews attribution which the cached record does not support. Suggestion 5 (anti-TNF for granulomas) declined: the cached GeneReviews record contains no TNF or granuloma text and PMID:42170584 describes rituximab and HSCT for CHH granulomas, so the claim is unsourceable from cached evidence. Also wired two previously dangling phenotypes (Scoliosis, Abnormal spermatogenesis) into the pathograph. Validated with just validate and just validate-disorders, both passing with 207/207 snippets verified against cached references; pathograph re-checked for a single root, no dangling phenotypes and no model-organism-only phenotype support; just check-title-snippets clean; compliance 86.1 percent global (383/445 fields, up from 352/445 in absolute terms).

Create: Cartilage-hair hypoplasia · 2026-08-14T18:34:09Z · View source

Created the CHH entry de novo. Deep research: claude_code provider (research/Cartilage-Hair_Hypoplasia-deep-research-claude_code.md; 63 references, 63 verified, confabulation_rate 0.0, no unresolved_references). NEC preflight PASS against MONDO:0009595 (canonical gene RMRP dominant, 43 mentions). GeneReviews baseline PMID:22420014 (CHH-AD spectrum chapter) read and cross-referenced; its Clinical Characteristics phenotypes are all represented, and its Agents/Circumstances to Avoid warning on live vaccines is carried on a dedicated treatment entry alongside the countervailing evidence from PMID:32849667. Pathograph is 13 nodes with a single root (RMRP Non-Coding RNA Loss of Function) fanning into four molecular substrate arms (pre-rRNA processing, Cyclin B2 mRNA cleavage/G2-to-M, telomere maintenance, RMRP-derived small RNA silencing) and reconverging on tissue outcomes. Deliberately kept distinct from the existing sibling entry Anauxetic_Dysplasia (MONDO:0011773), which covers the severe end of the same RMRP allelic spectrum; CHH is cited there as a differential and vice versa. Three KNOWLEDGE_GAP discussions (Hirschsprung mechanism, surveillance vs cell-autonomous lymphomagenesis, post-transcriptional telomerase defect) and one HUMAN_MODEL_MISMATCH (no viable mammalian model; Rmrp knockout mice die before E6.5). Validated with just validate (schema, terms, references) and just validate-disorders, both passing with 190/190 snippets verified against cached references; just compliance 86.9 percent global, 87.0 percent weighted; just check-title-snippets clean.

Claude Code ▸

Cartilage-Hair Hypoplasia (CHH) — Comprehensive Research Report

claude-haiku-4-5-20251001, claude-opus-5[1m] 24 citations 2026-08-14T13:54:08.257756

Cartilage-Hair Hypoplasia (CHH) — Comprehensive Research Report

Prepared: 2026-08-14 · Target KB entry: kb/disorders/Cartilage-Hair_Hypoplasia.yaml

0. Evidence-verification status (read this first)

I pulled abstracts through Europe PMC. These I have verbatim and safe to quote:

PMID	Short handle
11207361	Ridanpää 2001 Cell — gene discovery
31379817	Vakkilainen 2019 Front Immunol — 30-yr follow-up, mortality
30410491	Vakkilainen 2018 Front Immunol — autoimmunity/allergy
35115551	Robertson 2022 Nat Commun — ribosomopathy
31551465	Vakkilainen 2019 Sci Rep — G2 cell-cycle delay
31237961	Sun 2019 JBMR — zebrafish rmrp model
28126377	Aubert 2017 JACI — telomere biology
33675005	Vakkilainen 2021 J Clin Immunol — lung imaging
32849667	Vakkilainen 2020 Front Immunol — live vaccines
20375313	Bordon 2010 Blood — EBMT HSCT cohort
42170584	Vakkilainen 2025 J Hum Immun — comprehensive review

These I have paraphrase only — re-fetch before quoting: 18698627, 17701897, 16252239, 16254002, 18804272, 24009312, 25764362, 8444246, 11391344, 37115363, 38862721, 34956076, 38676846, 38187867, 22420014 (GeneReviews — a book chapter, not abstract-shaped anyway).

Ontology IDs below are suggestions. Every one needs just validate-terms before it lands. I flag the shakier ones explicitly.

1. Disease Information

Overview

Cartilage-hair hypoplasia is what happens when you break the cell's ribosome factory in a way that's bad but not lethal. It's an autosomal recessive, multi-system disorder in which a single non-protein-coding RNA gene — RMRP — is disabled, and the fallout lands hardest on the tissues that need to divide fastest: growth-plate cartilage, hair follicles, the T-cell compartment, and the erythroid line. Hence the four-part clinical signature: short-limbed short stature, fine sparse hair, combined immunodeficiency, and macrocytic anemia. Layered on top are Hirschsprung disease, autoimmunity, and a genuinely alarming lymphoma risk.

The 2025 review states it cleanly (verbatim, PMID:42170584):

"Cartilage-hair hypoplasia (CHH) is a rare syndromic inborn error of immunity, caused by variants in the noncoding RNA gene RMRP. The effects of RMRP deficiency are pleiotropic, affecting the ribosomal RNA processing, cell cycle, and gene regulation. Typical clinical manifestations of CHH include chondrodysplasia with short stature, hair hypoplasia, combined immunodeficiency, and anemia. In addition, individuals with CHH have increased prevalence of malignancies, Hirschsprung's disease, and autoimmunity. The only curative option for immunodeficiency or severe anemia in CHH remains hematopoietic stem cell transplantation."

Historically it's McKusick's disease — described in 1965 in the Old Order Amish of Lancaster County, Pennsylvania (PMID:14284412, "DWARFISM IN THE AMISH. II. CARTILAGE-HAIR HYPOPLASIA").

Identifiers

Resource	ID	Confidence
MONDO	MONDO:0009595 — "cartilage-hair hypoplasia"	Verified via OLS4 this session
OMIM	250250 (CHH)	High
OMIM	157660 (RMRP* gene)	Medium — verify
OMIM	607095 (Anauxetic dysplasia 1)	Medium — verify
OMIM	250460 (Metaphyseal dysplasia without hypotrichosis)	Medium — verify
Orphanet	ORPHA:175	High (Orphanet blocked my fetch — cite via the cached `ORPHA:175` structured source instead)
ICD-10	Q78.5 (Metaphyseal dysplasia)	Medium
ICD-11	VERIFY — I could not confirm	Low
UMLS	C0175787	Medium — verify
HGNC	HGNC:10031 (RMRP) → dismech form `hgnc:10031`	Medium — verify

MONDO exact synonyms confirmed from OLS4: cartilage hair hypoplasia, metaphyseal chondrodysplasia, McKusick type, autosomal recessive metaphyseal chondrodysplasia, McKusick Type Metaphyseal Chondrodysplasia. Related: CHH.

Other names in the wild: metaphyseal chondrodysplasia McKusick type, McKusick-type metaphyseal dysplasia, CHH.

Sibling entities worth their own dismech entries or a Grouping: - Anauxetic dysplasia 1 (RMRP, severe end of the same allelic spectrum) - Metaphyseal dysplasia without hypotrichosis / MDWH (RMRP, mild end) - Anauxetic dysplasia 2 (POP1, PMID:27380734) — same holoenzyme, different subunit - Anauxetic dysplasia 3 (NEPRO, PMID:31250547, PMID:37294112) — likewise

There's a real modeling decision here: GeneReviews treats MDWH–CHH–AD as one "CHH–AD spectrum" (PMID:22420014). Given dismech's lump/split conventions, the cleanest shape is probably a separate Cartilage-Hair_Hypoplasia entry plus a Grouping (grouping_basis: SHARED_GENE_FAMILY + SHARED_MECHANISM) covering the RNase MRP holoenzyme disorders, with POP1/NEPRO entries as future members. Flagging it, not deciding it.

Data provenance

Nearly everything quantitative comes from aggregated disease-level cohort studies, not EHR. The Finnish national CHH cohort (Helsinki; Mäkitie, Taskinen, Vakkilainen) is the dominant source — ~80–123 genetically confirmed patients followed prospectively since 1985, cross-linked to the Finnish Cancer Registry and national Cause-of-Death Registry. That's why the epidemiology is unusually good for a disease this rare, and also why you should treat the numbers as Finnish-founder-population numbers rather than universal ones.

2. Etiology

Primary cause

Biallelic pathogenic variants in RMRP (9p13.3), which encodes the ~267–268 nt non-coding RNA subunit of the RNase MRP ribonucleoprotein. It's an RNA polymerase III transcript — no protein product, ever. This is the historically important bit: RMRP was the first nuclear non-coding RNA gene tied to a human disease (verbatim, PMID:31551465: "RMRP was the first non-coding nuclear RNA gene implicated in a disease.").

Ridanpää's original Cell paper, verbatim (PMID:11207361):

"The recessively inherited developmental disorder, cartilage-hair hypoplasia (CHH) is highly pleiotropic with manifestations including short stature, defective cellular immunity, and predisposition to several cancers. The endoribonuclease RNase MRP consists of an RNA molecule bound to several proteins. It has at least two functions, namely, cleavage of RNA in mitochondrial DNA synthesis and nucleolar cleaving of pre-rRNA. We describe numerous mutations in the untranslated RMRP gene that cosegregate with the CHH phenotype. Insertion mutations immediately upstream of the coding sequence silence transcription while mutations in the transcribed region do not. The association of protein subunits with RNA appears unaltered. We conclude that mutations in RMRP cause CHH by disrupting a function of RNase MRP RNA that affects multiple organ systems."

That last sentence is a genuinely good dismech evidence snippet for a top-level pathophysiology node.

Genetic risk factors

Not a susceptibility-locus disease — it's straight Mendelian recessive. Two functional classes of allele:

Transcribed-region variants (e.g. n.71A>G, the big one) — the RNA is made but works badly.
Promoter insertions/duplications — transcription is knocked down or silenced. Ridanpää: "Insertion mutations immediately upstream of the coding sequence silence transcription while mutations in the transcribed region do not." Tan 2023 (PMID:37115363) showed homozygous promoter duplications cause severely reduced transcript abundance and, notably, SCID-level immunodeficiency.

No established modifier genes. No GWAS loci. Carriers are asymptomatic and — worth stating explicitly for counseling — not at increased cancer risk (GeneReviews, PMID:22420014). The one hint of a heterozygote effect is biochemical, not clinical: Aubert found telomerase activity varied by gene dose between carriers and patients (verbatim, PMID:28126377: "telomerase activity is affected in a gene dose-dependent manner when comparing heterozygote RMRP carriers with patients with CHH.").

Environmental risk factors

None established for causation — this is a fully penetrant genetic disease. But there are real environmental modifiers of outcome, and dismech should model them as influences_mechanisms with environmental_effect: EXACERBATES rather than as causes:

Varicella-zoster exposure — potentially fatal in CHH with significant cellular immunodeficiency; historically a named cause of death. Prompts the "immediate high-dose IV acyclovir" rule.
Live attenuated vaccines, especially oral poliovirus — vaccine-associated paralytic poliomyelitis in a CHH child is one of the oldest reports in the literature (PMID:165279, 1975, "Combined immunodeficiency and vaccine-related poliomyelitis in a child with cartilage-hair hypoplasia"). Note this is now nuanced — see §13.
UV exposure — a plausible modifier of the basal-cell / squamous-cell carcinoma excess, though I found no CHH-specific dose-response study. Treat as inferred, not evidenced.
Respiratory pathogen burden — recurrent pneumonia is one of the strongest mortality predictors (§11).

Protective factors

Consanguinity avoidance / outbreeding in founder populations — mechanically obvious, no CHH-specific study.
No protective alleles reported.
No dietary or lifestyle protective factor with evidence. Growth hormone specifically does not help (GeneReviews: "no sustained benefit, not recommended").

Gene–environment interaction

The clean, well-evidenced one: genotype sets immune competence, and immune competence sets the consequence of pathogen and vaccine exposure. Vakkilainen 2020 (PMID:32849667) is the direct test — live viral vaccines turned out to be tolerated in Finnish CHH patients with mild/absent clinical immunodeficiency, with no serious adverse events across 40 MMR and 10 VZV recipients, while remaining contraindicated at the SCID end. That's a genotype→immune-phenotype→exposure-outcome chain, and it's exactly the shape dismech's influences_mechanisms slot wants.

3. Phenotypes

Frequencies below are mostly from GeneReviews (PMID:22420014) and the Finnish cohorts. Every frequency: you curate needs its own quantitative snippet — most of these come from the GeneReviews summary rather than from a quotable abstract sentence, so per the frequency-evidence SOP, omit the band rather than manufacture support.

Skeletal (near-universal)

Phenotype	Suggested HP	Freq	Notes
Disproportionate short-limb short stature	HP:0003026 (Short long bone) / HP:0008873 (Disproportionate short-limb short stature)	100%	Recognizable at birth, sometimes prenatally
Metaphyseal dysplasia	HP:0002980 (Femoral bowing) + HP:0000944 (Abnormal metaphysis morphology)	100% (75/75 with films, PMID:25764362)	Flaring, cupping, marginal serration, fragmentation, scalloping; cystic radiolucencies extending into diaphysis
Genu varum / bowed legs	HP:0002970 (Genu varum)	87% (85/96)	Commonest reason for orthopaedic referral
Short metacarpals/phalanges, "short pudgy hands"	HP:0010049 (Short metacarpal)	100%	Bullet-shaped middle phalanges; cone-shaped epiphyses
Joint hypermobility	HP:0001382 (Joint hypermobility)	100%	Rarely symptomatic
Limited elbow extension	HP:0001377 (Limited elbow extension)	81% (56/69)	Radial head subluxation/dislocation; "not a single patient had any issues of consequence"
Coxa vara	HP:0002812 (Coxa vara)	27% (19/71)
Lumbar lordosis	HP:0002938 (Lumbar hyperlordosis)	common	Rarely needs treatment
Scoliosis	HP:0002650 (Scoliosis)	variable	Observation → bracing → fusion
Atlantoaxial instability	HP:0003318? VERIFY — better: HP:0003468 (Atlantoaxial instability)	AD >> CHH	Prominent in anauxetic dysplasia; PMID:25764362 found no surgical cases in 12 CHH C-spines

Adult height (PMID:25764362, n=135): males median 131.1 cm (110.7–149.0), females median 122.5 cm (103.7–137.4). GeneReviews gives the spectrum range as 104–151 cm for CHH, versus <85 cm for anauxetic dysplasia. Growth: short at birth, further deceleration in the first 2 years, and a "very weak or absent pubertal growth spurt." Model this as clinical_course: PROGRESSIVE on a growth-failure node with onset_category: CONGENITAL_ONSET.

Craniofacial (PMID:34956076, 17 patients vs 34 controls): significantly decreased length of upper jaw, lower jaw, and clivus. Basilar invagination not observed. Midfacial hypoplasia, macroglossia, and dental anomalies are AD-predominant features.

Hair and skin

Hypotrichosis — HP:0001006 (Hypotrichosis) or HP:0002212 (Fine hair) + HP:0002213 (Fine hair)/HP:0008070 (Sparse hair). Fine, silky, sparse, often light-colored; eyebrows and eyelashes involved. Classic old-literature finding: reduced hair shaft diameter with absent or small pigment core (PMID:5533438, PMID:4787841).
Complete alopecia — HP:0002293 (Alopecia of scalp) — ~15%, involving scalp, eyelashes and body hair (GeneReviews).
Neonatal erythroderma — HP:0001019 (Erythroderma) — an emerging, under-recognized presentation (PMID:40110983, PMID:41616907). Nice detail for a "diagnostic pitfall" note.
Hypopigmentation / light hair — common in the Finnish cohort.

Immunologic

The heart of the disease. GeneReviews: cellular immune deficiency in ~88%, clinical infections in 35–65%, mostly infancy and childhood.

Feature	Suggested HP	Freq / detail
Combined immunodeficiency	HP:0005387 (Combined immunodeficiency)	24% symptomatic in the Finnish prospective cohort
Humoral immunodeficiency alone	HP:0004313 (Decreased circulating antibody level)	19%
Asymptomatic	—	57% (46/80) — critical for framing
T-cell lymphopenia	HP:0005403 (Decreased T cell count)	Near-universal on labs
CD8 lymphocytopenia	HP:0005407? VERIFY	Novel phenotype flagged by Kavadas 2008 (PMID:18804272)
Impaired lymphocyte proliferation	HP:0031381 (Abnormal lymphocyte proliferation) VERIFY	9/12 severe in Kavadas
SCID	HP:0004430 (Severe combined immunodeficiency)	Minority; associated with promoter duplications (PMID:37115363)
Recurrent respiratory infections	HP:0002205 (Recurrent respiratory infections)
Bronchiectasis	HP:0002110 (Bronchiectasis)	29–52% (PMID:33675005, verbatim)
Recurrent pneumonia	HP:0006532 (Recurrent pneumonia)	Major mortality driver
Severe varicella	HP:0004429? VERIFY	Historically fatal
Neutropenia	HP:0001875 (Neutropenia)	Reported since 1970 (PMID:4188537)

The Finnish 30-year data (verbatim, PMID:31379817) is the single best structured source here:

"Half of the patients (57%, n = 46) manifested no symptoms of immunodeficiency during follow-up while 19% (n = 15) and 24% (n = 19) demonstrated symptoms of humoral or combined immunodeficiency, including six cases of adult-onset immunodeficiency. In a significant proportion of patients (17/79, 22%), clinical features of immunodeficiency progressed over time."

That "22% progressed over time" plus "six cases of adult-onset immunodeficiency" is the clinically load-bearing insight: CHH immunodeficiency is not a fixed congenital deficit you can rule out once. It creeps.

Immune dysregulation / autoimmunity / allergy

From verbatim PMID:30410491 (n=104, median age 39.2 y):

"Clinical autoimmunity was common (11/104, 10.6%) and included conditions previously undescribed in subjects with CHH (narcolepsy, psoriasis, idiopathic thrombocytopenic purpura, and multifocal motor axonal neuropathy). Patients with autoimmunity more often had recurrent pneumonia, sepsis, high immunoglobulin (Ig) E and/or undetectable IgA levels. The mortality rates were higher in subjects with AI diseases (χ(2)2 = 14.056, p = 0.0002). ... We confirmed the high prevalence of asthma (23%) and allergic rhinoconjunctivitis (39%). Gastrointestinal complaints, mostly persistent diarrhea, were also frequently reported (32/104, 31%)."

So: autoimmunity 10.6%, asthma 23% (HP:0002099), allergic rhinoconjunctivitis 39% (HP:0003193/HP:0000509), chronic diarrhea 31% (HP:0002028, temporality: CHRONIC). And a lovely mechanistic oddity worth a notes: line — "Despite the history of allergic rhinitis, no eosinophils were observed in nasal cytology in five tested patients." The allergy phenotype may not be conventionally eosinophilic.

Also: serum autoantibody positivity frequently occurs without matching clinical disease (Biggs 2017, PMID:28631025). Don't curate autoantibody positivity as an autoimmune phenotype.

Granulomas (cutaneous/systemic, including lymphomatoid granulomatosis, PMID:29744913) occur and drive anti-TNF-α or HSCT decisions.

Hematologic

Mild macrocytic anemia — HP:0001889 (Macrocytic anemia) — ~80% of CHH, typically resolves in childhood.
Severe persistent anemia — ~6%, phenocopying Diamond-Blackfan anemia; 50–75% of those needed transfusion or transplant (GeneReviews).
Neutropenia and lymphopenia as above.

The DBA resemblance isn't a coincidence — it's the ribosomopathy family showing its hand (PMID:20194897, Blood ribosomopathy review, which explicitly names CHH).

Gastrointestinal

Hirschsprung disease — HP:0002251 — 7–8% of CHH, concentrated in severe phenotypes (Mäkitie 2001, PMID:11391344, "Hirschsprung disease is associated especially with severe cartilage-hair hypoplasia" — paraphrase, re-fetch). Massively enriched over the ~1/5000 population baseline (PMID:11694544). It is not reported in AD or MDWH.
Malabsorption — secondary to infection in the first two years.
Chronic diarrhea — 31% (above).

Reproductive

Males: impaired spermatogenesis — reduced sperm concentration, motility, and morphology; testicular volume below age norms with normal gonadotropins/testosterone (GeneReviews). HP:0000798 (Abnormal spermatogenesis) VERIFY.
Females: possible hypogonadotropic or normogonadotropic hypogonadism with absent puberty; a dedicated gynecologic series exists (PMID:30445974, PMID:30561899) and pregnancies do occur (14 women, 42 pregnancies — Holopainen preprint).

Malignancy

Treated in §11 — it's a prognostic feature more than a "phenotype," but for HP purposes: HP:0002665 (Lymphoma), HP:0002671 (Basal cell carcinoma), HP:0001909 (Leukemia).

Quality of life

Genuinely thin. I found no EQ-5D, SF-36, or PROMIS study in CHH. Per-phenotype QoL statements would be speculation. What is documented: 43% undergo lower-limb realignment surgery (PMID:25764362); the elbow contracture and joint laxity are radiographically striking but functionally near-silent ("not a single patient had any issues of consequence with that loss of motion"); and adult stature ~122–131 cm carries the accessibility burdens common to skeletal dysplasia. This is a real knowledge gap — worth a discussions entry with kind: KNOWLEDGE_GAP.

4. Genetic/Molecular Information

The gene

RMRP — RNA component of mitochondrial RNA processing endoribonuclease. Chromosome 9p13.3. Single-exon, non-protein-coding, RNA polymerase III transcript, ~267–268 nt. Suggested hgnc:10031 (verify).

The clinically decisive practical consequence: it's non-coding, so standard exome pipelines miss it. Multiple sources say this outright. This belongs in the diagnostics section of the entry as a first-class fact, not a footnote.

Variant landscape

The dominant allele. The founder variant is written several ways across the literature — n.71A>G, g.70A>G, 70A→G, c.70A>G, n.72A>G — because numbering conventions for this transcript have shifted. Pick one and note the aliases; this is a classic curation trap. GeneReviews reports it as g.71A>G and gives its distribution:

100% of Old Order Amish CHH alleles
92% of Finnish CHH alleles
48% of non-Finnish CHH alleles

Ancient shared founder haplotype across populations (Nature EJHG worldwide mutation spectrum study — "ancient founder origin of the major 70A→G mutation").

Other recurrent alleles: - n.262G>T — historically cited as an Amish-associated allele (verify against current sources; GeneReviews now emphasizes 71A>G at 100% in Amish) - n.197C>T — Brazilian founder effect on a shared haplotype of predominantly European ancestry (PMID:38862721) - n.64C>T — homozygous, reported in Italy (PMID:33444820) - Promoter insertions/duplications — the transcription-silencing class. GeneReviews notes the mechanism precisely: they increase the spacing of regulatory elements, and insertions of 24–26 bp reduce transcription efficiency. Homozygous promoter duplications → severely reduced transcript → SCID (PMID:37115363).

Variant classes: point substitutions in the transcribed region; promoter insertions/duplications; rarely whole-gene deletions. Sequence analysis detects ~100%; deletion/duplication analysis is a low-yield add-on (GeneReviews).

Origin: germline, biallelic. No somatic CHH. (RMRP is separately over-expressed as an oncogenic lncRNA in various sporadic cancers — PMID:33996836 — which is a completely different biology and should not be conflated in the entry.)

Functional consequence: loss of function / hypomorphic. Complete null is presumed non-viable — no human has been reported with two true null alleles, and RNase MRP is essential in yeast. Suggested functional_impact_category: PARTIAL_LOSS_OF_FUNCTION for most transcribed-region alleles, LOSS_OF_FUNCTION for promoter-silencing ones.

Allele frequency: gnomAD coverage of RMRP is poor (non-coding, short, historically excluded from exome capture). The carrier frequencies below come from population studies, not gnomAD.

Genotype–phenotype correlation — the good bit

This is unusually well worked out, and it maps beautifully onto a two-branch dismech pathograph. Thiel 2007 (PMID:17701897, paraphrase — re-fetch):

rRNA cleavage impairment (ribosome assembly) → severity of bone dysplasia
mRNA cleavage impairment (cell-cycle regulation) → presence of hair hypoplasia, immunodeficiency, and hematologic abnormality

GeneReviews adds that anauxetic dysplasia arises from variants that severely impair both, particularly 5.8S rRNA cleavage and cyclin B1 mRNA processing.

So the entry should carry two parallel mechanism branches from a shared upstream node, not one linear chain. That's the structurally interesting thing about this disease.

Modifier genes

None established. Kavadas 2008 documented "significant, even intrafamilial, phenotypic heterogeneity" — siblings with identical genotypes diverging clinically — which is strong evidence that modifiers (genetic or stochastic) exist without any being identified. Good KNOWLEDGE_GAP candidate.

Epigenetics

No CHH-specific methylation or chromatin study found. Not available.

Chromosomal abnormalities

None. Not a CNV/aneuploidy disorder (rare whole-gene deletions aside).

5. Environmental Information

Short section, honestly. CHH is not an environmental disease.

Environmental factors: no toxin, radiation, or occupational exposure implicated in causation. CTD has no CHH entry of substance.
Lifestyle: no evidence of dietary or behavioral modification of disease course. GH therapy explicitly unhelpful.
Infectious agents: no infectious cause, but infection is the dominant complication. Named organisms/entities across the literature: varicella-zoster virus (severe/fatal disease), vaccine-derived poliovirus (PMID:165279), Epstein-Barr virus (EBV-positive Hodgkin lymphoma in CHH-AD siblings, PMID:41460196), and the usual recurrent bacterial respiratory pathogens driving bronchiectasis. EBV is the most mechanistically interesting — it links the immunodeficiency node to the lymphoma node.

For the pathograph: model infections as influences_mechanisms targeting the immunodeficiency node with environmental_effect: EXACERBATES, and remember the CLAUDE.md guidance that only TRIGGERS/EXACERBATES count as causal for compliance scoring — don't inflate.

6. Mechanism / Pathophysiology

Here's the causal architecture. I'd build it as one upstream lesion fanning into two mechanistic arms that reconverge on tissue-specific outcomes.

The enzyme

RNase MRP is a nucleolar ribonucleoprotein — one catalytic RNA (RMRP) wrapped in ~10 protein subunits: POP1, POP4 (RPP29), POP5, RPP14, RPP20 (POP7), RPP21, RPP25, RPP30, RPP38, RPP40, plus NEPRO. It's an evolutionary sibling of RNase P — same architectural family, different substrate menu. Think of it as a pair of molecular scissors that got repurposed for several unrelated jobs over evolutionary time, which is exactly why breaking it produces such a scattered, pleiotropic mess.

Structural work exists: RPP20–RPP25 in complex with the P3 domain of the RNA (PMID:33571640) — useful if the entry wants a protein-structure claim.

Critically, Ridanpää showed the CHH mutations don't stop the proteins binding: "The association of protein subunits with RNA appears unaltered." Robertson 2022 refines this — the 70AG allele reduces the amount of intact complex, rather than making a mis-assembled one.

Known catalytic functions (i.e. the fan-out)

Pre-rRNA processing. Cleaves internal transcribed spacer 1 (ITS1, site A3 in yeast) during ribosome biogenesis, feeding 5.8S rRNA maturation. This is the arm that makes CHH a ribosomopathy.
Cell-cycle control via cyclin mRNA cleavage. Degrades cyclin B2 (and per GeneReviews, cyclin B1) mRNA at mitotic exit. Break this and you break the G2→M transition.
Mitochondrial DNA replication. Processes the RNA primer at the mtDNA heavy-strand origin — the "MRP" in the name.
Telomere biology. RMRP associates with TERT; the TERT–RMRP complex has RNA-dependent RNA polymerase activity producing double-stranded RMRP RNA processed into siRNA (Rogler 2014 lineage).
Small-RNA gene silencing. RMRP is processed into RMRP-S1 and RMRP-S2, which act as miRNAs (PMID:24009312).

Arm A — the ribosomopathy arm (→ skeleton, growth)

Verbatim, PMID:35115551 (this is the single best mechanistic snippet available):

"RMRP encodes a non-coding RNA forming the core of the RNase MRP ribonucleoprotein complex. Mutations cause Cartilage Hair Hypoplasia (CHH), characterized by skeletal abnormalities and impaired T cell activation. Yeast RNase MRP cleaves a specific site in the pre-ribosomal RNA (pre-rRNA) during ribosome synthesis. CRISPR-mediated disruption of RMRP in human cells lines caused growth arrest, with pre-rRNA accumulation. Here, we analyzed disease-relevant primary cells, showing that mutations in RMRP impair mouse T cell activation and delay pre-rRNA processing. Patient-derived human fibroblasts with CHH-linked mutations showed similar pre-rRNA processing delay. Human cells engineered with the most common CHH mutation (70AG in RMRP) show specifically impaired pre-rRNA processing, resulting in reduced mature rRNA and a reduced ratio of cytosolic to mitochondrial ribosomes. Moreover, the 70AG mutation caused a reduction in intact RNase MRP complexes. Together, these results indicate that CHH is a ribosomopathy."

Chain: biallelic RMRP lesion → reduced intact RNase MRP complex → delayed/impaired pre-rRNA cleavage at ITS1 → reduced mature cytosolic rRNA → reduced cytosolic:mitochondrial ribosome ratio → reduced translational capacity → impaired proliferation of growth-plate chondrocytes → metaphyseal dysplasia and short-limb short stature.

That ribosome-ratio finding is unusually specific and quotable. Also worth an attaches_to link: Hermanns 2005 (PMID:16254002) showed the 70A>G allele shifts the 5.8S rRNA ratio in yeast — i.e. it's not just less rRNA, it's the wrong mixture of 5.8S isoforms.

The p53 connection completes the arm: ribosome biogenesis stress activates p53, and "this pathway appears to be a critical mediator of many of the clinical features of ribosomopathies" (PMID:20194897, needs re-fetch to quote).

Arm B — the cell-cycle arm (→ hair, immunity, blood, cancer)

Verbatim, PMID:31551465:

"Transcriptome analysis identified 35 significantly upregulated and 130 downregulated genes in CHH fibroblasts. The downregulated genes were significantly connected to the cell cycle. Multiple other pathways, involving regulation of apoptosis, bone and cartilage formation, and lymphocyte function, were also affected, as well as PI3K-Akt signaling. Cell-cycle studies indicated that the CHH cells were delayed specifically in the passage from G2 phase to mitosis."

Chain: RMRP lesion → impaired cyclin B1/B2 mRNA cleavage → dysregulated mitotic cyclin turnover → G2→M transition delay → reduced proliferative output in high-turnover lineages (T cells, erythroid progenitors, hair follicle matrix keratinocytes) → combined immunodeficiency + macrocytic anemia + hypotrichosis.

Hermanns adds a transcriptional flavor: upregulation of cytokine and cell-cycle genes, linking altered ribosomal processing to "modified cytokine signaling and cell cycle progression in lymphocytic and chondrocytic lineages" (paraphrase — re-fetch).

Arm C — telomere maintenance (→ immune senescence, cancer)

Verbatim, PMID:28126377:

"Lymphocyte cultures from patients with CHH display growth defects in vitro, which is consistent with an immune deficiency cellular phenotype. Here we show that telomere length and telomerase activity are impaired in primary lymphocyte subsets from patients with CHH. Notably, telomerase activity is affected in a gene dose-dependent manner when comparing heterozygote RMRP carriers with patients with CHH. Telomerase deficiency in patients with CHH is not mediated by abnormal telomerase gene transcript levels relative to those of endogenous genes."

That last sentence is a genuinely nice piece of negative evidence — the telomerase defect is post-transcriptional, which rules out the simplest explanation. The mechanism remains unidentified ("through an as yet unidentified mechanism") — perfect KNOWLEDGE_GAP material.

Note the phenotypic overlap with dyskeratosis congenita this creates. Worth a differential_diagnosis entry.

Arm D — small-RNA gene silencing (→ tissue-specific programs)

Rogler 2014 (PMID:24009312, paraphrase — re-fetch): RMRP yields RMRP-S1/S2, which are significantly reduced in CHH patient fibroblasts and a CHH B-cell line. Over 900 genes were regulated (~75% down), with pathway enrichment in skeletal development, hair development, and hematopoietic differentiation, naming PTCH2 (hedgehog) and SOX4. This is the most direct mechanistic bridge to the hair phenotype specifically, which the ribosome arm alone doesn't explain well.

Arm E — Wnt/β-catenin in cartilage (from the zebrafish)

Verbatim, PMID:31237961:

"We found that rmrp is required for the patterning and shaping of pharyngeal arches. Rmrp mutation inhibits the intramembranous ossification of skull bones and promotes vertebrae ossification. The abnormalities of endochondral bone ossification are variable, depending on the degree of dysregulated chondrogenesis. Moreover, rmrp mutation inhibits cell proliferation and promotes apoptosis through dysregulating the expressions of cell-cycle- and apoptosis-related genes. We also demonstrate that rmrp mutation upregulates canonical Wnt/β-catenin signaling; the pharmacological inhibition of Wnt/β-catenin could partially alleviate the chondrodysplasia and increased vertebrae mineralization in rmrp mutants."

The pharmacological rescue is the payload — it identifies Wnt/β-catenin as a druggable node. Tag evidence_source: MODEL_ORGANISM and, per dismech policy, don't let it stand alone for a human phenotype.

Complementary chondrocyte work: RMRP expression is dynamically regulated during chondrocyte hypertrophy and determines chondrogenic differentiation (PMID:28743979); CHH fibroblast chondrogenic-differentiation pathway analysis in PMID:34988338.

Cellular / molecular annotations

Suggested GO biological processes (all VERIFY): - rRNA processing — GO:0006364 - maturation of 5.8S rRNA — GO:0000460 VERIFY - ribosome biogenesis — GO:0042254 - mRNA cleavage — GO:0006379 VERIFY - G2/M transition of mitotic cell cycle — GO:0000086 - regulation of cell cycle — GO:0051726 - telomere maintenance via telomerase — GO:0007004 - canonical Wnt signaling pathway — GO:0060070 (modifier: INCREASED per the zebrafish) - endochondral ossification — GO:0001958 - chondrocyte differentiation — GO:0002062 - T cell activation — GO:0042110 (modifier: DECREASED) - mitochondrial DNA replication — GO:0006264 - gene silencing by miRNA — GO:0035195

Suggested GO molecular functions: - ribonuclease activity / endoribonuclease activity — GO:0004521 / GO:0004519

Suggested GO cellular components: - nucleolus — GO:0005730 (primary site of RNase MRP action) - mitochondrion — GO:0005739 - cytosolic ribosome — GO:0022626

Suggested CL cell types (VERIFY): - chondrocyte — CL:0000138 - growth plate chondrocyte / hypertrophic chondrocyte — VERIFY - T cell — CL:0000084; CD8-positive alpha-beta T cell — CL:0000625 - erythroid progenitor cell — CL:0000038 VERIFY - hair follicle keratinocyte / matrix cell — VERIFY - fibroblast — CL:0000057 (the workhorse of the in-vitro literature) - enteric neuron / neural crest cell — CL:0007011 VERIFY (for the Hirschsprung branch)

Molecular profiling summary

Transcriptomics: yes — CHH fibroblast RNA-seq, 35 up / 130 down, cell cycle + PI3K-Akt (PMID:31551465). Rogler's >900 small-RNA-regulated genes (PMID:24009312). Hermanns' cytokine/cell-cycle upregulation (PMID:16254002).
Proteomics: none CHH-specific found.
Metabolomics / lipidomics: none found. Not available.
Single-cell / spatial: none found. Not available — and a legitimate gap given the tissue-specific ribosome-ratio finding practically begs for it.
Functional genomics: CRISPR disruption of RMRP in human cell lines → growth arrest with pre-rRNA accumulation (PMID:35115551); targeted CRISPR disruption revealing a role for RNase MRP RNA (Goldfarb & Cech, PMID:28115465).

7. Anatomical Structures Affected

Primary organs / systems:

Structure	Suggested UBERON	Involvement
Long bone metaphysis	UBERON:0002225 (bone metaphysis) VERIFY	Primary — femur, tibia especially
Epiphyseal/growth plate cartilage	UBERON:0006255? VERIFY (epiphyseal plate)	Primary lesion site
Femur / tibia	UBERON:0000981 / UBERON:0000979	Bowing, varus
Vertebral column	UBERON:0000955? no — UBERON:0002240 (spinal cord) is wrong; use UBERON:0000956? VERIFY — want vertebral column UBERON:0002412	Lordosis, scoliosis; AD cervical instability
Hair follicle	UBERON:0002073	Hypoplastic
Thymus / T-cell compartment	UBERON:0002370	Impaired T-cell output
Bone marrow	UBERON:0002371	Macrocytic anemia, neutropenia
Lung / bronchus	UBERON:0002048 / UBERON:0002185	Secondary — bronchiectasis
Large intestine / colon	UBERON:0001155	Hirschsprung (aganglionic segment)
Enteric nervous system	UBERON:0002005 VERIFY	Absent ganglion cells
Testis / ovary	UBERON:0000473 / UBERON:0000992	Impaired spermatogenesis; hypogonadism
Skin	UBERON:0002097	BCC/SCC; granulomas; neonatal erythroderma
Mandible / maxilla / clivus	UBERON:0001684 / UBERON:0002397 / VERIFY	Shortened (PMID:34956076)

Body systems: skeletal, immune, hematopoietic, integumentary, gastrointestinal, respiratory (secondary), reproductive.

Subcellular: nucleolus (GO:0005730) is the star — that's where the ribosome-biogenesis lesion lives. Mitochondrion (GO:0005739) for the mtDNA primer function. Cytosolic ribosome (GO:0022626) for the depleted product.

Lateralization: bilateral and symmetric throughout. Metaphyseal changes, bowing, and hair involvement are symmetric. Asymmetry should prompt reconsideration of the diagnosis.

8. Temporal Development

Onset: congenital. Short limbs are recognizable at birth and increasingly prenatally — there's now a whole small literature on it (PMID:41525162 narrative review of prenatal diagnosis; PMID:41720498 familial prenatal ultrasound; PMID:33567347 early prenatal presentation of the CHH/AD spectrum). GeneReviews notes ultrasound may detect severe cases at 16–18 weeks. Suggested onset_category: CONGENITAL_ONSET (with ANTENATAL_ONSET for the severe end).

Course by domain — and they diverge, which is the key structural point:

Domain	Course
Growth	Progressive deceleration through the first 2 years, then proportionate tracking with a weak/absent pubertal spurt. Final height reached in adolescence.
Immunodeficiency	Variable and often progressive. 22% progressed over follow-up; adult-onset immunodeficiency documented in 6 patients (PMID:31379817). Not a static congenital deficit.
Anemia	Usually remitting — mild macrocytic anemia typically resolves during childhood. ~6% persist severely.
Infections	Peak burden in infancy and childhood (35–65%), then generally decreasing.
Bronchiectasis	Prevalence high (29–52%) but progression is slow or absent — see below.
Malignancy	Late and progressive risk — cumulative, rising with age (41% by age 65).
Autoimmunity	Adult-onset and mortality-associated.

That bronchiectasis finding deserves its own mention because it overturned an assumption (verbatim, PMID:33675005):

"We determined the rate and correlates of progression of structural lung changes in a prospectively followed cohort of 16 patients with cartilage-hair hypoplasia. ... Imaging findings remained identical or improved due to disappearance of inflammatory changes in all evaluated patients. ... In conclusion, our results suggest slow if any development of bronchiectasis in selected subjects with cartilage-hair hypoplasia."

Disease duration: chronic, lifelong. No spontaneous remission of the underlying disorder. The only "remission" available is treatment-induced — HSCT resets the immune and hematologic arms (and only those arms).

Critical intervention windows: 1. Newborn screening period — TREC-based SCID screening can catch the severe end before first infection (PMID:41831046, PMID:41727503). 2. Before major organ damage — Bordon's central argument: transplant "before the development of severe infections, major organ damage, or malignancy might jeopardize the outcome." 3. Late childhood/adolescence — timing for corrective osteotomy. 4. Lifelong — malignancy surveillance never stops, because 8 of 15 non-skin cancers occurred in patients with no preceding clinical immunodeficiency symptoms.

9. Inheritance and Population

Epidemiology

Population	Figure	Source
Finland	Incidence 1:23,000; carrier frequency 1:76	GeneReviews (PMID:22420014)
Old Order Amish	Prevalence 1–2:1,000; carrier frequency 1:10	GeneReviews
Global	~700 individuals documented in the literature	GeneReviews
Anauxetic dysplasia	<10 reported cases	GeneReviews

For a dismech prevalence block, normalizing: Finland 1:23,000 → rate_per_100000 ≈ 4.3, measure_type: ANNUAL_INCIDENCE (it's stated as incidence), prevalence_class: BAND_1_9_PER_100000. Amish 1–2:1,000 → rate_per_100000 = 100–200, prevalence_class: ABOVE_1_IN_1000. Global rarity elsewhere: ULTRA_RARE. Note these are wildly different populations — do not collapse them into one record.

Inheritance

Autosomal recessive, HP:0000007. Recurrence risk 25% affected / 50% carrier / 25% unaffected non-carrier per pregnancy.
Penetrance: essentially complete for the skeletal phenotype. Markedly incomplete/variable for the extraskeletal features — 57% of the Finnish cohort never manifested clinical immunodeficiency. This is the single most important counseling nuance in the disease.
Expressivity: highly variable, including intrafamilial variability among identical genotypes (PMID:18804272).
Anticipation: not applicable — no repeat expansion.
Germline mosaicism: not reported.
Founder effects: yes, prominently — Amish, Finnish, and Brazilian (n.197C>T, PMID:38862721). The 71A>G allele traces to an ancient shared founder haplotype.
Consanguinity: contributory in non-founder populations (Turkish, Pakistani, Moroccan case reports). PMID:27740950 documents the Finnish founder allele appearing in a Pakistani family — nice illustration that "founder" ≠ "confined to that population."

Demographics

Ethnic distribution: highest in Old Order Amish and Finns; described worldwide (Brazil, Turkey, Korea, Japan, Italy, Spain, Pakistan, India). First Korean cases reported only in 2024 (PMID:38787970) — ascertainment, not absence.
Sex ratio: ~1:1, as expected for autosomal recessive. No reported skew. (Sex-specific manifestations differ — spermatogenic failure vs. hypogonadism — but incidence does not.)
Age distribution: diagnosed in infancy/early childhood classically; increasingly prenatally; and mild cases can be diagnosed late — PMID:28094436 reports CHH with normal height in childhood, and PMID:31413121 reports MDWH presenting with late-onset manifestations. Median age in the Finnish adult cohort was 39.2 years, with a range to 73.6 — people do reach old age with this.

10. Diagnostics

The one thing that matters most

RMRP is non-coding, so exome sequencing does not cover it. A negative WES does not exclude CHH. This is the most consequential practical fact in the whole diagnostic section, and it should be prominent in the entry (a definitions note or a notes: line on the genetic block).

Diagnostic pathway

Clinical + radiographic suspicion: short-limb disproportionate short stature; metaphyseal dysplasia on skeletal survey; bowed femora/tibiae; bullet-shaped middle phalanges; joint hypermobility with limited elbow extension; fine silky hair; ± infections, anemia, GI dysfunction.
Confirmatory: direct Sanger sequencing of RMRP (including the promoter — don't sequence only the transcribed region, or you'll miss the promoter duplication class). Detects ~100% of variants. Deletion/duplication analysis as a low-yield adjunct.
Panel testing: skeletal dysplasia panels and IEI panels that explicitly include the RMRP locus. Check the panel design.
WGS: works (covers non-coding regions) where WES does not.
Karyotype/CMA/FISH/mtDNA/repeat testing: not indicated.

Laboratory / immunologic workup

CBC with indices — macrocytic anemia (↑MCV), neutropenia, lymphopenia
Lymphocyte subsets — CD3/CD4/CD8 (CD8 lymphocytopenia is the Kavadas signature), naive vs memory
TRECs — newborn SCID screening detects the severe end
Lymphocyte proliferation to mitogens/antigens
Immunoglobulins IgG/IgA/IgM/IgE — note the association of high IgE and/or undetectable IgA with autoimmunity and mortality (PMID:30410491); low IgM associated with subtle bronchiectasis (PMID:33675005)
Vaccine antibody titers
Autoantibody panel — with the caveat that positivity often has no clinical correlate (PMID:28631025)
Erythrocyte adenosine deaminase — normal in CHH; historically used to separate it from DBA (PMID:1151542, PMID:23252420)

Imaging

Skeletal survey (diagnostic)
Lower-limb alignment films (surgical planning)
Cervical spine films — mandatory in AD, annual; lower yield in classic CHH
Chest HRCT or MRI for bronchiectasis. Vakkilainen's imaging study supports MRI and argues against frequent repeat imaging given the slow progression — a radiation-sparing point worth curating.
Abdominal ultrasound every 1–2 years in children for malignancy surveillance

Histopathology

Growth plate: hypoplastic, disorganized chondrocyte columns, reduced proliferative zone
Hair shaft: reduced diameter, absent/small pigment core
Rectal suction biopsy: absent ganglion cells in the Hirschsprung subset
Skin/nodes: granulomas, lymphomatoid granulomatosis in a subset

Differential diagnosis

Condition	Gene	Discriminator
Schmid metaphyseal chondrodysplasia	COL10A1	No extraskeletal features at all — no hair, immune, or anemia involvement
Shwachman-Diamond syndrome	SBDS	Pancreatic exocrine insufficiency + neutropenia dominate; milder skeletal disease
Diamond-Blackfan anemia	ribosomal proteins	Severe anemia dominates; normal erythrocyte ADA in CHH, elevated in DBA
Omenn syndrome	RAG1/2 etc.	Ichthyosiform erythroderma, septicemia, more acutely severe (and note CHH itself can present with neonatal erythroderma — real overlap)
Schimke immuno-osseous dysplasia	SMARCAL1	Nephropathy, spondyloepiphyseal (not metaphyseal) dysplasia, hyperpigmented macules (PMID:18627050)
Dyskeratosis congenita	DKC1, TERT etc.	Overlapping telomere biology, but nail dystrophy/leukoplakia/reticular pigmentation
Anauxetic dysplasia 2	POP1	Skeletal phenotype without clinical immunodeficiency (reduced lymphocyte proliferation on labs only)
Anauxetic dysplasia 3	NEPRO	Sparse hair but no immunodeficiency
EXTL3-related	EXTL3	Spondyloepimetaphyseal dysplasia + developmental delay + liver cysts

Screening

Newborn SCID/TREC screening — catches severe CHH, and GeneReviews notes it may carry prognostic information. Multiple recent papers put CHH in the syndromic-IEI-detected-by-TREC bucket (PMID:41831046, PMID:41727503).
Carrier screening — high value in Amish and Finnish populations given 1:10 and 1:76 carrier frequencies.
Cascade testing of at-risk relatives once family variants are known.
Prenatal / PGT — available once the familial variants are identified; ultrasound detects severe cases from 16–18 weeks.

11. Outcome / Prognosis

Mortality — the headline numbers

From verbatim PMID:31379817, the 30-year Finnish prospective cohort (n=80):

"Altogether 20 patients had deceased (SMR = 7.0, 95%CI = 4.3-11); most commonly from malignancy (n = 7, SMR = 10, 95%CI = 4.1-21) and lung disease (n = 4, SMR = 46, 95%CI = 9.5-130)."

So: overall standardized mortality ratio 7.0 against the Finnish national rate. Lung disease carries an SMR of 46 — the highest single ratio in the study, and the reason pulmonary follow-up gets its own literature.

Validated risk factors for early death (same source, verbatim):

"Mortality associated with birth length below -4 standard deviation (compared to normal, SMR/SMR ratio = 5.4, 95%CI = 1.5-20), symptoms of combined immunodeficiency (compared to asymptomatic, SMR/SMR ratio = 3.9, 95%CI = 1.3-11), Hirschsprung disease (odds ratio (OR) 7.2, 95%CI = 1.04-55), pneumonia in the first year of life or recurrently in adulthood (OR = 7.6/19, 95%CI = 1.3-43/2.6-140) and autoimmunity in adulthood (OR = 39, 95%CI = 3.5-430)."

These were subsequently validated in an independent analysis (PMID:38676846) — and separately, shorter birth length plus decreased T-cell production/function predicted severe infections in non-SCID CHH children (PMID:38187867). Birth length below −4 SD is a beautifully simple, universally measured prognostic marker; it deserves to be a first-class item in the entry.

The paper's own conclusion is the clinical takeaway (verbatim):

"In conclusion, patients with CHH may develop adult-onset immunodeficiency or malignancy without preceding clinical symptoms of immune defect, warranting careful follow-up."

Malignancy

Taskinen 2008 (PMID:18698627, n=123 Finnish patients, 2,365 person-years — paraphrase, re-fetch before quoting): 14 cancers observed vs. 2 expected. Non-Hodgkin lymphoma most frequent (n=9), SIR 90.2 (CI 39.0–180). Conclusion: significantly increased risk of NHL and basal cell carcinoma at early age, with poor overall prognosis.

GeneReviews adds: ~11% developed malignancy over 39-year follow-up (14/123); Kaplan-Meier estimate 41% probability by age 65; commonest are NHL, squamous cell carcinoma, and leukemia; median survival after cancer diagnosis: 3 months (9 of 14 died). A separate series of 16 CHH lymphoma patients: DLBCL predominant, 69% mortality (11/16).

An SIR of 90 for NHL is one of the highest in any inherited condition. This should be a prominent, well-evidenced node.

The countercurrent worth curating: PMID:41460196 reports two CHH-AD siblings with relapsed/refractory EBV-positive Hodgkin lymphoma achieving durable (30-month) remission with gemcitabine/vinorelbine + brentuximab vedotin without transplant — evidence that targeted consolidation may change this grim picture.

Morbidity and function

Adult height 122–131 cm median with associated accessibility burden
~43% undergo lower-limb realignment surgery
Bronchiectasis in 29–52%, though slowly progressive
Chronic diarrhea in 31%
Subfertility in both sexes
Recurrent infection burden in the symptomatic 43%

Formal QoL instrument data: not available. Flag as a gap.

Prognostic factors — summary table

Factor	Direction	Evidence
Birth length < −4 SD	↑ mortality (SMR ratio 5.4)	PMID:31379817
Symptomatic combined immunodeficiency	↑ mortality (SMR ratio 3.9)	PMID:31379817
Hirschsprung disease	↑ mortality (OR 7.2)	PMID:31379817
Pneumonia, first year of life	↑ mortality (OR 7.6)	PMID:31379817
Recurrent pneumonia in adulthood	↑ mortality (OR 19)	PMID:31379817
Adult autoimmunity	↑ mortality (OR 39)	PMID:31379817, PMID:30410491
Undetectable IgA and/or high IgE	↑ autoimmunity, ↑ mortality	PMID:30410491
Decreased T-cell production/function	↑ severe infection	PMID:38187867
Malignancy (esp. NHL)	catastrophic — median 3 mo survival	GeneReviews / PMID:18698627
Asymptomatic status at follow-up (57%)	favorable — but not protective against later cancer	PMID:31379817

That last row matters: 8 of 15 patients with non-skin cancer had no preceding clinical immunodeficiency symptoms. Being asymptomatic does not earn you a pass on surveillance.

12. Treatment

No disease-modifying therapy exists. Management is complication-directed, with one curative option that fixes exactly half the disease.

Hematopoietic stem cell transplantation

The only curative option for the immune and hematologic arms. It does not correct growth failure. Bordon 2010 (verbatim, PMID:20375313):

"Previous reports in single CHH patients with significant immunodeficiencies have demonstrated that allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment for the severe immunodeficiency, while growth failure remains unaffected. ... we performed a European collaborative survey reporting on 16 patients with CHH and immunodeficiency who underwent HSCT. Immune dysregulation, lymphoid malignancy, and autoimmunity were important features in this cohort. Thirteen patients were transplanted in early childhood (approximately 2.5 years). The other 3 patients were transplanted at adolescent age. Of 16 patients, 10 (62.5%) were long-term survivors, with a median follow-up of 7 years. T-lymphocyte numbers and function have normalized, and autoimmunity has resolved in all survivors. HSCT should be considered in CHH patients with severe immunodeficiency/autoimmunity, before the development of severe infections, major organ damage, or malignancy might jeopardize the outcome of HSCT and the quality of life in these patients."

GeneReviews puts overall survival at 63–80% and notes normalization of T cells, resolution of autoimmunity, and catch-up growth in some series — worth flagging as a discrepancy with Bordon's "growth failure remains unaffected." Curate the discrepancy honestly rather than picking a side; it might be a KNOWLEDGE_GAP or a real difference in conditioning era.

Suggested annotation: treatment_term NCIT:C15431 (Hematopoietic Cell Transplantation) verify; therapeutic_modality: CELL_THERAPY (per the CLAUDE.md mechanical-backfill table, C15431 → CELL_THERAPY); target_mechanisms pointing at the immunodeficiency and anemia nodes with treatment_effect set appropriately.

Immunologic / infectious management

Intervention	Detail	Suggested NCIT
Immunoglobulin replacement	For documented hypogammaglobulinemia / impaired specific antibody	NCIT:C15986 Pharmacotherapy + agent verify
Antibiotic prophylaxis	For recurrent infections	NCIT:C15986
High-dose IV acyclovir	Immediately on varicella exposure/infection — potentially life-saving	NCIT:C15986 + CHEBI:2453 (aciclovir) verify
Airway clearance physiotherapy	Bronchiectasis, per pulmonologist	NCIT:C15302 Physical Therapy → `BEHAVIORAL`
Anti-TNF-α therapy	For granulomas — carries a rare fatal PML risk, per GeneReviews	NCIT:C15986 + NCIT:C20401 Monoclonal Antibody

Hematologic

Red cell transfusion with iron chelation for severe persistent anemia
HSCT for transfusion-dependent anemia (rarely needed)

Skeletal / orthopaedic

Corrective osteotomy for varus deformity — late childhood/adolescence; 43% of patients, mean age ~11.7–14.5 years (PMID:25764362). NCIT:C16186 Orthopedic Surgical Procedure → SURGERY.
Scoliosis: observation → bracing → fusion by curve magnitude
AD-specific: cervical fusion for atlantoaxial instability; special anaesthetic precautions for airway/neck manipulation; kyphoscoliosis surgery if lung function is compromised
Growth hormone: not recommended — no sustained benefit (GeneReviews). Curate this as an explicit negative treatment recommendation; it's the kind of thing families ask about.

Gastrointestinal

Surgical management of Hirschsprung disease (pull-through). Note the poor prognosis association (PMID:11391344) — HSCR in CHH is a mortality marker, not just a surgical problem.

Endocrine / reproductive

Hormonal induction of puberty where indicated
Fertility counseling for both sexes

Malignancy

Standard protocols; NHL carries poor prognosis with conventional cytotoxic regimens
Emerging: brentuximab vedotin + gemcitabine/vinorelbine achieved 30-month HSCT-free remission in refractory Hodgkin lymphoma in CHH-AD (PMID:41460196)
Caution warranted with cytotoxic intensity given the underlying proliferation defect and marrow reserve — inferred, not directly evidenced

Pharmacogenomics

No CHH-specific pharmacogenomic data found. Not available.

Experimental / future directions

Wnt/β-catenin inhibition — pharmacological inhibition partially rescued chondrodysplasia and vertebral mineralization in the zebrafish model (PMID:31237961). The only mechanism-directed lead with in-vivo rescue data. Preclinical only.
PI3K-Akt — flagged as affected in CHH fibroblast transcriptomics (PMID:31551465); the authors explicitly note the findings "indicate possible pathways for therapeutic intervention."
L-leucine / mTOR activation — established as a ribosomopathy strategy in DBA and del(5q) MDS (PMID:22734070). Not tested in CHH. Speculative, but a defensible proposed_experiments item.
RNA-based replacement/correction — conceptually attractive for a single non-coding RNA gene. No published program found.
ClinicalTrials.gov: the only CHH trial I identified is NCT02383797, the live VZV vaccine safety trial (5 subjects) in PMID:32849667. Worth a clinical_trials entry with phase as an enum value and target phenotypes bound to HP terms.

13. Prevention

Primary prevention of the disease itself isn't possible — it's a congenital genetic disorder. What's available:

Genetic counseling (NCIT:C15240 Genetic Counseling → the entry's treatments or a prevention block): 25% recurrence risk; carrier testing for relatives; special weight in Amish and Finnish communities where carrier frequency is 1:10 and 1:76.
Carrier screening in founder populations.
Prenatal diagnosis / PGT once familial variants are known; ultrasound from 16–18 weeks for severe phenotypes.

Secondary prevention (early detection):

Newborn TREC/SCID screening — identifies the severe immunodeficient end pre-symptomatically.
Immune function testing at diagnosis in every patient, including the asymptomatic — because 57% look fine and 22% will progress.

Tertiary prevention (complication avoidance) — this is where most of the value is:

GeneReviews' surveillance schedule, which maps cleanly onto a dismech management block:

Domain	Frequency
Growth (CHH-specific curves)	Annually through childhood
Immune function	At diagnosis; interval by initial result
Joints and spine (clinical + radiographic)	Annually in childhood
Spine radiographs (AD)	Annually
Respiratory assessment	By infection frequency; HRCT/MRI if bronchiectasis suspected
CBC (if prior anemia)	Annually
Malignancy screening — exam, CBC, LDH, uric acid	Annually
Abdominal ultrasound (children)	Every 1–2 years
Pubertal assessment	Annually through adolescence

Plus: immediate high-dose IV acyclovir on varicella exposure — the single highest-yield prophylactic rule in the disease.

Immunization — the nuanced one

Default: live vaccines contraindicated in SCID; inactivated vaccines safe and encouraged. But Vakkilainen 2020 (verbatim, PMID:32849667) genuinely moved this:

"A large proportion of patients have been immunized with live viral vaccines, including measles-mumps-rubella (MMR) (n = 40, 38%) and VZV (n = 10, 10%) vaccines, with no serious adverse events. ... Patients with CHH demonstrated seropositivity rates of 96%/75%/91% to measles, mumps and rubella, respectively, measured at a medium of 24 years post-immunization. Clinical trial participants developed humoral and cellular responses to VZV vaccine. One trial participant developed post-immunization rash and knee swelling, both resolved without treatment. Conclusion: No serious adverse events have been recorded after immunization with live viral vaccines in Finnish patients with CHH. Patients generate humoral and cellular immune response to live viral vaccines. Immunization with live vaccines may be considered in selected CHH patients with no or clinically mild immunodeficiency."

Curate that as a conditional recommendation gated on immune phenotype, not a blanket one. And keep the historical vaccine-associated poliomyelitis case (PMID:165279) as the counterweight — it's why the rule existed.

Public health / environmental interventions: not applicable beyond general infection control and, plausibly, sun protection given the BCC/SCC excess (inferred).

14. Other Species / Natural Disease

Thin section, and honestly interesting for what's absent.

Taxonomy: human — NCBITaxon:9606. No naturally occurring CHH homolog reported in companion animals or wildlife.
OMIA: I found no OMIA entry for an RMRP disorder in any species. Not available.
Breed (VBO): not applicable.
Orthologs: RMRP is conserved across eukaryotes — RNase MRP is present in yeast (NME1), where it's essential. Mouse Rmrp, zebrafish rmrp. The yeast work is where the ITS1/A3 cleavage function was originally defined, and Hermanns 2005 used yeast to show the 70A>G allele shifts 5.8S rRNA ratios. That's a genuinely useful piece of evolutionary conservation evidence — the disease-causing base change breaks the enzyme the same way a billion years of divergence apart.
Zoonotic potential / cross-species transmission: not applicable (genetic disorder).
Comparative biology: the deep conservation of RNase MRP's rRNA-processing role is the strongest cross-species claim available. The divergent bits — the miRNA-generating and telomerase-associating functions — appear more vertebrate/human-specific, which is worth noting as a limitation on how far yeast data can carry a human mechanistic claim.

15. Model Organisms

Zebrafish — the workhorse

rmrp knockout zebrafish (PMID:31237961) is the best-characterized whole-organism model, and the paper explicitly frames itself as filling a void: "there are no viable animal models for CHH."

Recapitulates: dysregulated chondrogenesis, abnormal endochondral ossification, inhibited intramembranous skull ossification, pharyngeal arch patterning defects, reduced proliferation, increased apoptosis, upregulated canonical Wnt/β-catenin.

Does not capture: hair (fish don't have any), the adaptive immune phenotype, anemia, Hirschsprung disease, malignancy predisposition. Also promotes vertebral ossification — a direction opposite to the general hypo-ossification story, which the authors themselves flag as variable.

Applications: skeletal development mechanism; and crucially it's the only system with a pharmacological rescue (Wnt inhibition), making it the natural platform for drug screening.

Suggested dismech shape: animal_models entry, species: Zebrafish, modeled_mechanisms with target: <chondrodysplasia node>, relationship: PARTIALLY_RECAPITULATES, fidelity: MODERATE, limitations naming the missing hair/immune/hematologic arms, and readouts for chondrogenesis and vertebral mineralization. The Wnt-inhibitor arm gets a RESTORED readout.

Mouse

No viable germline Rmrp knockout mouse exists — constitutive loss is presumed embryonic lethal (RNase MRP is essential). What does exist:

Mouse primary T cells carrying Rmrp mutations — Robertson 2022 (PMID:35115551) showed "mutations in RMRP impair mouse T cell activation and delay pre-rRNA processing." This is the model for the immune arm specifically.
Rogler 2014 (PMID:24009312) used transgenic/knockdown approaches for the small-RNA silencing work.

relationship: RECAPITULATES for the T-cell activation node only; fidelity: MODERATE; limitations: cell-level, not organismal; doesn't address skeletal or hair phenotype.

Human cellular models — the strongest evidence base

This is where CHH is actually best modeled, which makes sense for a disease this developmentally embedded.

System	Findings	PMID
Patient-derived fibroblasts	Delayed pre-rRNA processing; G2→M delay; 35 up/130 down transcriptome; reduced RMRP-S1/S2	35115551, 31551465, 24009312
*CRISPR RMRP* disruption, human cell lines**	Growth arrest with pre-rRNA accumulation	35115551, 28115465
Engineered 70AG human cells	Specifically impaired pre-rRNA processing; reduced mature rRNA; reduced cytosolic:mitochondrial ribosome ratio; reduced intact RNase MRP complexes	35115551
Patient B-cell line	Reduced RMRP-S1/S2	24009312
CHH patient lymphocyte cultures	In-vitro growth defect; short telomeres; reduced telomerase activity	28126377
CHH fibroblast chondrogenic differentiation	Pathway dissection of chondrogenesis	34988338
Chondrocyte hypertrophy models	RMRP expression dynamically regulated; determines chondrogenic differentiation	28743979
*Yeast (S. cerevisiae)*	70A>G alters 5.8S rRNA ratio	16254002

For dismech, most of these belong in experimental_models: (non-animal systems) with modeled_mechanisms links, per the CLAUDE.md distinction. The engineered 70AG human cell line is the single highest-fidelity model of the causal mechanism available and deserves fidelity: HIGH for the pre-rRNA processing node.

Notably absent: iPSC-derived chondrocytes or organoids from CHH patients; no CHH entry in DepMap-style functional-genomics resources beyond the CRISPR growth-arrest observation. Real opportunity, real gap.

Model limitations, collectively

Nothing available reproduces the full pleiotropy. The skeleton has a fish, the immune system has mouse T cells and human lymphocytes, the ribosome mechanism has engineered human cells — and nothing at all models the hair phenotype, the Hirschsprung association, or the lymphoma predisposition in vivo. If the entry carries a HUMAN_MODEL_MISMATCH discussion, that's the shape of it: the models are each faithful to one arm and blind to the others, so no single system can test a claim about the disease as a whole.

Suggested dismech pathograph skeleton

Sketching the node/edge structure since that's the actual deliverable target:

Biallelic RMRP loss-of-function                      [MOLECULAR]
  ├─▸ Reduced intact RNase MRP complex               [MOLECULAR]
  │     ├─▸ Impaired pre-rRNA ITS1 cleavage          [MOLECULAR]   ← Arm A
  │     │     └─▸ Reduced mature cytosolic rRNA / ribosome deficit [CELLULAR]
  │     │           ├─▸ Impaired chondrocyte proliferation [CELLULAR]
  │     │           │     └─▸ Metaphyseal dysplasia   [TISSUE]
  │     │           │           └─▸ Short-limb short stature [ORGANISM]
  │     │           └─▸ Impaired erythroid progenitor proliferation [CELLULAR]
  │     │                 └─▸ Macrocytic anemia       [ORGANISM]
  │     ├─▸ Impaired cyclin B1/B2 mRNA cleavage       [MOLECULAR]   ← Arm B
  │     │     └─▸ G2→M transition delay               [CELLULAR]
  │     │           ├─▸ Impaired T-cell proliferation/activation [CELLULAR]
  │     │           │     └─▸ Combined immunodeficiency [ORGANISM]
  │     │           │           ├─▸ Recurrent infection → bronchiectasis [TISSUE]
  │     │           │           └─▸ Immune dysregulation → autoimmunity [ORGANISM]
  │     │           └─▸ Impaired hair follicle keratinocyte proliferation [CELLULAR]
  │     │                 └─▸ Hypotrichosis           [ORGANISM]
  │     ├─▸ Impaired telomerase activity / telomere shortening [MOLECULAR] ← Arm C
  │     │     └─▸ Lymphocyte replicative exhaustion   [CELLULAR]
  │     └─▸ Reduced RMRP-S1/S2 small RNAs             [MOLECULAR]   ← Arm D
  │           └─▸ Dysregulated PTCH2/SOX4 developmental programs [CELLULAR]
  └─▸ (zebrafish) Upregulated canonical Wnt/β-catenin [CELLULAR]    ← Arm E

Combined immunodeficiency + telomere dysfunction ──▸ Lymphomagenesis (NHL) [ORGANISM]

Candidate module conformance: this entry is a natural conformer for a ribosomopathy module if one gets built (alongside Diamond-Blackfan, Shwachman-Diamond, Treacher Collins — note pharyngeal_arch_patterning_serial_homology already covers the TCOF1 ribosome-biogenesis→neural-crest route, and the zebrafish pharyngeal arch finding here is a suggestive but not sufficient link — don't wire it without evidence). Also plausibly myelosuppression-adjacent for the cytopenia arm, though that module is scoped to drug toxicity, so probably not.

Gaps and cautions for curation

Ontology IDs above are suggestions. Run just validate-terms before any of them land. I flagged the ones I'm least sure of; the vertebral-column and hair-follicle-keratinocyte ones especially.
Variant nomenclature is genuinely inconsistent across the literature (n.71A>G / g.70A>G / n.72A>G / c.70A>G for the same allele). Pick one canonical form, record aliases in notes:, and don't let two forms coexist in the entry as if they were different variants.
Most frequency figures come from GeneReviews prose, not from quotable abstract sentences. Per the frequency-evidence SOP, omit the band rather than attach a snippet that only supports the association.
The Finnish cohort dominates the quantitative literature. Prevalence, mortality, autoimmunity, and cancer figures are all Finnish-founder-population estimates. Say so in population: fields rather than presenting them as global.
Genuine knowledge gaps worth discussions entries: the mechanism of the telomerase defect ("as yet unidentified"); the absence of identified modifier genes despite documented intrafamilial variability; the HSCT-and-growth discrepancy between Bordon and GeneReviews; no QoL instrument data; no metabolomic/proteomic/single-cell data; no model of the hair, Hirschsprung, or lymphoma arms.
Don't conflate germline RMRP loss-of-function (this disease) with RMRP over-expression as an oncogenic lncRNA in sporadic cancers. Same gene, opposite direction, unrelated biology.

Sources

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	63
Resolved	63
Unresolved (possible confabulation)	0
Unverifiable	0

All extracted references resolved successfully.

Ask OpenScientist

OpenScientist Report

Classifications

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Diagnosis

Prevalence

Differential Diagnoses

Related Datasets

Clinical Trials

Experimental Models

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Cartilage-Hair Hypoplasia (CHH) — Comprehensive Research Report

0. Evidence-verification status (read this first)

1. Disease Information

Overview

Identifiers

Data provenance

2. Etiology

Primary cause

Genetic risk factors

Environmental risk factors

Protective factors

Gene–environment interaction

3. Phenotypes

Skeletal (near-universal)

Hair and skin

Immunologic

Immune dysregulation / autoimmunity / allergy

Hematologic

Gastrointestinal

Reproductive

Malignancy

Quality of life

4. Genetic/Molecular Information

The gene

Variant landscape

Genotype–phenotype correlation — the good bit

Modifier genes

Epigenetics

Chromosomal abnormalities

5. Environmental Information

6. Mechanism / Pathophysiology

The enzyme

Known catalytic functions (i.e. the fan-out)

Arm A — the ribosomopathy arm (→ skeleton, growth)

Arm B — the cell-cycle arm (→ hair, immunity, blood, cancer)

Arm C — telomere maintenance (→ immune senescence, cancer)

Arm D — small-RNA gene silencing (→ tissue-specific programs)

Arm E — Wnt/β-catenin in cartilage (from the zebrafish)

Cellular / molecular annotations

Molecular profiling summary

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

Epidemiology

Inheritance

Demographics

10. Diagnostics

The one thing that matters most

Diagnostic pathway

Laboratory / immunologic workup

Imaging

Histopathology

Differential diagnosis

Screening

11. Outcome / Prognosis

Mortality — the headline numbers

Malignancy

Morbidity and function

Prognostic factors — summary table